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ABSTRACT 
 
 
Malignant melanoma is the most dangerous form of skin cancer and accounts for 
about 75% of skin cancer deaths. Once diagnosed at the metastatic stage, it has a very 
poor prognosis with a median survival rate of 6 months and a 5-year survival rate of less 
than 5%. In addition, melanoma has become an important public health hazard owing to 
its rising incidence, which has been well documented over the past 50 years. Currently 
there is no effective way to treat melanoma. It is highly resistant to existing 
chemotherapy, radiotherapy, and immunotherapy. Over the past 30 years, only two drugs 
have been approved by the Food and Drug Administration (FDA) for metastatic 
melanoma: dacarbazine (DTIC) and interleukin-2 (IL-2). But even with these two drugs, 
fewer than 15% of patients have a favorable response and fewer than 5% of patients 
reach complete remission. On the other hand, the toxicity associated with DTIC and IL-2 
is often significant, resulting in serious or life threatening side effects in many patients. In 
recent years, great efforts have been made in fighting metastatic melanoma. But neither 
combinations of DTIC with other chemotherapy drugs (e.g., cisplatin, vinblastine, and 
carmustine) nor adding interferon-α2b to DTIC have shown a survival advantage over 
DTIC treatment alone. Extensive clinical trials with a lot of antibodies and vaccines to 
treat metastatic melanoma have also failed to demonstrate satisfactory efficacy. Therefore, 
developing more effective drugs for melanoma is urgently needed.  
 
We started our efforts in finding new drugs for melanoma by screening a large 
compound library. The in vitro cytotoxicity data on several melanoma cell lines led us to 
the discovery of three active structure scaffolds: serine amides, serine amino alcohols, 
and arylthiazolidine-4-carboxylic acid amides (ATCAAs). Because ATCAAs showed 
better selectivity between cancer cells and normal fibroblast cells, the chemists in our 
group focused on this scaffold and performed extensive structure modifications for 
structure-activity-relationship (SAR) studies. The SAR results were then used to guide 
further synthesis in an effort to maximize activity and selectivity. Two active compounds 
identified during the process were sent to the U.S. National Cancer Institute for 
anticancer screening using 60 human tumor cell lines. Results showed that these two 
compounds have extensive cytotoxic activity against all nine types of cancer cells with 
IC50 values ranging from 120 nM (leukemia, CCRF-CEM cell line) to 11 μM (colon 
cancer, HCC-15 cell line). One compound showed particularly good activity against 
melanoma cells (IC50=130 nM~1 M against all eight melanoma cell lines). I then 
evaluated ATCAAs inhibitory effect on melanoma colony formation and in vivo 
melanoma tumor growth. The in vivo data were very encouraging. One tested compound 
significantly inhibited melanoma tumor growth at a dose of 10 mg/kg and showed higher 
efficacy than did DTIC at a dose of 60 mg/kg. These findings built up a strong basis for 
the development of novel chemotherapeutic drugs for advanced melanoma. 
  
Furthermore, the chemists in our group also synthesized some new imidazole and 
imidazoline analogs by focusing on the SAR studies of the central five-member ring. 
Although the current compounds displayed lower potency when compared with our lead 
thiazolidine analogs, they may have the distinct advantage of being more stable in vivo 
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with the reduced necessity of chiral separations. Some of these new compounds have 
activity similar to Sorafenib, an FDA-approved drug that has been tested clinically in 
melanoma patients.  
 
To further expand our understanding of SARs and to potentially identify new 
platforms for active compounds, Dr. Li and Dr. Seibel explored a compound library from 
the University of Cincinnati’s Drug Discovery Center. This library contains 342,910 
small molecules. Based on the structure of our lead molecule, two ligand-based virtual 
screening approaches were used: 1) similarity search based on atom connectivity by using 
Scitegic Pipeline Pilot software and 2) similarity search based on molecular shape by 
using Schrodinger software. Results showed that these two approaches are highly 
complementary and lead to different active molecular structures. These structures are 
quite suitable for further structural modification and provide new platforms for our 
anticancer drug discovery efforts.  
 
Subsequently, further lead structure optimization led to the discovery of 
substituted methoxylbenzoyl-aryl-thiazole (SMART) compounds. To improve solubility 
and to circumvent the metabolic instability brought by the thiazole ring, our team 
designed and synthesized a new series of analogs: 2-aryl-4-benzoyl-imidazoles (ABIs). 
These two classes of compounds showed great in vitro cytotoxicity against melanoma, 
and the IC50 of the most active compound was below 10 nM. They also showed equal 
potency against multi-drug resistant melanoma cells and the sensitive parent cells, 
indicating that these compounds can effectively overcome multi-drug resistance, which is 
a major cause of cancer chemotherapy failure. In vivo testing on C57BL/6 mice bearing 
B16-F1 melanoma allograft and on double homozygous SCID (severe combined 
immunodeficiency) hairless outbred (SHO) mice or athymic nude mice bearing A375 
human melanoma xenograft showed these two classes of compounds significantly 
inhibited melanoma tumor growth. Some compounds even showed substantially better 
activity than did DTIC, the gold standard anti-melanoma drug. Meanwhile, preliminary 
toxicity studies suggested that mice can tolerate tested compounds well at effective dose 
levels. No sign of acute toxicity was observed from the experiments. More importantly, I 
identified the cellular target for ABI and SMART compounds through a series of 
biotechniques and molecular modeling studies. Strong experimental evidence has shown 
that these compounds bind to tubulin at the colchicine binding site in the α/β-tubulin 
heterodimers to disrupt functional microtubule formation. In the meantime, I also tested 
the pharmacokinetic properties of some active compounds in mice together with Mr. 
Chien-ming Li. With their good in vivo anti-melanoma activity and their ability to 
overcome multi-drug resistance, these new classes of compounds have great potential for 
melanoma therapy. 
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CHAPTER 1.  LITERATURE REVIEW 
 
 
1.1 Introduction 
 
Melanoma is a cancer derived from melanocytes which produce pigment called 
melanin. This cancerous transformation can be initiated from either localized pre-existing 
nevi or de novo, arising from the single melanocyte that is located at the junction of the 
epidermis (1). Under normal condition, melanocytes proliferation and migration are 
regulated by keratinocytes through direct cell-cell contact or soluble growth factors (2). 
Upon malignant transformation, melanoma cells initially have a superficial spreading 
(radial growth phase), followed by tumor cells invading the dermis (vertical growth 
phase). Then they can advance to a more aggressive metastatic phase in which the tumor 
cells can metastasize lymphatically or haematologically to regional and distant sites in the 
body (3). 
 
 Metastatic melanoma is the most dangerous form of skin cancer, accounts for 
about 75% of skin cancer deaths (4). If detected at an early stage, cutaneous melanoma is 
curable with complete surgical excision in most patients. But once the disease progresses 
in regional or distant sites, it is very difficult to treat. And when disseminated, it is a 
devastating illness. Metastatic melanoma has a very poor prognosis, with a median 
survival rate of 6~10 months and a 5-year survival rate of less than 5% (5). 
 
Melanoma has become an important public health hazard owing to its rising 
incidence as this has been well documented over the past 50 years. There has been a 3 to 
7% worldwide annual age standardized incidence increase over the past five decades. The 
incidence of melanoma is rising steadily in Western populations. The number of cases 
has doubled in the past 20 years. The current lifetime risk is 1.9% for men and 1.37% for 
women (6). Melanoma is the fastest rising form of cancer among men and the second 
fastest rising form of cancer among women. The overall mortality from melanoma has 
increased because of the increase in incidence. Around 160,000 new cases of melanoma 
are diagnosed worldwide each year, and it is more frequent in males and Caucasians (7). 
According to a WHO Report, about 48,000 melanoma-related deaths occur worldwide 
per year. Because melanoma affects young- and middle-aged individuals, the number of 
years of life lost to this malignancy is high and exceeds all other adult solid tumors 
except testicular carcinoma (8). 
 
 
1.2 Current Treatment Agents for Metastatic Melanoma 
 
According to the current 6th edition American Joint Committee of Cancer (AJCC) 
staging system, melanoma can be pathologically classified to the following stages: 0, IA, 
IB, IIA, IIB, IIC, IIIA, IIIB, IIIC,  and IV. Stage 0 is in situ melanoma. Stage I and II are 
growth phase of localized cutaneous melanoma with increasing thickness. Stage III has 
regional involvement of lymph node. Stage IV means distant metastasis. Normally stage 
III and IV melanoma are called metastatic melanoma. Localized melanoma is curable 
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with complete surgical excision in most patients. But currently there is no effective way 
to treat metastatic melanoma. Only two agents in current use have been approved by the 
Food and Drug Administration (FDA) for metastatic melanoma: dacarbazine (DTIC) and 
interleukin-2 (IL-2). But even with these two drugs, only less than 15% patients have 
response and less than 5% patients can reach complete remission. On the other hand, the 
toxicity associated with DTIC and IL-2 is often significant, resulting in serious or life 
threatening side effects in many of the patients treated. 
 
 In this section, I will focus on the usage and performance of DTIC and IL-2 first. 
Of cause surgery is often used as a treatment for melanoma whenever a surgical removal 
is possible. Radiation therapy is often used after surgical resection for patients with 
regionally advanced melanoma or for patients with unresectable distant metastases. But 
these two strategies of treatment for metastatic melanoma are beyond the scope of this 
review.  
 
 
1.2.1 Chemotherapy Agent DTIC 
 
Currently DTIC is the only FDA approved chemotherapy drug for metastatic 
melanoma. This drug gained FDA approval in May 1975 as DTIC-Dome for the 
treatment of metastatic melanoma. It was initially marketed by Bayer. The therapeutic 
effect of DTIC is believed to be produced through alkylation of DNA. While its 
anticancer mechanism of action is still not fully understood, DTIC is believed to be first 
metabolically bioactivated through a series of reactions involving CYP450. Initial 
demethylation to MTIC [3-methyl-(triazen-1-yl)imidazole-4-carboxamide] is followed 
by formation of diazomethane, the active moiety of DTIC and a potent methylating 
agent (9). 
      
DTIC has produced response rates of from 15% to 25% in single-institution trials. 
But the overall response rate has fallen over the years from 15% to 7% and less than 5% 
of responses are complete in phase 3 trials. The median response durations to DTIC are 
5 to 6 months. Long-term follow-up of patients treated with DTIC alone shows that only 
<2% can be anticipated to survive for more than 6 years. In recent phase 3 trials that 
used strict response assessment criteria, the response rates with single-agent DTIC did 
not exceed 12% (10).  
 
Over the past 30 years after its approval by the FDA, DTIC remains the only 
currently used cytotoxic drug for the treatment of metastatic melanoma. Despite its low 
single-agent activity, DTIC has remained the mainstay of many combination 
chemotherapy regimens and evaluations of resistance-reversing agents. After more than 
20 years of research, DTIC is still the standard against which most new chemotherapy 
agents are compared (11). 
 
As for the dose, it has been demonstrated that 850~1000 mg/m2 single dose of 
DTIC is tolerated. This single dose administration appears to deliver clinical 
improvements similar to those observed with multiple doses that provide the same total 
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dose per cycle. This should be the reference standard for randomized trials comparing 
new therapies with DTIC (12).  
 
 
1.2.2 Immunotherapy Agent IL-2 
 
In 1998, the FDA approved intermittent high-dose bolus IL-2 based on its ability 
to mediate durable complete response in metastatic melanoma patients (13). IL-2 is a type 
of cytokine immune system signaling molecule, which is a leukocytotrophic hormone 
that is instrumental in the body's natural response to microbial infection and in 
discriminating between foreign (non-self) and self. It’s a glycosylated 15,500 dalton 
single protein molecule. IL-2 mediates its effects by binding to IL-2 receptors, which are 
expressed by lymphocytes, the cells that are responsible for immunity. It is one of the 
only two FDA approved agents for the treatment of metastatic melanoma. Although the 
overall response rate is only about 15% and less than 5% of patients achieve complete 
remission with IL-2, its performance on melanoma is better than DTIC.  
 
One of the major immunologic effects of IL-2 upon the immune system is to 
expand the total number of T-lymphocytes (CD4+ and CD8+) and to prevent lymphocyte 
apoptosis. Another key role of IL-2 is to provide the appropriate cytokine milieu 
necessary to overcome tumor-induced immune tolerance. But the exact molecular and 
genetic mechanisms involved in this complex interaction between the tumor and the host 
immune response is still largely unknown (14).  
 
There is currently a wide spectrum of dosing schedules and regimens for IL-2 
therapy, with the current standard used by most oncologists being 600,000 to 720,000 
IU/kg/dose, given at 8 h intervals. Although the optimal dosing schedule resulting in the 
best clinical response is currently unknown, previous data would suggest that the higher 
dose regimens as well as the number of total doses received correlates best with clinical 
response. Thus, several groups have begun to look at alternative dosing strategies to 
achieve an increased drug tolerance and tolerability profile, such as the continuous 
infusion of IL-2 (18 mIU/m2/day) over an extended period of 72 h (15). But the 
multiorgan toxicity of many IL-2 regimens limits its use. In addition, the tumor-killing 
cytotoxic T cells and natural killer cells, which are the presumed target cells for IL-2, are 
frequently inefficient in the tumor environment, partly due to suppressive and apoptosis-
inducing signals from tumor-infiltrating mononuclear phagocytes (16). 
 
 
1.3 Recent Research Efforts in the Treatment for Metastatic Melanoma 
 
Because of effective treatment shortage, the prognosis for metastatic melanoma 
patients remains very poor. Over the past 30 years, great efforts have been attempted to 
search for better agents or strategies to fight this deadly disease. Hundreds of different 
stages of clinical trials have been carried out. Although most of them have failed, some 
did show very promising results. Some new treatment strategies have resulted in 
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paradigm shift in our approach to therapy of melanoma patients. These shining examples 
may markedly change our philosophy about melanoma treatment.  
 
 
1.3.1 Chemotherapy 
 
 
1.3.1.1 Temozolomide 
 
Temozolomide (TMZ) is an orally active alkylating agent. It’s a prodrug of MTIC 
and congener of DTIC. It has been available in the US since August 1999 and in other 
countries since the early 2000s. The therapeutic benefit of temozolomide depends on its 
ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions 
of guanine residues. This methylation damages the DNA and triggers the death of tumor 
cells. However, some tumor cells are able to repair this type of DNA damage, and 
therefore diminish the therapeutic efficacy of temozolomide, by expressing an enzyme 
called O-6-methylguanine-DNA methyltransferase (MGMT) or O-6-alkylguanine-DNA 
alkyltransferase (17).  
 
The single agent activity of TMZ in metastatic melanoma has been established in 
several phase 1 and 2 studies (18). In a randomized trial of 305 patients with advanced 
melanoma, TMZ showed efficacy at least equivalent to that of DTIC in terms of objective 
response rate, time to progression, and overall disease-free survival (19). TMZ was 
tolerated very well and showed an advantage in terms of improvement in the quality of 
life. More patients showed improvement or maintenance of physical functioning at Week 
12. That trial excluded patients who had brain metastases. Because the trial design was 
intended to demonstrate the superiority of TMZ over DTIC, rather than equivalence, the 
FDA did not accept the results of that trial as grounds for approving a melanoma 
indication for TMZ. But in clinical practice, patients with metastatic melanoma often are 
treated off-label with TMZ. 
 
TMZ has demonstrated efficacy in the treatment of variety of solid tumors, 
especially in brain malignancies, which is a manifestation of its far greater ability to 
penetrate the central nervous system (CNS). Taking into account the high rate of CNS 
recurrence as a site of failure after cytotoxic chemotherapy, TMZ may represent a viable 
alternative to DTIC, which is ineffective against melanoma CNS metastases. 
 
 
1.3.1.2 Sorafenib 
 
Sorafenib (BAY43-9006, developed by Bayer Pharmaceuticals, West Haven CT, 
trade name Nexavar) is an orally administered tyrosine kinase inhibitor that is a potent 
inhibitor of the B-Raf kinase that is frequently mutated in melanoma, as well as an 
inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor and other kinases. 
It targets the adenosine triphosphate-binding site of the B-Raf kinase and inhibits both 
wild-type and mutant B-Raf in vitro. Sorafenib was approved by the FDA in December 
 5 
 
2005 for use in the treatment of advanced renal cancer. Preclinical studies demonstrated a 
significant retardation in the growth of human melanoma tumor xenografts with 
Sorafenib. In a phase 1 study, the maximum tolerated dose of Sorafenib as a single agent 
was established at 400 mg twice daily, and the most common toxicities were 
gastrointestinal (mainly diarrhea), dermatologic (skin rash, hand-foot syndrome), and 
fatigue (20).  
 
But in further phase 2 clinical trials, Sorafenib had shown relatively little activity 
in metastatic melanoma when using alone. In a phase 2 trial that was conducted in 20 
patients with refractory metastatic melanoma, Sorafenib showed modest activity with 1 
partial response and 3 patients who achieved stable disease (21). In another phase 2, 
randomized, discontinuation trial, no objective responses were achieved, and 19% of 
patients achieved stable disease (22). 
 
Sorafenib combined with other chemotherapy drugs were also tested clinically. 
In a phase 1 and 2 study that combined carboplatin and paclitaxel with escalating doses 
of Sorafenib in 35 patients, a promising response rate of 31% was observed, and 
another 54% of patients experienced stable disease that lasted longer than 3 months. 
That study recently was updated to include 105 patients, and the current response rate is 
27% (23). On this basis, 2 phase 3 trials have been launched to assess the efficacy of 
carboplatin and paclitaxel plus Sorafenib versus placebo in chemotherapy-naive 
patients and in previously treated patients. In December 2006, Bayer reported the 
combinations failed to show significant improvement of progression-free survival in 
melanoma patients (24).  
 
 
1.3.1.3 Other Single Chemotherapy Agents 
 
Cisplatin and carboplatin have shown modest activity as single agents in patients 
with metastatic melanoma. Cisplatin as single-agent therapy induced a 15% response rate 
with a short median duration of 3 months (25). A response rate of 19% has been reported 
in 26 chemotherapy-naive patients with metastatic melanoma who received carboplatin. 
In those patients, there were 5 partial responses, and thrombocytopenia was the dose-
limiting toxicity (26). In vitro studies suggested that oxaliplatin may be more active than 
cisplatin or carboplatin. But a small phase 2 trial in 10 patients who had received and 
failed prior chemotherapy produced no objective responses (27). 
 
The nitrosoureas (carmustine, lomustine, and semustine) induce objective 
responses in 13~18% patients. They can cross the blood-brain barrier. But at 
conventional doses, little or no activity was observed against melanoma brain metastases 
(28). Another drawback of the nitrosureas is they induce prolonged myelosuppression. 
Despite these, they have been included frequently in multi-agent chemotherapy 
combinations, presumably for their ability to penetrate into the CNS and lack of viable 
alternatives for metastatic melanoma. 
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The vinca alkaloids (vindesine and vinblastine) have produced responses in 
approximately 14% of patients (29). The taxanes have produced responses in 16~17% 
patients (30). All of these response rate data were obtained from phase 2 trials. None of 
those drugs have been evaluated as single agents in phase 3 trials. Based on the 
experience with DTIC, it is likely that the phase 3 trial objective response rates would be 
less than the rates reported from phase 2 trials. All of these drugs are rarely used 
currently as single-agent therapy in metastatic melanoma, but they frequently have been 
incorporated into combination chemotherapy and biochemotherapy regimens. 
 
 
1.3.1.4 Chemotherapy Drug Combinations  
 
Theoretically drug combination should be based on laboratory or clinical evidence 
of synergistic effect. But since single-agent chemotherapy regimens only provided 
modest activity against metastatic melanoma and lack of viable alternatives, many 
combination regimens have been evaluated in clinical trials. Initially two-agent 
combinations were tested in which DTIC was combined with a nitrosourea, vinca 
alkaloid, or platinum compound. In most of these trials, only 10~20% response rates were 
observed. There was little evidence to suggest superiority of these combinations 
compared with DTIC treatment alone (31-33).  
 
In order to improve response rates, more aggressive multi-drug combinations 
using 3 or 4 different drugs were also tested clinically. Two most widely studied 
combinations are cisplatin, vinblastine, and DTIC (CVD) and the Dartmouth regimen. 
The later is a 4-drug combination of cisplatin, DTIC, carmustine, and tamoxifen (also 
called CBDT). Both combinations showed improved response rates that ranged from 30% 
to 50% in single-institution phase 2 studies (34, 35). But in further randomized phase 3 
trials which involved more patients, they all showed much lower efficiency: In a 
randomized trial comparing CVD with single-agent DTIC that involved approximately 
150 patients, the CVD arm produced a 19% response rate compared with 14% for the 
DTIC arm, and there was no differences in either response duration or survival. In 
another randomized phase 3 trial, the CDBT combination was compared with single-
agent DTIC. That cooperative group trial involved 240 patients, and the response rate 
was 10% for the DTIC regimen compared with 19% for the CDBT regimen (P=0.09). 
The median survival was 7 months, with no significant difference between the 2 
treatment arms (11).  
 
The main reason for such discrepancies between the findings from single-
institution studies and the findings from large, multicenter, cooperative trials probably is 
selection bias. Differences in performance status, percentages of patients with visceral 
involvement, and number of metastatic sites easily could account for some of the 
observed differences. In fact, all of those factors are known to have an impact on both 
response rate and survival (36). 
 
Overall, controlled trials have produced no compelling evidence to support the 
value of combination chemotherapy, with or without tamoxifen, in patients with 
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metastatic melanoma. Toxicity was substantially greater for the combination regimen, 
with bone marrow suppression, nausea, emesis, and fatigue significantly more frequent 
with CDBT than with DTIC (11). So it is difficult to justify the use of either CVD or 
CBDT instead of single-agent DTIC or TMZ for the treatment of most patients with 
metastatic melanoma. 
 
 
1.3.2 Immunotherapy 
 
 
1.3.2.1 Interferon α 
 
Interferons (IFNs) are proteins made and released by the cells of most vertebrates 
in response to the presence of pathogens or tumor cells. They allow communication 
between cells to trigger the protective defenses of the immune system that eradicate 
pathogens or tumors. IFNs belong to the large class of glycoproteins known as cytokines. 
They are named after their ability to "interfere" with viral replication within host cells. 
IFNs have other functions: they activate immune cells, such as natural killer cells and 
macrophages; they increase recognition of infection or tumor cells by up-regulating 
antigen presentation to T lymphocytes; and they increase the ability of uninfected host 
cells to resist new infection by virus.  
 
Based on the type of receptor through which they signal, human interferons have 
been classified into three major types. The type I interferons present in human are IFN-α, 
IFN-β and IFN-ω (37). High-dose IFN therapy using IFN-α was the first form of medical 
therapy to be approved by the FDA for use in high-risk melanoma in the adjuvant setting. 
Adjuvant normally means using IFN- α weeks after the surgical excision of the 
melanoma tumor. Common treatment scheme is IFN-α2b at 20 million units 
(MU)/m2/day intravenous injection 5 days a week for 4 weeks, then 10 MU/m2/day 
subcutaneous injection 3 days a week for the next 48 weeks for a full year’s. But IFN-α2b 
can also be used one month before definitive surgical lymphadenectomy. This is called 
‘neoadjuvant’ treatment (38).  
 
The first randomized comparison of high-dose IFN versus observation found the 
median relapse-free survival was 1.72 years in the high-dose IFN arm versus 0.98 year in 
the observation arm (P=0.0023) and the median overall survival was 3.82 versus 2.78 
years (P=0.0237) respectively (39). But in a later pooled analysis of more patients in 
more clinical trials, the relapse-free survival benefit was maintained but no overall 
survival benefit was seen (40). 
 
The exact mechanism of IFN IFN-α’s anti-tumor efficacy is still unknown. But it 
was found that the STAT1/STAT3 expression ratios rose in association with IFN 
treatment. The clinical effects of IFN-α2b in human melanoma are also found to be 
inversely related to STAT3 expression (41). Induction of apoptosis has been shown to be 
important in vitro, if not in vivo. IFN-α can induce apoptosis in transformed cell lines as 
well as primary tumor cells (42). 
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High-dose IFN is the standard of care for high-risk melanoma patients in the 
adjuvant setting. However, it is associated with significant toxicity. The incidence and 
severity of these adverse events is clearly dose-related. Consequently, there has been a 
great deal of interest in intermediate- and low-dose regimens administered through 
subcutaneous injection. However, none of the trials using intermediate or low dosing so 
far have been able to demonstrate any reliable benefit in terms of relapse-free survival or 
overall survival (43). 
 
 
1.3.2.2 Anti-CTLA4 Antibodies: Ipilimumab and Tremelimumab 
 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) also known as CD152 (Cluster of 
differentiation 152) is a member of the immunoglobulin super family, which is expressed 
on the surface of Helper T cells and transmits an inhibitory signal to T cells that 
eventually shuts off the activated state. The rationale for involving this in treatment of 
metastatic melanoma is to block the negative signal sending by CTLA4 by using anti-
CTLA4 antibodies, thus reduce the sensitivity of activated T cells to negative regulatory 
signals and enhance the immune response of the host to tumor cells.   
 
As of October 2007 there are two fully human monoclonal anti-CTLA4 
antibodies in advanced clinical trials, one from Medarex, Inc. (Princeton, NJ) and Bristol-
Myers Squibb (New York), called ipilimumab (MDX-010), and one from Pfizer (New 
York), called tremelimumab (formerly ticilimumab, CP-675,206) (44). These antibodies 
were produced using different types of mice with engineered immune systems, and are 
thus fully human, with long half-lives of 2– 4 weeks. 
 
Ipilimumab (MDX-010) is an IgG1 monoclonal antibody. Preclinical and early 
clinical studies of patients with metastatic melanoma show that ipilimumab promotes 
antitumor activity as monotherapy and in combination with treatments such as 
chemotherapy, vaccines, or cytokines. The initial success with these antibodies has 
encouraged the rapid development of new agonistic and antagonistic antibodies that alter 
immune regulation, such as anti-PD-1, anti-4-1BB, anti-CD40, and anti-OX-40. On 
December 10, 2007, Bristol-Myers Squibb and Medarex released the results of three 
studies on ipilimumab (44). The three studies tested 487 patients with metastatic 
melanoma. Short-term tumor progression prior to delayed regression has been observed 
in ipilimumab-treated patients, and objective responses may be of prolonged duration. In 
some patients clinical improvement manifests as stable disease, which may also extend 
for months or years. One of the three studies failed to meet its primary goal of shrinking 
tumors in at least 10% of the study's 155 patients. Overall the medication produced 
weaker-than-anticipated efficacy on melanoma patients.  
 
In the meantime, the side effect profile was high in the ipilimumab treated group, 
with the generation of autoimmune-like effects, such as diarrhea, dermatitis and effects 
upon the thyroid and pituitary glands. Several patients also experienced vitiligo, 
indicative of anti-melanocyte autoimmunity. However, the majority of the side effects 
were noted to be transient (except the vitiligo), improving or disappearing after the 
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completion of therapy. Early clinical data suggest a correlation between these side effects 
and response to ipilimumab treatment and most likely reflect the drug mechanism of 
action and corresponding effects on the immune system (44).  
 
Tremelimumab is an IgG2 monoclonal antibody produced by Pfizer. It blocks the 
binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4, resulting in 
inhibition of B7-CTLA-4-mediated down-regulation of T-cell activation. Subsequently, 
B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in 
a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition. 
Tremelimumab is thought to stimulate patients’ immune systems to attack their tumors. It 
has been shown to induce durable tumor responses in patients with metastatic melanoma 
in phase 1 and phase 2 clinical studies (45). 
 
On April 2, 2008, Pfizer announced that it has discontinued a phase 3 clinical trial 
for patients with metastatic melanoma after the review of interim data showed that the 
trial would not demonstrate superiority to standard chemotherapy (46). Studies for other 
tumors are planned as of October 2009, namely for prostate cancer and bladder cancer.  
 
 
1.3.2.3 Anti-Integrin Antibody: Etaracizumab 
 
Etaracizumab (also known as etaratuzumab, MEDI-522, trade name Abegrin) is 
an IgG1 humanized monoclonal antibody directed against the αVβ3 integrin. αVβ3 is 
essential for endothelial cell proliferation, maturation, and survival. When it is blocked, 
proliferating endothelial cells undergo apoptosis and regress. In addition, αVβ3 is highly 
expressed in melanomas and is associated with tumor growth and invasion. In preclinical 
studies using αVβ3 antagonists, inhibition of melanoma tumor growth independent of its 
antiangiogenic effects was reported (47). Etaracizumab has been investigated in 3 phase 1, 
dose-escalation studies in patients with refractory melanoma. In the phase 2 trial, 57 
patients received etaracizumab alone, and 55 patients received etaracizumab plus DTIC. 
Etaracizumab with or without DTIC generally was well tolerated and was active in 
patients with metastatic melanoma. The median survival was 12.6 months for the group 
that received etaracizumab with DTIC and 9.4 months for the group that received 
etaracizumab without DTIC (48). These results encouraged people to further test this 
antibody in more clinical trials.  
  
Early 2010, a study by the Etaracizumab Melanoma Study Group was reported. In 
this study, 112 patients were randomized to receive etaracizumab alone or etaracizumab 
plus DTIC. None of the patients in the etaracizumab alone study arm and 12.7% of 
patients in the etaracizumab plus DTIC study arm achieved an objective response. Stable 
disease occurred in 45.6% of patients in the etaracizumab alone study arm and 40.0% of 
patients in the etaracizumab plus DTIC study arm. Despite a modest increase in survival, 
12.6 months in the etaracizumab alone arm, versus 9.4 months in the etaracizumab plus 
DTIC arm, the researchers concluded that the survival results in both treatment arms of 
this study were considered unlikely to result in clinically meaningful improvement over 
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DTIC alone (49). At the present time, clinical development of etaracizumab has been 
interrupted 
 
 
1.3.2.4 Vaccines Based on Tumor Cells: Canvaxin, Melacine, and MVax 
 
The basic idea is to use tumor cell-based vaccine to stimulate and activate the host 
immune system to recognize, contain and eliminate cancer cells. This effect may be 
based on the following two pathways: direct migration of the tumor cells to the draining 
lymph node basin after injection, or uptaking of apoptotic or necrotic tumor cells by host 
dentritic cells located within the skin (50).  
 
The most extensively studied tumor cell-based vaccine is a polyvalent, antigen-
rich whole cell vaccine called Canvaxin (CancerVax Corp., Carlsbad, CA). It is 
comprised of three melanoma cell lines that contain over 20 immunogenic melanoma 
tumor antigens, given intradermally every two weeks for 3 to 5 doses, followed by 
monthly injections for the remainder of the first year. However, several small, single-
institution phase 1 and 2 clinical trials of Canvaxin have not yielded a striking clinical 
benefit in most patients when administered with BCG as an immunoadjuvant (51). But 
the rare complete responder to Canvaxin therapy has prompted the initiation of two 
multicenter phase 3 randomized trials of Canvaxin therapy in 1998. In these trials, 
patients who have undergone complete resection of regional (stage III) or distant (stage 
IV) metastatic melanoma receive postoperative adjuvant immunotherapy with Canvaxin 
plus Bacillus of Calmette and Guerin (BCG) or BCG alone. In April 2005, CancerVax 
announced the discontinuation of their phase 3 clinical trial of Canvaxin in patients with 
Stage IV melanoma based upon the clinical funding that it was unlikely that the trial 
would provide significant evidence of a survival benefit for Canvaxin-treated patients 
versus those receiving placebo. On October 3, 2005, CancerVax announced the 
discontinuation of another phase 3 clinical trial of Canvaxin in patients with Stage III 
melanoma base on the similar reason (52).  
 
The second tumor cell-based vaccine that has been well studied since 1988 is 
Melacine. It is an allogeneic melanoma cell lysate combined with an immunologic 
adjuvant which is composed of a mixture of detoxified endotoxin, cell wall cytoskeleton 
and monophosphoryl lipid A. Early phase 1 and 2 clinical trials in 1987 and 1988 
revealed some promising results, with one complete and three partial responses seen in 25 
patients treated with Melacine. These results prompted the completion of seven open-
label phase 2 trials involving 139 patients with stage III/IV melanoma and a multicenter 
phase 3 clinical trial of Melacine versus the Dartmouth regimen. The objective response 
rates for all of the above studies have been between 5 and 10%. Based largely upon these 
former results and the clinical results of other phase 3 trials, a phase 3 observation 
controlled trial of Melacine in melanoma patients was conducted. But the results revealed 
no evidence of a benefit from Melacine in patients with melanoma (53). 
 
One very promising autologous cell vaccine is MVax which is now in active 
phase 3 clinical trial sponsored by AVAX Technologies, Inc. This vaccine is derived 
from autologous tumor cells that have been irradiated and then modified with the hapten 
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dinitrophenyl (DNP) (54). In February 2004 the Journal of Clinical Oncology published 
an article by Dr. David Berd on the treatment of 214 Stage IIIb and IIIc melanoma 
patients that showed a five-year survival rate of 44%. Comparison to published results of 
similar patients treated with surgery alone showed five-year survival figures of 22%. In 
stage IV patients MVax has demonstrated significant response rates as a monotherapy 
and in published reports MVax plus adjuvant IL-2 have reported response rate of 35% 
(13% Complete Response, 22% Partial Response). This compares to published response 
rates in low dose IL-2 of 3% (55).  
 
In October 2006, AVAX obtained a Special Protocol Assessment (SPA) 
agreement with the FDA for its phase 3 protocol. The SPA allows for the start of the 
phase 3 registration clinical trial for MVax for the treatment of patients with metastatic 
melanoma. In addition, the SPA addressed AVAX’s ability to use a surrogate endpoint as 
a basis for accelerated approval.  Based on this SPA, a phase 3 trial for stage IV 
melanoma was started on May 2007. AVAX plans to enroll up to 387 patients who will 
be assigned in a double-blind fashion at a 2:1 ratio to MVax or placebo vaccine. The 
MVax arm will consist of an initial dose of MVax followed by cyclophosphamide and 
then six weekly doses of MVax administered with BCG. Following vaccine 
administration patients will receive a specific schedule of low dose IL-2. Patients 
assigned to the control group will receive a treatment identical to the MVax group, except 
that a placebo vaccine will replace MVax. The primary endpoints of the study are best 
overall anti-tumor response rate and the percentage of patients surviving at least 2 years. 
Secondary endpoints of the study will include overall survival time, response duration, 
percentage complete and partial responses, progression free survival and treatment 
related adverse events (56). 
 
 
1.3.2.5 Vaccines Based on Peptides: MDX-1379, Astuprotimut-R, and Others 
 
The identification of tumor antigens that are present on the surface of melanoma 
cells is the basis for developing cancer vaccines that utilize peptide based immunotherapy. 
There are several melanoma differentiation antigens known involved in the synthesis of 
melanin and recognized by melanoma-reactive T cells, for example, gp100, MART-
1/Melan-A, tyrosinase, TRP-1 and TRP-2, NY-ESO-1and the melanoma-associated 
antigen (MAGE) etc. One big advantage of peptide based-vaccination is that it has few 
toxic side effects or adverse reactions. Data suggests that most tumor cell lines 
established from fine needle aspiration biopsies of patients with metastatic melanoma 
exhibit a relatively homogeneous co-expression of MART-1 and tyrosinase, with a much 
more heterogeneous expression of other tumor antigens, such as gp100, NY-ESO 1 and 
the MAGE antigens (57).  
 
Rosenberg and his colleagues developed a with a peptide based-vaccine using 
modified immunodominant peptide of the gp100 antigen, g209-2M. They used this agent 
vaccinated stage IV melanoma patients subcutaneously every three weeks. Following two 
immunizations, 10 of 11 (91%) of patients showed a consistently high level of 
immunization against the native g209~217 peptide, but not against the control peptide 
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g280~288. This study also demonstrated that the majority of patients immunized with the 
g209-2M peptide in incomplete Freund’s adjuvant (IFA) consistently developed high 
levels of circulating immune precursors reactive against the native g209~217 peptide. 
Clinically, one of nine patients who received the g209~217 peptide in IFA experienced 
an objective cancer regression that lasted 4 months. Three of the eleven patients exhibited 
mixed responses with complete or partial regression of several lesions. However, all 
patients eventually developed progressive disease (58). 
 
MDX-1379 vaccine consists of two gp100 melanoma peptides. These peptides are 
part of a protein normally found on melanocytes, or pigmented skin cells, and on 
melanoma cells. These melanoma peptides are recognized by cytotoxic T cells in 
melanoma patients that are positive for HLA-A2, a human immune system compatibility 
antigen that is expressed in approximately half of the melanoma population. Phase II data 
show limited evidence of MDX-1379's clinical activity although there is strong proof-of-
concept for therapeutic vaccines based on gp100 in melanoma. Medarex is currently 
conducting a phase 3 clinical trial with ipilimumab and MDX-1379 combination therapy 
in stage III and IV melanoma at multiple sites within the United States. Preliminary data 
showed MDX-1379 plus ipilimumab induced a modest percentage of durable response in 
stage IV melanoma. But autoimmune events could make the risk/benefit ratio for MDX-
1379 plus ipilimumab unfavorable (59). 
 
Astuprotimut-R (also called recombinant MAGE-A3 antigen-specific cancer 
immunotherapeutic GSK1203486A) is a cancer vaccine consisting of a recombinant form 
of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with 
potential immunostimulatory and antineoplastic activities. Upon administration, 
astuprotimut-R may stimulate a cytotoxic T-lymphocyte response against tumor cells 
expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumor-
associated antigen (TAA) originally discovered in melanoma cells, is expressed by 
various tumor types including melanoma, non-small cell lung cancer, head and neck 
cancer, bladder cancer, with no expression in normal cells. MAGE-A3 protein has been 
in-licensed by GlaxoSmithKline (GSK) from the Ludwig Institute for Cancer 
Research. The proprietary immunostimulating adjuvant in this agent is composed of a 
specific combination of immunostimulating compounds selected to increase the anti-
tumor immune response to MAGE-A3. Using this vaccine as intramuscular 
administration together with GSK’s two proprietary adjuvant systems, AS15 or AS02B, 
they have developed a treatment regimen for cancer patients called Antigen-Specific 
Cancer Immunotherapeutic (ASCI).  
 
In 2008, GSK reported a randomized, open-label phase 2 study designed to 
evaluate Astuprotimut-R. A total of 72 patients with measurable metastatic MAGE-A3-
positive cutaneous melanoma (unresectable or in transit stage III or stage IV M1a) were 
randomized to receive immunization with MAGE-A3 protein combined with either AS15 
or AS02B as first-line metastatic treatment. Patients were to receive a maximum of 24 
immunizations over four years. Clinical activity is assessed by the Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria, the international standards for evaluation of 
solid tumors.  Complete response (CR) and partial response (PR) i.e., disappearance or 
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significant reduction of tumor, were reported in 4 patients in the AS15 group (3 CR and 1 
PR) with two of these ongoing for more than two years; in the AS02B arm, 1 patient 
showed a partial response which lasted for 6 months. The safety profile was similar in 
both groups with the majority of  reported adverse events being mild or moderate local or 
systemic reactions (60). Currently this agent still is under phase 2 clinical development 
for progressive metastatic cutaneous melanoma. 
 
Because melanoma tumors are heterogeneous in their antigenic profile, it is very 
difficult to make vaccines that can elicit cytotoxic T-cell responses universally in all the 
host immune systems. Rosenberg’s group analyzed 28 different peptide-based vaccines 
utilized in stage IV melanoma patients. A total of 381 patients were treated with 370 
patients showing no response, 9 patients showing a partial response and 2 patients with a 
complete response, for an overall objective response rate of only 2.9%. This suggested 
the lack of effectiveness with this single peptide based vaccination approach (61).  
 
Next logical step is to make vaccines with multiple peptides to overcome tumor 
cell antigenic heterogeneity. A recent randomized phase 2 trial was performed in 26 
patients with metastatic melanoma, vaccinating with four melanoma peptides. Although a 
high level of specific T-cell responses were noted (in 42% of the peripheral blood, 80% 
of sentinel lymph nodes), only three patients had a clinical response (62).  
 
Here is the biggest issue in this area, actually many peptide based-vaccinations 
have resulted in a significant increase in the number of lymphocyte precursors reactive 
against a variety of tumor differentiation antigens by immunization with native or 
modified peptides. However, such immunological responses to peptide-based therapy 
have not translated into meaningful clinical responses for the vast majority of patients. To 
date, there is no study that has clearly shown a direct correlation between an 
immunologic response to therapy (immune cell activation) and a clinical response 
(regression of established tumor). 
 
 
1.3.2.6 Vaccines Based on Dendritic Cells  
 
In the normal human epidermis and dermis, dendritic cells (DC) are present as 
relatively immature antigen presenting cells, exhibiting relatively low levels of class II 
major histocompatibility complex (MHC) molecules and co-stimulatory molecules. But 
these immature DC are quite capable of capturing various soluble protein antigens, such 
as apoptotic and necrotic tumor cells and then cross-presenting such tumor-associated 
antigens to cytotoxic CD8+ T cells. When relatively immature DC in the skin is triggered 
to enter afferent lymphatic channels, this migrating pathway also initiates a phenotypic 
conversion that has profound immunological consequences [30]. When the DC arrives in 
the lymph node, it is characterized by an abundant levels of class II MHC antigens, as 
well as high surface levels of costimulatory molecules, such as CD40, CD54, CD80, 
CD83, and CD86. The matured DC is then capable of forming stable MHC class II-
peptide complexes available to activate antigen specific CD4+ T cells (63). 
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To make the dendritic cell-based vaccine, the monocyte-derived, autologous DC 
can be pulsed in vitro with either whole irradiated, autologous tumor cells or tumor cell 
lysate. Once the tumor cells are “fed” to the DC in vitro, the apoptotic or necrotic cells 
are then processed and tumor-specific peptide antigens are then transported to the surface 
in both an MHC class I- and II-restricted fashion. Both immature and mature DC can be 
administered to patients as vaccine safely with few adverse side effects. The 
administration of DC via various routes of vaccination (intradermal, intranodal and 
intravenous) is also feasible. The first published clinical trial of DC vaccination was in 
1995 and has since been followed by 98 additional clinical trials describing more than 
1,000 DC-based vaccines performed in 15 different countries. Twenty-eight trials focused 
on patients with various advanced stages of melanoma. The safety profile was again 
noted to be quite remarkable, however, despite the treatment of over 1,000 patients with 
DC-based vaccines, the record of effectiveness have been disappointing (64). 
 
One pretty successful DC-based trial for patients with advanced, metastatic 
melanoma was reported by Nestle et al. He used plastic adherent monocytes matured 
with a xenogenic-based 10% fetal calf serum, subsequently pulsed with either tumor cell 
lysate or multiple HLA-matched peptides injected intranodally. This trial involved 16 
patients who were immunized on an outpatient basis. Overall, 5 of 16 patients 
experienced an objective response, 2 complete and 3 partial responses. The side effects 
were noted to be minimal in all cases, with the development of vitiligo in a few patients. 
One dramatic feature of this treatment was the durability of the clinical responses, with 
the 2 complete responders remaining free of disease for over 15 months (65). 
 
One phase 3 clinical trial about using DC-based vaccine to treat metastatic 
melanoma was report by Schadendorf and colleagues recently. The trial was a 
prospective, randomized trial that analyzed the therapeutic effects of an autologous 
peptide-pulsed DC-based vaccine in patients with stage IV melanoma compared to 
standard chemotherapy with DTIC alone. The results revealed that the overall response in 
the vaccine group was 3.8% compared to 5.5% in the DTIC group, with no statistically 
significant differences noted in response, toxicity, overall and progression-free survival 
between the two groups. The median time to progression was 2.8 months versus 3.2 
months respectively and the median survival was 11 months for the DTIC arm but only 9 
months for the vaccine arm (66).  
 
Although disappointed by many trials, several new avenues of DC-based 
immunotherapy are actively being pursued and in various stages of development, 
focusing on different ways to enhance the therapeutic efficacy of DC in combination with 
various immunoadjuvants and other anticancer agents. 
 
 
1.3.2.7 Individual Therapy Based on Activated T-Cells  
 
One very promising approach to treat metastatic melanoma is to use fully 
activated anti-tumor T-cells as warhead. This regimen involves the adoptive autologous 
transfer of highly selective tumor-reactive T-cells directed against over-expressed self-
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derived differentiation antigens after lymphodepleting chemotherapy. Rosenberg group 
reported in 2004 a clinical trial using this method. Cancer regression in patients with 
refractory metastatic melanoma with large, vascularized tumors was noted in a 
remarkable 18 of 35 patients (51% response rate), including four patients with a complete 
regression of all metastatic disease. Such results may stem from the ability to infuse a 
large number of fully activated tumor infiltrating lymphocytes with anti-tumor activity 
into a host that is depleted of regulatory T-cells (67). 
 
 
1.3.3 Gene Therapy 
 
The recent developments in the field of gene transfer have advanced the use of 
gene therapy as a novel strategy against a variety of human malignancies. Because of its 
unique set of characteristics, melanoma represents a suitable target for gene therapy. 
Several strategies have been used by gene therapy to treat melanoma. First is to target 
melanoma cells to introduce "suicide" genes. Second is to transfer tumor suppressor 
genes. Third is to inactivate aberrant oncogene expression. Fourth is to introduce genes 
encoding immunologically relevant molecules. Last is to target the host's immune cells to 
redirect immune responses against melanoma. Clinical trials have shown the feasibility 
and safety of gene therapy against malignant melanoma. Although no major successes 
have been reported, the positive results observed in some patients support the potential 
for gene therapy in the management of this disease. To make gene therapy as an effective 
modality of treatment for malignant melanoma, better vector technology as well as 
increased understanding of the "bystander effect" triggered by gene transfer approaches 
are needed (68).  
 
The gene therapy in our discussion is to introduce oligonucleotide or DNA 
sequence into host body thus to stimulate immune response to tumor cells. So it is also 
called DNA vaccination. This approach has been shown to induce long-lasting immunity 
against infectious agents and protection from tumor outgrowth in several animal models 
(69). Likewise, intramuscular injections of DNA (composed of naked DNA expression 
plasmids) into humans have also resulted in the development of an immunologic response 
(70). It is hypothesized that one mechanism of tumor antigen expression may involve the 
DNA introducing the appropriate genes into dendritic cells for subsequent processing and 
presentation to the host immune system. One of the obvious advantages of DNA 
vaccinations is that they can be administered to patients regardless of HLA-phenotype 
and without identifying immunogenic epitopes. 
 
 
1.3.3.1 Anti-BCL2 Antisense Oligonucleotide Genasense 
 
Genasense (Oblimersan sodium developed by Genta Inc. which is a 
biopharmaceutical company based in Berkeley Heights, New Jersey) is a 
phosphorothioate antisense oligonucleotide directed against the first six codons of the 
Bcl-2 messenger RNA. Binding of the drug to the mRNA recruits RNAse H, resulting in 
cleavage of the mRNA. As a result, further translation is halted and intracellular protein 
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concentrations of Bcl-2 decrease with time. Melanoma cell lines having Bcl-2 
overexpression have been shown to enhance activity of metastasis-related proteinases, in 
vitro cell invasion, and in vivo tumor growth (71). Many in vitro studies have 
demonstrated increased sensitivity of melanoma cells to chemotherapy when combined 
with antisense Bcl-2 therapy (72). Genasense is the first oncology drug of its kind to 
directly target the biochemical pathway (known as apoptosis) whereby cancer cells are 
ultimately killed by chemotherapy. Genasense is believed to inhibit the production of 
Bcl-2, a protein that is believed to be a fundamental cause of resistance to anticancer 
therapy. By inhibiting Bcl-2, Genasense may greatly improve the activity of anticancer 
therapy. 
 
Encouraged by previous data, numerous clinical trials were started to evaluate the 
addition of oblimersan to chemotherapy in various solid tumors, including melanoma. 
Updated analysis from a randomized phase 3 trial, comparing DTIC combined with 
oblimersan, with DTIC alone in 771 patients with Stage IV or unresectable Stage III 
melanoma who had not previously received chemotherapy has shown a response rate of 
12.4% in the former compared with 6.8% in the latter group (P=0.007) (73). Median 
progression-free survival for the oblimersan group was 2.4 months as compared with 1.6 
months for the DTIC group, with a relative risk reduction of 27% (P=0.0003). The 
median survival was increased from 7.8 months in the DTIC arm to 9 months in the 
oblimersan arm with a P value of 0.077, which became significant when the patients with 
normal baseline LDH were analyzed. In terms of toxicity, no new or unexpected adverse 
events were observed in this study, which had not been seen with DTIC alone. 
 
However, in May 2004, a new drug application (NDA) based on 6-months of 
minimum follow-up data from this trial failed to receive an affirmative vote for approval 
by an advisory committee to the FDA. Genta subsequently withdrew that application, and 
the Company has not yet made a decision regarding re-filing the U.S. application (74).  
 
 
1.3.3.2 DNA Plasmid-Lipid Complex Allovectin-7 
 
Allovectin-7 is a bicistronic plasmid formulated with a cationic lipid system 
containing the DNA sequences encoding HLA-B7 and beta-2 microglobulin, which 
together form a MHC1 antigen. Injection of Allovectin-7 directly into tumors is designed 
to stimulate an immune response against both local and distant metastatic tumors. 
Allovectin-7 is a novel gene therapy approach for cancer with a unique mechanism of 
action that is fundamentally different from currently approved treatments. The following 
three mechanisms were believed to play roles in this agent’s efficacy. Mechanism one, in 
HLA-B7 negative patients, a vigorous allogeneic immune response may be initiated 
against the foreign MHC class I antigen. Mechanism two, in all patients, ß2 
microglobulin may reconstitute normal class I antigen presentation and/or increase tumor 
antigen presentation to the immune system. Mechanism three, in some patients, an innate 
pro-inflammatory response may occur that induces tumor responses following 
intralesional injection of the DNA/lipid complex. The final outcome of all these 
mechanisms is to initially cause recognition of the tumor at the local site to allow a then 
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sensitized immune response to recognize un-injected tumors at distant metastatic sites 
(75). 
 
In 2001, Dr. Richards and his colleagues began a high-dose, 2 mg, phase 2 trial 
evaluating the Allovectin-7 immunotherapeutic alone for patients with stage III or stage 
IV melanoma, who have few other treatment options. The high-dose phase 2 trial 
completed enrollment in 2003. The data showed that the trial had a total of 15 responders 
among the 127 patients receiving the high dose (11.8%), with four of the patients having 
complete responses and 11 having partial responses. The Kaplan-Meier estimated median 
duration of response was 13.8 months. The Kaplan-Meier median survival was 18 months. 
The safety profile was excellent with no reported Grade 3 or Grade 4 adverse events 
associated with Allovectin-7 (76). 
 
Allovectin-7 has been granted orphan drug designation for the treatment of 
invasive and metastatic melanoma by the FDA’s Office of Orphan Products Development. 
Orphan drug designation provides U.S. marketing exclusivity for seven years if 
marketing approval is received from the FDA 
 
Vical is conducting the AIMM (Allovectin-7 Immunotherapeutic for Metastatic 
Melanoma) trial, a phase 3 pivotal trial of  Allovectin-7 as first-line therapy in 
approximately 375 patients with Stage III or IV recurrent metastatic melanoma in 
accordance with a SPA agreement completed with the FDA. The trial is being conducted 
at approximately 60 clinical sites worldwide. They designed the trial to include patients 
most likely to benefit from our treatment, and specifically excluded patients with brain or 
liver metastases, patients previously treated with chemotherapy, and patients with 
elevated lactate dehydrogenase (LDH) levels. 
 
In January 2010 Vical announced that the company has completed enrollment of 
the planned 375 subjects in its multinational phase 3 trial of Allovectin-7 in patients with 
metastatic melanoma. Allovectin-7®’s safety profile is excellent with no drug-related 
serious adverse events reported to date in the phase 3 trial (75). 
 
 
1.3.3.3 Herpes Simplex Virus Based OncoVEX 
 
OncoVEX (GM-CSF) is an enhanced potency, immuneenhanced oncolytic herpes 
simplex virus type 1 (HSV-1). It is deleted for infected-cell protein gene 34.5 (ICP34.5), 
providing tumor selective replication, and ICP47 gene which otherwise blocks antigen 
presentation. In addition, ICP47 deletion increases unique short region protein 11 (US11) 
gene expression thereby enhancing virus growth and replication in tumor cells. The 
coding sequence for human granulocyte-macrophage colony-stimulating factor (GM-CSF) 
is inserted, replacing ICP34.5, to enhance the immune response to tumor antigens 
released following virus replication. 
 
OncoVEX is developed by BioVex (Woburn, MA). It is a first-in-class oncolytic, 
or cancer destroying virus, that works by replicating and spreading within solid tumors 
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(leaving healthy cells unaffected), thereby causing cancer cell death and stimulating the 
immune system to destroy un-injected metastatic deposits. Both modes of action have 
been clearly validated in the clinic, where multiple patients with metastatic disease 
progressing at enrollment have been declared disease free. 
 
BioVex recently concluded a 50-patient phase 2 trial for OncoVEX (GM-CSF) as 
a stand-alone therapy in patients with Stage IIIc and Stage IV melanoma. The trial was 
designed to measure overall objective response, which is defined as a complete response, 
where disease is completely eliminated, or partial response, where there is a >50% 
reduction in disease burden. 74% of patients who entered the study were progressing after 
having failed prior therapy. 13 objective systemic responses (26% objective response rate) 
were achieved including eight CRs, seven of which remain free of disease. 12 responses 
have so far continued for more than 6 months (ranging from 6 to more than 29 months). 
Responses were observed in patients with all stages of disease, including the complete 
resolution of un-injected visceral deposits. Adverse effects were primarily limited to 
transient flu-like symptoms (77). 
 
In April 2009, BioVex Inc. announced that its OPTiM (OncoVEX Pivotal Trial in 
Melanoma) phase 3 study with OncoVEX (GM-CSF) in previously treated patients with 
Stage III and Stage IV melanoma had initiated. The study has commenced recruiting 
patients in the U.S. and with sites in the United Kingdom, Germany and Australia. The 
OPTiM trial is a multi-national, open label, randomized study designed to assess the 
efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to 
subcutaneously administered GM-CSF in patients with unresectable stage III (b-c) and 
stage IV (M1a-c) disease. Patients will have received at least one prior therapy for active 
disease which includes any type of therapy including investigational drugs. A total of 360 
patients will be enrolled (240 to the OncoVEX (GM-CSF) arm and 120 to the control 
arm). The study design was agreed with the FDA under the special protocol assessment 
process (78). 
 
 
1.4 Possible Reasons for Failure 
 
Despite an epic number of clinical trials to test a wide variety of anticancer 
strategies, the average survival rate for patients with metastatic melanoma remains 
unimproved during the past 30 years (41). Though constant clinical trials effort, although 
some approaches showed promising intermediate results, still no any agents for 
approaches have been granted a FDA approval for the treatment of metastatic melanoma. 
There are several reasons that may be accountable for the extremely high resistance of 
metastatic melanoma to current treatment modalities.  
 
 
1.4.1 Reasons for Chemotherapy Failure 
 
Melanoma cells are quite resistant to most chemotherapy reagents. This is 
associated with the specific feature of melanoma cells. In nature, these cells have low 
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levels of spontaneous apoptosis in vivo compared with other tumor cell types, and they 
are relatively resistant to drug-induced apoptosis in vitro (4). The natural role of 
melanocytes is to protect inner organs from UV light, a potent DNA damaging agent. 
Therefore, it is not surprising that melanoma cells may have special DNA damage repair 
systems and enhanced survival properties (79). Moreover, recent studies showed that, 
during melanoma progression, it acquired complex genetic alterations that led to 
hyperactivation of efflux pumps, detoxification enzymes, and a multifactorial alteration 
of survival and apoptotic pathways. All these have been proposed to mediate the multi-
drug resistant phenotype of melanoma (80).  
 
 
1.4.2 Barriers for Successful Immunotherapy 
 
The major barrier is immunosuppressive effects activated by tumors. Tumor cell 
can escape immune rejection and induce immunosuppression through the following five 
major paths. Firstly, tumor cells may lose or down-regulate either the melanoma 
associated antigens or MHC molecules. Secondly, tumor cells may produce a plethora of 
immunosuppressive factors such as interleukin-10, VEGF and transforming growth factor. 
These factors create an inherently unfavorable microenvironment that limits the host 
immune response, in addition to tolerating the T-cell response to established tumor. Third 
possible reason is intrinsic inefficiency of DC whereby the appropriate co-stimulatory 
molecules are not being presented on the cell surface. Fourth possible reason is tumor-
related alterations in T-cell signaling and a skewing of the immune response from a Th1 
(immunoactivating) to a Th2 response (immunotolerant).  Lastly, the concept of tumor 
cell escape and immune tolerance is an exceedingly complex process. We need to further 
understand these mechanisms before we can have successful immunotherapy to 
melanoma (14). 
 
Specifically for cancer vaccines, there are some further barriers. First is the 
characterization of vaccines potency and toxicity. This is especially important in the 
transition from phase 2 to phase 3 trials. To select a meaningful and validated end point 
for trials is a big challenge most of the time. Second barrier is selection of the maximum 
tolerated dose of cancer vaccine, particularly compared with traditional anticancer agents. 
Cancer vaccines are typically not very toxic. So the optimum dose often has to be based 
on the immune response of patients. But if the patients have previously been heavily 
treated with other anticancer agents, this can lead to a compromised immune system that 
makes it difficult to detect an evoked immune response. The third barrier is appropriate 
trial design and statistical data process. This is also a key part and can substantially affect 
final trial outcome (54).    
 
 
1.5 Future Directions 
 
With the rapidly rising incidence and the high resistance to current therapeutic 
agents, developing more effective drugs for metastatic melanoma is urgently needed. But 
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before we can thoroughly understand all the major molecular pathological changes 
associated with melanoma malignancy, it is very difficult to reach a cure for it.  
 
Melanoma is an extremely complicated disease, with many gene mutation and 
signaling pathway changes. Elevated signaling pathway in melanoma including mitogen-
activated protein kinase (MAPK) pathway, phosphatidylinositol 3 kinase (PI3K)-AKT 
pathway, Wnt-Frizzled-β-catenin pathway, JAK/Stat pathway and α-MSH-MC1R or 
microphthalmia-associated transcription factor (MITF) pathway. The first two are crucial 
pathway accounting for melanoma malignance. Gene mutation involved in melanoma 
including the following oncogenes: B-raf, N-ras, akt3; tumor suppressors: CDKN2A, 
PTEN, p53, APAF-1, p16, p15, p19; others: Cyclin D1, MITF etc (81).  
 
The binding of growth factors to their respective receptors leads to activation of 
RAS proteins. Ras will then activate Raf. Raf activate mitogen-activated protein kinase 
(MEK), which then act on extracellular-related kinase (ERK). Phosporylated ERK 
kinases (ERK-P) translocate to the nucleus and activate transcription factors, which 
promote cell cycle progression and proliferation. The PI3K-AKT pathway mediates cell 
survival signaling via growth factors. Phosphatase and tensin homolog (PTEN) inhibits 
growth factor signaling by inactivating phosphatidylinositol triphosphate (PIP3) 
generated by PI3K. Activated PI3K converts the plasma membrane lipid 
phosphatidylinositol 4,5-bisphosphonate to PIP3, which acts as a second messenger 
leading to the phosphorylation AKT and subsequent up-regulation of cell cycle, growth, 
and survival proteins. AKT can also up-regulate mTOR (mammalian target of rapamycin), 
S6K, and NFκb leading to cell growth and inhibition of apoptosis.  
 
Knowing the huge complexity of melanoma, it’s easy to understand why so many 
random trials of single agents or combinational treatment have failed. So targeted therapy 
in a systemic way based on the understanding about melanoma molecular pathology 
seems to be a reasonable way to fight this disease. 
 
In learning from our efforts in the past, we must continue to challenge the current 
paradigms of treatment as we forge new paths to more effective treatment options. This 
will likely involve a multimodal approach to therapy utilizing all of the available tools in 
our arsenal. Several agents given in unique combinations may then synergize with 
standard chemotherapeutic regimens resulting in prolonged clinical responses and long 
term survival. Like the example of Sorafenib, its failure maybe largely because of it only 
blocked the Raf-MEK-ERK signaling pathway. Melanoma cells still can survive by 
compensatory up-regulating other survival pathway like the PI3K-AKT pathway. Then it 
can develop drug resistance with time by over expressing MDR gene. Ideally, if we can 
use drugs to synergistically block all the major pathways for melanoma cell survival and 
then educate our immune system to fight the tumor cells, we will have a very high chance 
to conquer this deadly disease.  
 
Individualized T-cell-based therapy is a very promising approach. If combined 
with other suitable tumor killing agents, it maybe can improve the patient survival rate 
and time. But the selective tumor-reactive T-cells isolated from the patients only can be 
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used for themselves. Thus there is a pretty high cost associated with it. It may not be 
available to all the patients in the near future.   
 
Since all the combinational treatments are based on the performance of each 
individual agent, developing more effective single agents is essential. In the next several 
chapters, I will summary our efforts in identifying more active small molecule drugs for 
melanoma. That’s the basis for our future treatment. It also can provide more choice for 
combination treatment.  
 
For the dissertation research, my overall hypothesis was by synthesizing novel 
small molecule and further structure modification, we can find compounds that can 
inhibit melanoma tumor cell growth both in vitro and in vivo. My experimental plan was 
first establishing an in vitro method to test compounds activity in inhibiting melanoma 
cell growth. Then I would use this method to screen a large compound library to identify 
active lead structure. Next step was to further modify this structure to inpromve activity. 
Finially I would test active compounds’ in vivo activity. In the meantime, compounds’s 
pharmacokinetic properties would be also measured.  
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CHAPTER 2. DISCOVERY OF NOVEL THIAZOLIDINE, IMIDAZOLE, AND 
IMIDAZOLINE ANALOGS AS CYTOTOXIC AGENTS FOR MELANOMA* 
 
 
2.1 Introduction 
 
In a continuous effort in our laboratory, our team discovered that, by replacing the 
glycerol backbone in lysophosphatidic acid (LPA, 1-acyl-sn-glycerol-3-phosphate), the 
resulting 2-arylthiazolidine-4-carboxylic acid amides (ATCAAs) were potent cytotoxic 
agents for melanoma (82-87). Two of earlier derivatives (2RS, 4R)-2-phenyl-thiazolidine-
4-carboxylic acid octadecylamide 1a and (2RS, 4R)-2-(4-acetamidophenyl)-thiazolidine-
4-carboxylic acid hexadecylamide 1b (Figure 2-1) were sent to the U.S. National Cancer 
Institute for anticancer drug screen using 60 human tumor cell lines (NCI-60). The NCI-
60 screening data indicated that compounds 1a and 1b strongly inhibited the growth of all 
nine types of cancer cells with IC50 values ranging from 120 nM (leukemia, CCRF-CEM 
cell line) to 11 μM (colon cancer, HCC-15 cell line). 1b was very potent against 
melanoma (IC50=130 nM~1 M against all eight tumor cell lines) and prostate cancer 
(IC50=170~270 nM against two tumor cell lines). Based on these preliminary cytotoxic 
screenings, extensive structure-activity relationship (SAR) and in vivo studies were 
carried out. In this chapter, I will discuss the biological evaluation and SAR studies of 
ATCAA analogues based on 1a and 1b for both melanoma. These analogs were further 
assessed for their ability to inhibit melanoma colony formation. The in vivo efficacy of 
compound 1b was tested in a xenograft model using human A375 melanoma tumors. This 
class of compounds showed potent antitumor activity and selectivity, which could 
represent the basis for their development into novel chemotherapeutic drugs. 
 
 
2.2 Materials and Methods 
 
 
2.2.1 Compound Library 
 
Ninety-one compounds were selected to form a library for biological testing. 
Their activity was compared with the existing drugs, Taxol and DTIC (Sigma-Aldrich, 
Inc., St. Louis, MO). In addition, Sorafenib (Bay43-9006) has recently been used 
extensively in clinical trials for advanced melanoma and is well tolerated in patients (22). 
Hence, Dr. Wei Li also synthesized Sorafenib based on published procedures (88), and 
 
 
*Portions of this chapter adapted with permission from the following: 
1.   Li W, Wang Z, Gududuru V, et al. Structure-activity relationship studies of arylthiazolidine amides as 
selective cytotoxic agents for melanoma. Anticancer Res 2007;27:883-8. 
2.   Li W, Lu Y, Wang Z, et al. Synthesis and antiproliferative activity of thiazolidine analogs for 
melanoma. Bioorg Med Chem Lett 2007;17:4113-7. 
3.   Chen J, Wang Z, Lu Y, et al. Synthesis and antiproliferative activity of imidazole and imidazoline 
analogs for melanoma. Bioorg Med Chem Lett 2008;18:3183-7. 
4.   Lu Y, Wang Z, Li CM, et al. Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-
arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorg Med Chem 2010;18:477-95. 
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Figure 2-1. Structures of LPA and ATCAA. 
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used its activity as a standard to assess our lead compounds. Thiazolidine analogues were 
synthesized by Dr. Yan Lu. Imidazole and imidazoline compounds were synthesized by 
Mr. Jianjun Chen. I worked for the biological part.  
 
 
2.2.2 Cell Culture 
 
SK-MEL-188 cells were derived from primary tumors and cultured in Ham’s F10 
medium (Gibco Invitrogen, Inc., Grand Island, NY) plus 5% fetal bovine serum (FBS) 
(Cellgro Mediatech, Inc., Herndon, VA) and 1% antibiotic/antimycotic mixture (Sigma-
Aldrich, Inc., St. Louis, MO) (89). WM-164 cells were derived from metastatic tumors 
and were a gift from Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA). A375 
cells and B16-F1 cells were purchased from ATCC (American Type Culture Collection, 
Manassas, VA). Both WM-164 and human dermal fibroblast cells (purchased from 
Cascade Biologics, Inc., Portland, OR) were cultured in DMEM (Cellgro Mediatech), 
supplemented with 5% FBS, 1% antibiotic/antimycotic mixture and bovine insulin (5 
μg/mL; Sigma-Aldrich Inc., St. Louis, MO). Human dermal fibroblast (adult) cells 
(HDFa) were used as a control to examine the effect of compounds on the stromal 
environment. Thus, the effect of drugs on melanoma cells versus fibroblasts would 
document their potential selectivity. 
 
 
2.2.3 Sulforhodamine B Assay 
 
Cells were seeded into 96-well plates at 5000 cells/well. After 12 h, media were 
changed and serial dilutions of compounds were added (1 nM~100 M). Cells were 
incubated with each compound for 48 h. Fresh media containing the testing compound 
were changed every 24 h. Thereafter, total cell protein corresponding to cell numbers 
(both viable and non-viable cells) was measured using the sulforhodamine B (SRB) assay 
according to the manufacturer’s protocol (Sigma-Aldrich Inc., St. Louis, MO) (79, 90). 
Briefly, cells were fixed with trichloroacetic acid, washed, and incubated with 
sulforhodamine B for 30 min. After another wash, dye incorporated into the cells was 
solubilized and measured using a plate reader at 565 nm.  
 
 
2.2.4 Lactate Dehydrogenase Release Assay 
 
SK-MEL-188 cells were seeded at a density of 5000 cells per well in 96-well flat-
bottom microtiter plates. Media were changed after 12 h, and the testing compound was 
added at serial dilutions. Media were changed with fresh compound every 24 h. After 
incubation for 48 h, supernatants were collected and transferred to a new plate. Lactate 
dehydrogenase (LDH) in supernatants was measured using Cytotox 96 Non-Radioactive 
Cytotoxicity Assay (Promega, Madison, WI). Briefly, substrate mix solution (containing 
tetrazolium salt) was added to each well and incubated at room temperature for 30 min. 
At the end of incubation, stop solution was added to each well and the plate was read at 
490 nm. Cytotoxicity of compounds was calculated using the following formula: % 
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cytotoxicity=(experimental LDH release/maximum LDH release). Experimental LDH 
release was calculated by subtracting the absorbance corresponding to the media alone 
from the absorbance corresponding to control or compound-treated cells. Maximum LDH 
release was calculated by subtracting the absorbance corresponding to the media with 
added lysis solution from the absorbance corresponding to cells lysed with lysis solution. 
 
 
2.2.5 DNA Content Analysis  
 
Flow cytometry analysis was performed as described elsewhere (91). Briefly, SK-
MEL-188 cells were seeded in 10 cm Petri dishes at a density of 106 cells per dish; at 12 
h the medium was changed to 5% FBS with different concentrations (0, 6 and 60 M) of 
the testing compound. Cells were incubated for 48 h and media with compounds were 
changed every 24 h. Cells were trypsinized, washed with PBS, and fixed in ice-cold 70% 
ethanol.  Ethanol was removed by centrifugation and cells were incubated in phosphate-
citrate buffer (0.2 M Na2HPO4, 4 mM citric acid, pH 7.8) for 1 h. Finally, cells were 
centrifuged and 1 mL of propidium iodide solution (50 μg/mL) and RNAse (0.1 mg/mL) 
in PBS was added (92). Samples were shaken for 30 min and analyzed with a FACS 
Calibur cytometer (Beckton Dickinson, San Diego, CA). Data were analyzed and graphs 
prepared using the Modfit 2.0 program (Verity Software House, Topsham, ME). 
 
 
2.2.6 Cell Cycle Analysis 
 
Flow cytometry analysis was performed to study cell cycle phase distribution. 
Briefly, A375 cells (4106) were seeded in 10 cm dishes; Cells were synchronized using 
0.5% charcoal-stripped DMEM medium for 72 h. After that, the medium was changed to 
the media containing 10% FBS with different concentrations (0, 1, 5, 10 and 20 μM) of 
testing compounds. Cells were incubated for additional 24 h. All cells were collected by 
trypsinization. Cell pellets were washed by PBS. The supernatant was discarded, and the 
pellets were fixed in ice-cold 70% ethanol at 4°C overnight. Ethanol was removed by 
centrifugation and cell pallets were washed with PBS twice. 1 mL of PBS containing 100 
μg/mL RNAase A was then added and cell pallets were incubated for 1 h.  Cells were 
centrifuged and re-suspended in 1 mL of PBS containing propidium iodide (50 μg/mL). 
Cell cycle analysis was conducted with a FACS Calibur Autometer (Beckton Dickinson, 
San Diego, CA). Data were analyzed and graphs were prepared using the Modfit 2.0 
program (Verity Software House, Topsham, ME). 
 
 
2.2.7 Colony-Formation Assay 
 
 To measure colony formation and growth of melanoma, A375 cells were plated 
at a colony-forming density (2000 cells per well on 6-well plates). Cells were grown in 
DMEM supplemented with FBS (Atlanta Biologicals, Lawrenceville, GA) and an 
antibiotic–antimycotic solution (Sigma, St. Louis, MO) at 37°C in an atmosphere of 95% 
air and 5% CO2 (93). Cells were treated with compounds 1b and 3ad at different 
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concentrations (2, 20, and 100 M). Compounds were added to the medium from 1 mM 
DMSO stock solutions, and corresponding dilution of DMSO was used as negative 
(vehicle) control. Cells were grown for 14 days, and colonies were stained with 0.1% 
crystalline blue for 30 min and rinsed with distilled water to remove excess dye. Plates 
were photographed, and the number of colonies was measured by Artek 880 Automated 
Colony Counter (Artek Systems Corporation, Farmingdale, NY). 
 
 
2.2.8 In Vivo Evaluation of Anti-Melanoma Efficacy  
 
Compound 1b was dissolved into a co-solvent system that was composed of 80% 
Tween 80 (Sigma-Aldrich, St. Louis, MO) and 20% Captex 200 (Abitec Corporation, 
Columbus, OH). Dacarbazine (DTIC) (Sigma-Aldrich, St. Louis, MO) was dissolved in 
saline solution. Male athymic nude mice aged 4-5 weeks were purchased from Harlan 
Laboratories (Harlan Laboratories, Indianapolis, IN). The laboratory housing the animals 
met all Association for Assessment and Accreditation and Laboratory Animal Care 
specifications. All of the procedures were conducted in accordance with the guidelines of 
our Institutional Animal Care and Use Committee.  
 
A375 cells in a logarithmic growth phase were prepared in FBS-free DMEM 
medium (Cellgro Mediatech) at a concentration of 5×107 viable cells/mL and placed on 
ice. The cell suspension was mixed with BD Matrigel (BD Biosciences, Waltham, MA) 
at a 1:1 ratio. This cell suspension (100 L) was injected subcutaneously in the right 
dorsal flank of each mouse. When tumor sizes reached about 150 mm3, about 7 days after 
cell inoculation, all mice bearing tumors were divided into control and treatment groups 
based on tumor size (n=8 per group). Each group had similar average tumor size. Mice in 
control groups were injected intraperitoneally with 50 L vehicle solution only (negative 
control) or DTIC at 60 mg/kg (positive control) once daily. Tumor volume was measured 
twice weekly with a Traceable® electronic digital caliper (Fisher Scientific, Inc., 
Pittsburgh, PA) and calculated using the formula a×b2×0.5, where a and b represented the 
larger and smaller diameters, respectively (94). Tumor volume was expressed as cubic 
millimeters. Data were expressed as mean ± SE for each group and plotted as a function 
of time. Percentage tumor reduction at the conclusion of the experiment (22 days after 
initiating treatment) was calculated from the formula 100-100[(T-T0)/(C-C0)], where T 
represents mean tumor volume of a treated group on a specific day, T0 represents mean 
tumor volume of the same group on the first day of treatment, C represents mean tumor 
volume of a control on a specific day, and C0 represents mean tumor volume of the same 
group on the first day of treatment (95). Animal activity and average body weight of each 
group were monitored during the entire experiment period to assess compound toxicity. 
At the end of treatment, all mice were euthanized by CO2 followed by cervical 
dislocation, and tumors were harvested for further studies.  
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2.2.9 Statistical Analysis 
 
 Data are presented as mean ± SEM (n=6~8). IC50 (i.e., concentration that 
inhibited cell growth by 50% of untreated control) values were obtained by nonlinear 
regression analysis (GraphPad Prism, San Diego, CA). Statistical analyses were 
performed with the Student’s t-test (*p<0.05, **p<0.001). 
 
 
2.3 Results and Discussion 
 
 
2.3.1 Identification of Lead Structures for Melanoma  
 
In the first step of lead identification, cells were exposed to each compound at 10 
µM to identify those which are active for both SK-MEL-188 and WM-164 cell lines. The 
IC50 values of the seven most active compounds with 50% or more growth inhibition at 
10 µM were subsequently measured on both cancer cell lines and on the control cells 
(fibroblast cells). Activities of several compounds with similar structures to the active 
compounds were also measured in order to understand the structure-activity relationships 
(SAR). Sorafenib, DTIC and Taxol were assayed in the same way for comparison and 
served as internal quality controls in the different assay batches. The results for all three 
cell types are summarized in Table 2-1.   
 
Overall, three basic structures were found very active in inhibiting both melanoma 
cell lines: (A) serine amides (e.g. VG-III-15), (B) serine amino alcohols (VG-II-197), and 
(C) arylthiazolidine-4-carboxylic acid amides (ATCAA, e.g., VG-III-39) (Figure 2-2). 
Analogs of (A) and (B) did not possess acceptable selectivity for cancer cells. 
Thiazolidine derivatives (C) displayed the highest potency and selectivity with IC50 
values in the nano-mole range for cancer cells (Table 2-1, VG-III-39). Not surprisingly, 
data from this in vitro assay indicated that DTIC is inactive (IC50>100 µM) against both 
cancer cell lines due to the lack of bio-activation. This is consistent with the currently 
proposed mechanism of action for DTIC, as well as findings by Daidone and co-workers 
(96). Clearly, in vivo assay is needed to assess the true activity of DTIC and similar 
structures. While Taxol is outstanding in inhibiting cancer cell growth, it is not effective 
in killing melanoma cells (cytostatic). In contrast, all the lead compounds from these 
preliminary studies killed the cells completely at higher concentrations. The mechanisms 
of action of our compounds are clearly different from that of DTIC and Taxol.  
 
Sorafenib effectively killed all the melanoma cells at high concentrations, similar 
to that of our lead compounds. When measured by IC50 values, VG-III-39 is about 10 
times as potent as Sorafenib. Its selectivity, defined as the ratio of IC50 in fibroblast cells 
over IC50 in melanoma cells, is moderate when compared with that of Sorafenib (10 vs. 
larger than 3). Together with the clinical finding that Sorafenib has low toxicity and is 
well tolerated by patients (22). The potency and selectivity of Sorafenib provide an 
excellent standard to assess the activities of our compounds and represent the future goal 
for optimization of our lead structures.     
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Table 2-1. IC50 of the lead compounds, Sorafenib, DTIC and Taxol. 
 
Structure Name IC50 (µM) (n=3) 
SK-MEL-188 WM-164 HDFa 
HO N
H
C8H16
NH2 .HCl
C8H16
O
VG-II-189 >10 >10 ND 
HO N
H
(CH2)3
NHBoc xHCl
O
N
H
(CH2)3
O
C14H29 VG-III-15 4 3 3 
HO N
H
C18H37
NHMe .HCl  
VG-II-197 3 4 2 
HO N
H
C18H37
NH2 .HCl  
VG-II-201 3 4 3 
S
N
H
O
HN C18H37
HCl  
VG-III-215 ND >50 ND 
S
HN C18H37
N
H
O
HCl
VG-III-41 24 18 28 
S
HN C18H37
N
H
O
HCl  
VG-III-149 40 >50 >50 
S
N
H
O
HN C18H37
MeO HCl
VG-III-83 
 10 13 28 
S
N
H
O
HN C18H37
MeO HCl
MeO
VG-III-267 2 3 >10 
S
N
H
O
HN C18H37
OMe
MeO
MeO
HCl
VG-III-265 2 2 5 
S
N
H
O
HN C18H37
AcHN
VG-III-271 3 6 >10 
S
HN C14H29
N
H
O
HCl
VG-III-39 570 nM 460 nM 6 
 Sorafenib 4 5 15 
 Taxol 4 nM 6 nM 12 nM
 DTIC >100 >100 >100 
 
ND: not determined.  
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Figure 2-2. Identified active lead structures for melanoma. 
 
 
Several important SARs were revealed in examining the 91-member library. 
Firstly, amides were less active than the corresponding alcohols (Figure 2-2A and B 
respectively). Heteroatoms on the side chain substantially increased the potency (VG-III-
15), but unsaturation on the side chain had the opposite effect (VG-II-189). Secondly, an 
alkyl amine (VG-II-197) was about equipotent to the un-substituted amine (VG-II-201), 
suggesting that cyclization of the amine and alcohol may be possible. However, none of 
the open chain compounds displayed acceptable selectivity against cancer cells. Thirdly, 
the presence of the aromatic ring in the heterocyclic compounds improves selectivity and 
cytotoxicity of structure C (Figure 2-2) (VG-III-215 vs. VG-III-149). Fourthly, the 
potency of the compounds depended strongly on the chirality at C-4 position (VG-III-41 
vs. VG-III-149), the substitution on the aromatic ring (VG-III-149 vs. VG-III-265), and 
the chain length (VG-III-39 vs. VG-III-149). With a similar C18 chain, the S-isomer at 
the C-4 position (VG-III-41) showed higher potency than the R-isomer (VG-III-149). 
More electron donating substitutions on the aromatic ring progressively increased the 
potency of analogs of structure C (VG-III-149 vs. VG-III-83, VG-III-267, and VG-III-
265). N-substitution with the C14 chain was much more potent and selective against 
cancer cells than that of the C18 chain compound (VG-III-39 vs. VG-III-149). Clearly, 
further structural optimization is warranted and will likely improve both potency and 
selectivity for this class of compounds against melanoma.  
 
It is interesting to compare the activity in melanoma with that in prostate cancer 
for these compounds. In general, their activities are consistent in these two types of 
cancer cells, demonstrating potentially broad anticancer properties for ATCAA analogs. 
Compounds that are active or inactive in prostate cancer also displayed similar behavior 
in melanoma, but there are a few exceptions. For example, although VG-III-149 (C18 
chain length) showed excellent activity (IC50<3 µM) against prostate cancer cells, it was 
not active in both melanoma cell lines (IC50>40 µM). In addition, for compounds which 
are active in both cancer types, their relative potency and selectivity are not the same. For 
example, in prostate cancer studies, a compound with a C14 side chain was found to be 
slightly less active than that with a C18 chain. Substitutions on the aromatic ring with 
mono-, di- or tri-methoxyl groups were found to be favorable in prostate cancer cell lines. 
Both the potency and selectivity increased as more methoxyl substitutions were added to 
the aromatic ring (82). In melanoma, however, methoxyl substitutions did not have 
significant selectivity benefits when compared with nonsubstituted analogs (e.g. VG-III-
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83 vs. VG-III-265). A C14 chain displayed much better activity and selectivity than C18 
chain compounds (e.g. VG-III-39 vs. VG-III-265). Interestingly, Taxol behaves very 
differently in prostate cancer cells and melanoma cells. While Taxol killed all the prostate 
cancer cells, it only killed about half of the melanoma cells when compared with controls 
based on our in vitro assay. This may suggest different oncogenic properties between 
these two types of cancer. 
 
 
2.3.2 VG-III-39 Induced DNA Degradation and LDH Release  
 
To examine more closely the cell death induced by our compounds, I measured 
lactate dehydrogenase (LDH) release by colorimetric assay and analyzed DNA content 
by flow cytometry.  
 
LDH is a stable cytosolic enzyme that is released upon cell lysis. Treatment of 
cells with VG-III-39 resulted in a dramatic dose-dependent increase of LDH released to 
the cellular environment (Figure 2-3A). 
 
Analysis of the DNA content of control cells (Figure 2-3B) showed peaks 
corresponding to the cells in G1/0-cell phase (62%), S-phase (32%) and G2/M-phase 
(6%), a typical distribution of cells in culture (92). Treatment of cells with VG-III-39 at 6 
μM and 60 μM led to the disappearance of peaks corresponding to viable, proliferating 
cells and the appearance of single peaks corresponding to debris/degraded DNA.  
 
 
2.3.3 Early Stage SAR Study of Thiazolidine Derivatives 
 
The ability of thiazolidine derivatives to inhibit the growth of two melanoma 
cancer cell lines and fibroblast cells is summarized in Table 2-2. Sorafenib (Velcade) has 
been used extensively in clinical trials for melanoma. Hence I selected this compound 
and DTIC as reference standards to assess the activity of our compounds. At this early 
stage, all compounds were used as a diastereomeric mixture if they contain chiral centers 
in order to select the most promising compounds for further development.  
 
Examination of antiproliferative effects for a variety of substitutions on the 
phenyl ring revealed the chain-length dependence for these compounds (1~5, 6~9, 10~13, 
14~19). Short chain length such as a C10 chain (e.g., compound 2, 6, 10) displayed low 
potency for both cancer cells and fibroblast cells. As chain length increased, potency 
increased, as well as toxicity as measured on fibroblast cells except when the acetyl 
amino group was substituted on the phenyl ring (compound 14~17). Both C15 and C16 
chains with this substitution displayed both high potency and high selectivity against 
cancer cells, with an IC50 for melanoma cells as low as 600 nM (compound 17). Further 
chain increases, however, reduced potency and selectivity. At a chain length of C18 
(compound 19), the IC50 value was higher than 10 M for all three cell lines. 
Interestingly, adding either a cis-  or trans- double bond in the C18 side chain restored 
potency dramatically (compound 20Z and 20E), demonstrating that both length  
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Figure 2-3. Compound VG-III-39 induced DNA degradation and LDH release.  
SK-MEL-188 melanoma cells were incubated with VG-III-39 for 48 h. A: LDH released 
from the cells after treatment was then analyzed. Data is presented as mean±SEM (n=8), 
*p<0.05, **p<0.001. B: DNA content was analyzed using flow cytometry. Results are 
representative of two separate experiments. 
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Table 2-2. Cytotoxic activity of thiazolidine analogs, Sorafenib and DTIC. 
        
Structure Compound R R1 R2 IC50SEM (M) (n=3)
SK-MEL-188 WM-164 HDFa 
N
H
S
CONR1R2R  
1 3,4,5-trimethoxyl n-C8H17 H 171 201 2110 
2 3,4,5-trimethoxyl n-C10H21 H 153 20 74 
3 3,4,5-trimethoxyl n-C12H25 H 20 20 21 
4 3,4,5-trimethoxyl n-C14H29 H 21 20 30 
5 3,4,5-trimethoxyl n-C16H33 H 20 10 20 
6 3,4-dimethoxyl n-C10H21 H 126 63 61 
7 3,4-dimethoxyl n-C12H25 H 31 21 52 
8 3,4-dimethoxyl n-C14H29 H 21 10 31 
9 3,4-dimethoxyl n-C16H33 H 20 10 21 
10 3,4 -OCH2O- n-C10H21 H 71 50 83 
11 3,4 -OCH2O- n-C12H25 H 40 30 51 
12 3,4 -OCH2O- n-C14H29 H 20 10 41 
13 3,4 -OCH2O- n-C16H33 H 20 20 62 
14 NHCOCH3 n-C12H25 H 20 10 40 
15 NHCOCH3 n-C14H29 H 20 10 41 
16 NHCOCH3 n-C15H31 H 20 10 142 
17 NHCOCH3 n-C16H33 H 20 10 198 
18 NHCOCH3 n-C17H35 H 90 20 365 
19 NHCOCH3 n-C18H37 H 223 121 >60 
20Z NHCOCH3 (Z)-Octadec-8-enyl H 10 10 111 
20E NHCOCH3 (E)-Octadec-8-enyl H 30 10 184 
21 H n-C14H29 H 21 10 30 
22 H n-C16H33 H 20 10 20 
23 H OCH3 CH3 >100 >100 >100 
26 NH2 n-C12H25 H 20 10 41 
27 NH2 n-C16H33 H 20 10 71 
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Table 2-2. (continued) 
 
Structure Compound R R1 R2 IC50SEM (M) (n=3) 
SK-MEL-188 WM-164 HDFa 
N
H
S
CONR1R2R  
24 3,4,5-trimethoxyl n-C14H29 H 20 10 41 
25 NHCOCH3 n- C16H33 H 30 10 233 
N
S
CONR1R2R  
28 H n-C14H29 H 425 >50 >50 
29 3,4-dimethoxyl n-C14H29 H 192 4310 >50 
N
CH3
S
CONR1R2R  
30 NHCOCH3 n-C16H33 H 291 >100 >100 
N
S
C
N
S
C
O
O
R
R
 
31 3,4,5-trimethoxyl N/A N/A >50 >50 >50 
 DTIC    >100 >100 >100 
 Sorafenib    51 50 151 
 
NA: not available. 
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and composition of the side chain are critical for their activity. There is no significant 
difference in their activity between the cis- and trans- isomers. 
 
Removing the acetyl amino group on the phenyl ring (compound 21 and 22) 
resulted in the loss of selectivity, although potency was similar to those with this 
substitution (compounds 15 and 17). Replacing the alkyl chain with a methoxyl group 
completely abolished potency (compound 23). Changing the chirality from an R to S 
configuration at the C4 position on the thiazolidine ring did not substantially affect either 
potency or selectivity (compound 4 vs. 24 and compound 17 vs. 25). Selectivity has a 
strong dependence on the substitutions in the phenyl ring. For example, with a C12 chain, 
potency is similar for all the substitutions I studied (compounds 3, 7, 11, 14, and 26). 
However, selectivity improves dramatically when proper substitutions are present 
(compound 17 vs. compounds 5, 9, 13, 22, and 27). 
 
When the amino group in the thiazolidine ring is substituted (compound 30) or a 
double bond is introduced (compounds 28 and 29), the resulting compounds are largely 
inactive with IC50 values above 20 µM. I also tested the intermediate compound in which 
the amino group is protected by a Boc group, and that compound is inactive also (data not 
shown). Furthermore, when Dr Yan Lu removed the aliphatic chain and the amino group 
by synthesizing a dimer, she obtained an inactive compound (compound 31). These 
results clearly demonstrate the importance of the amino group in the thiazolidine ring. 
 
 
2.3.4 Further SAR Studies with New Thiazolidine Derivatives 
 
The diastereomeric mixtures of compounds 3aa-15c were used to evaluate their in 
vitro inhibitory activity and toxicity against two human melanoma cell lines (A375 and 
WM-164), one mouse melanoma cell line (B16-F1), fibroblast cells (control cell line for 
melanoma). Because preparing pure diastereomers was not easy to achieve, the IC50 
values were obtained on diastereomeric mixtures to select the most promising 
compounds. The standard sulforhodamine B (SRB) assay was used to evaluate the 
antiproliferative activity of different compounds in melanoma cells. The results are 
summarized in Table 2-3. Compound 1a and 1b were chosen as control compounds for 
both tumor cell lines in these in vitro studies. Cisplatin (CDDP), DTIC, and Sorafenib 
(Nexavar, Bay43-9006, which had been granted Fast Track designation by FDA to treat 
advanced melanoma) were used as reference compounds for melanoma (97). The 
antiproliferative data showed that all three melanoma cell lines were resistant to cisplatin. 
DTIC was inactive because of the lack of bioactivation in vitro (98, 99). The average IC50 
value of Sorafenib on three melanoma cell lines is 5 µM, and the selectivity of Sorafenib 
between fibroblast cells and melanoma cells is 3-fold. Our purpose in modifying 
chemical structure was to enhance the selectivity between tumor cells and control cells 
and to increase or maintain antitumor potency. Thus, I used the average IC50 value of all 
melanoma and prostate cancer cells for comparison. Selectivity is defined as the ratio of 
IC50 values in the control cell line and the average in tumor cell lines. From Tables 2.3, 
the most selective compound (3id) had a selectivity of 11.3-fold in melanoma cells 
against fibroblast cells. 
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Table 2-3. Cytotoxic activity of ATCAA on three melanoma cell lines and a fibroblast 
cell line. 
 
 
 
ID X R1 R2 R3 R4
IC50SEM (M) (n=3) 
B16-
F1 A375 
WM- 
164 HDFa
3aa CON 3, 4, 5-trimethoxy n-C18H37 H H 60 50 30 50
3ab CON 3, 4, 5-trimethoxy (Z)-octadec-8-enyl H H 50 20 10 50
3ac CON 3, 4, 5-trimethoxy (E)-octadec-8-enyl H H 30 20 10 40
3ad CON 3, 4, 5-trimethoxy n-C16H33 H H 20 10 10 20
3ba CON 3, 4-dimethoxy n-C18H37 H H 141 70 30 201
3bb CON 3, 4-dimethoxy (Z)-octadec-8-enyl H H 30 20 10 181
3bc CON 3, 4-dimethoxy (E)-octadec-8-enyl H H 30 10 10 161
3ca CON 2-OMe n-C16H33 H H 40 30 20 70
3da CON 3-OMe n-C16H33 H H 30 20 10 30
3ea CON 4-OMe n-C16H33 H H 20 20 10 81
3fa CON 4-NMe2 n-C16H33 H H 71 20 20 213
3ga CON 2-NHAc n-C16H33 H H 80 91 41 284
3ha CON 3-NHAc n-C16H33 H H 20 20 10 60
3ia CON 4-NHAc n-C18H37 CH3 H 191 212 111 >100 
3ib CON 4-NHAc 1-adamantanyl H H 974 1384 1283 >100 
3ic CON 4-NHAc 2-adamantanyl H H 1085 662 643 >100 
3id CON 4-NHAc 9H-fluoren-2-yl H H 40 20 20 291
3ie CON 4-NHAc anthracen-2-yl H H 60 30 10 141
3if CON 4-NHAc 4-biphenyl H H 60 60 40 334
3ig CON 4-NHAc 2-benzothiazolyl H H 553 464 >100 >100 
3ih CON 4-NHAc (Z)-hexadec-9-enyl H H 20 20 20 141
3ii CON 4-NHAc nonadec-10-ynyl H H 20 30 10 70
3jb CON H (Z)-octadec-8-enyl H H 61 51 20 121
3jc CON H (E)-octadec-8-enyl H H 101 50 20 121
4 CON 4-NHAc n-C16H33 H Ac 151 131 201 581
5 COO 4-NHAc n-C16H33 H H 423 282 190 >100 
8a CH2N H n-C16H33 H H 50 130 50 601
8b CH2N 4-NHAc n-C16H33 H H 120 140 30 853
15a CON 4-NHSO2CH3 n-C16H33 H H 1142 512 191 >100 
15b CON 4-NHCOCH2Cl n-C16H33 H H 934 201 60 251
15c CON 4-NHCONH2 n-C16H33 H H 61 40 20 70
1a CON H n-C18H37 H H 161 151 40 302
1b CON 4-NHAc n-C16H33 H H 20 20 10 163
DTIC      >100 >100 >100 >100 
CDDP      >100 >100 >100 >100 
Sorafenib      50 51 50 151 
 
  
R1 N
R4
S
XR2R3
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2.3.4.1 SAR of Different Amide Chains and Chain Length of ATCAA 
 
ATCAA molecules were designed from LPA structure, which contains a long 
aliphatic chain. To examine whether the fatty chain played an essential role in 
cytotoxicity, we explored the possibilities of mimic fatty chain with bulky ring or 
aromatic systems such as adamantanyl, fluorenyl, and anthrancenyl. Although the 
antiproliferative data showed that 1- or 2-adamantanyl amides and 2-benzothiazolylamide 
(3ib, 3ic, and 3ig) had lower activity against most melanoma cells, introducing certain 
aromatic bulky groups such as 9H-fluoren-2-yl (3id), anthrancen-2-yl (3ie), and 4-
biphenyl (3if) retained their proliferative activity. Of particular interest, while introducing 
9-fluoren-2-yl (3id) showed a comparable IC50 value of 3 µM with 1b (2 µM) on 
melanoma cells, the selectivity of 3id increased to 11 fold from 9 fold in 1b. This 
structural modification provided us a new approach to optimize the drug-like properties 
of ATCAA molecules, in which the hydrophobic fatty lipid chain could be modified with 
other groups (100).  
 
Hexadecyl chains (3ad) displayed both the highest potency and selectivity against 
cancer cells among the examined chains, with an IC50=1 µM for WM-164 cells. 
However, further increasing chain length (18 carbons, 3aa) reduced potency and toxicity. 
Interestingly, adding either a cis- or trans- double bond in the C18 side chain restored 
potency dramatically (cis- and trans-octadec-8-enyl), demonstrating that both length and 
composition of the side chain are critical for their activity. Trans-octadec-8-enyl chain 
(3ac, 3bc, 3jc) showed slightly better activity than did the cis-isomers (3ab, 3bb, 3jb) 
against melanoma cells. Introducing a cis-double bond in the C16 fatty chain (3ih) or an 
alkyne in the C18 chain (3ii) did not increase overall potency. Introducing a branched 
aliphatic chain (3ia) decreased the potency in both melanoma cells (average IC50=17 µM, 
9.3 fold decrease) compared with 1b (average IC50=2 µM). 
 
 
2.3.4.2 SAR of Substitutions on 2-Phenyl of ATCAA 
 
 The antiproliferative effects indicated that when methoxy, 3, 4-dimethoxy, and 3, 
4, 5-trimethoxy were introduced to 2-phenyl (3aa-3ea), potent activity was preserved or 
increased compared with that of 1a. For example, (2RS, 4R)-2-(3, 4, 5-trimethoxy-
phenyl) thiazolidine-4-carboxylic acid octadecylamide (3aa) (average IC50=5 µM) was 3 
fold more potent than was 1a (average IC50=12 µM). Subsequently, different groups were 
introduced to the para-phenyl position. Replacements of 4-NHCOCH3 (1b) with 4-N 
(CH3)2 (3fa) showed comparable activity on A375 (IC50=2 vs. 2 µM) and WM-164 cells 
(IC50=2 vs. 1 µM) but slightly lower selectivity on fibroblast cells (IC50=21 vs. 16 µM).  
 
 Although 4-N (CH3)2 (3fa) substituted ATCAAs were more potent than was 1a 
(average IC50=3 µM for 3fa, and 12 µM for 1a), they were less potent than 1b (average 
IC50=2 µM and selective ratio=8.9 for 1b). Methanesulfonamide (15a) or 2-
chloroacetamide (15b) were less potent (IC50=6~114 µM) and less toxic (IC50= 25~>100 
µM) on melanoma cell lines compared with 1b. Introducing an ureido, 4-NHCONH2 
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(15c) instead of a 4-NHCOCH3 kept partial potency (average IC50=4 µM) but resulted in 
loss of selectivity against melanoma cells (1.8-fold for 15c vs. 8.9-fold for 1b).  
 
We also investigated the importance of o-, m-, and p- substitutions in the 2-phenyl 
ring relative to acetylamino and methoxy groups. Interestingly, o-, m-, and p- isomers 
showed different activities. P-Isomers (3ea, 1b) had the best selectivity and activity. M-
Isomers (3da, 3ha) had similar average IC50s against melanoma compared with p-
isomers, but their toxicity also increased on fibroblast (3 µM). o-MeO and o-NHAc 
analogues (3ca, 3ga) showed slightly less potency and selectivity.  
 
 
2.3.4.3 SAR of 4-Linkage of ATCAA and Thiazolidine Ring 
 
To investigate the importance of amide linkage on C4 of ATCAA, the 
carboxamide was replaced with an ester and amine. The isosteric replacement of the 
amide by an ester resulted in 5 with markedly decreased activity against all cancer cell 
lines. The amine derivatives 8a and 8b also failed to show any increased potency, 
although they did show lower toxicity (60-85 µM) than did 1a (30 µM) and 1b (16 µM) 
in fibroblast cells.  
 
Thiazolidine-4-carboxylic acid has been reported to be effective for treating 
advanced cancers (101, 102). To examine the importance of a central thiazolidine ring, 
Dr Yan Lu synthesized 3-acetyl-thiazolidine compound 4 and a series of thiazolidine 
ring-opened compounds 16a-16d. The structure of these ring-open and their relationship 
is shown if Figure 2-4. Antiproliferative activity of 16a-16d against melanoma is 
summarized in Table 2-4. When acetyl was introduced to 3-NH of thiazolidine, activity 
decreased in both cancer cell lines (average IC50=16 and 10 µM against melanoma and 
prostate cancer, respectively). Cleavage of both the C-S and C-N bond (16a) led to 
substantial decrease in both potency (13~14 µM on melanoma cell lines) and toxicity (61 
µM on the control cells) compared with 1b and 3ja (1~2 µM on cancer cells, 2~16 µM on 
control cells). Opening the thiazolidine ring from the C-S bond (16b) caused a loss of 
potency on both cancer and control cells (>100 µM). Cleavage of the C-N bond in the 
thiazolidine ring (16c) also resulted in decreased activity (13~15 µM) and no 
improvement on selectivity compared with 3ja. Removing the C-S bond (16d) reduced 
the activity of 1b from IC50=1~2 µM to 10~12 µM. These results suggested that the 
presence of the thiazolidine ring is critical for activity. Attempts to reduce the amide with 
LAH or B2H6 resulted in the C-S bond cleavage in thiazolidine. A disulfanyl dimer, 
which completely lost anticancer activity, was obtained, and this result is consistent with 
the above finding that the thiazolidine ring played an essential role in ATCAA potency.  
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Figure 2-4. Structure relationship of thiazolidine ring-open compounds. 
 
 
 
 
Table 2-4. Cytotoxic activity of thiazolidine ring-open compounds against melanoma. 
 
ID 
IC50SEM (M) (n=3) 
A375 WM-164 HDFa 
16a 131 141 614 
16b 1095 1455 >100 
16c 151 132 161
16d 121 111 241 
3ja ND 10 20
1b 20 10 163
 
ND: not determined 
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2.3.5 SAR Summary of ATCAA for Melanoma 
 
After extensive chemical structure modification and in vitro activity studies on 
melanoma cells, the overall SAR of ATCAA compounds on melanoma cells was 
summarized in Figure 2-5. From the above studies, we generalized several important 
SAR. Firstly, Thiazolidine ring and the free NH on the ring are very critical for the anti-
melanoma activity. The carbon 4 chiral center on the thiazolidine ring is not important for 
activity because both isomers showed similar potency. Secondly, for the side chain, 
aliphatic chain with a length of 16 carbons was best for activity. It also can be replaced 
by 9H-fluoren-2-yl group. Thirdly, the link between the thiazolidine ring and the side 
chain prefer amide to ester and amine. Lastly, for the substituents on the phenyl ring, 
electron donating group (EDG) is better than electron withdrawing group (EWG), para- 
and meta- substitution are the same, ortho-substitution is slightly worse.  
 
 
2.3.6 SAR of Newly Synthesized Imidazole and Imidazoline Analogs 
 
I found that the chirality at position 4 in thiazolidine ring of ATCAA analogs is 
not critical for their activity. However, the importance of chirality at position 2 is 
unknown, because all our previous compounds were tested as diastereomers. Separation 
of these stereoisomers by chromatographic methods turned out to be extremely difficult. 
Dr. Li asked for assistance from scientists from Chiralcel Technologies who tried both 
normal-phase and reverse-phase conditions with their nine chiral columns, but none of 
the combinations could separate these stereoisomers satisfactorily.  
 
 
N
S
X R2R3
R4
R1
b. Fatty chains (C-16 optimum) and
9H-fluoren-2-yl are the best for activity
c. amide is better than ester and amine
a. Free NH and thiazolidine ring contribute to anticancer 
activity; 4R and 4S isomers have similar potency
d. Phenyl substitutions: EDG is better than EWG; para- and meta- 
substituents are comparable; ortho-substituents are slightly worse
*
*
 
Figure 2-5. SAR summary of ATCAA for melanoma. 
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Converting the thiazolidine ring to an imidazoline or imidazole ring represents a 
very productive approach. First, the nitrogen-containing ring would be very stable. 
Imidazoline and imidazole rings are important biological building blocks and are present 
in many existing drugs (103). Second, the imidazoline ring contains only one chiral 
center, and the imidazole ring contains no chiral center at all. These attributes may 
alleviate or even eliminate the need for future chiral separations. So Mr. Jianjun Chen 
made the following modification to ATCAA: a) replacing sulfur with nitrogen or carbon 
to understand the importance of the heteroatom in the ring, b) introducing one or two 
double bonds in the ring (imidazoline and imidazole) to understand the importance of the 
chiral centers, and c) introducing various spacers between the five-member ring and the 
aromatic ring to understand the relative spatial arrangements for the two rings. 
 
I examined the antiproliferative activity of these imidazoline and imidazole 
analogs in two melanoma cell lines (human A375 cells and mouse B16 cells) and in a 
fibroblast cell line. The ability of these new analogs to inhibit the growth of melanoma 
cancer cell lines and fibroblast cells is summarized in Table 2-5. 
 
In summary, none of the new analogs is as active as the lead compound. Although 
they do not contain any chiral centers, analogs containing an imidazole ring (compounds 
5-11) did not have activity at concentrations below 10 M. Replacing the imidazole ring 
with an imidazoline ring slightly improved the activity in general (compounds 15-19), 
with substantial improvement when trimethoxyl or amino acetyl substitutions were added 
(compounds 20-21). The structure activity for the side chain was similar to that of the 
thiazolidine analogs, with a saturated C14~C16 chain or an unsaturated C18 chain to be 
optimal for activity against melanoma cells. Similarly, electronic donating substitutions 
on the paraposition of the aromatic ring increased activity (compounds 20-21). Replacing 
sulfur with carbon in the five-member ring produced an inactive compound (compound 
30). Collectively, these results indicate that the thiazolidine ring is critical for the activity 
of this series of compounds.  
 
When a spacer was inserted between the imidazoline/thiazolidine ring and the 
phenyl ring (compounds 22-29), there is no noticeable improvement in their activity 
(compound 20 vs. compound 22). Increasing the size of the spacer by replacing one 
hydrogen in the methylene group with a methyl group reduced the activity (compound 23 
vs. 26, and compound 24 vs. 27). Both of these results seemed to indicate detrimental 
effects of spacers for the activity. Finally, replacing the side chain with a fluorene group 
resulted in complete loss of activity (compound 23 vs. 25). However, with proper 
parasubstitution on the aromatic ring, the activity dramatically improved (compound 25 
vs. compound 29) for this series of compounds. On the other hand, with a C16 side chain, 
the substitution on the phenyl ring had the opposite effect (compound 23 vs. 26) in sharp 
contrast to the non-chain analogs such as 29 and may indicate a different mechanism of 
action when the long side chain is replaced by a conjugated ring system.  
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Table 2-5. Cytotoxic activity of imidazolines, imidazoles and comparison with Sorafenib and the lead thiazolidine compounds. 
 
Structure Compound R R1 R2 IC50SEM (M) (n=3) 
A375 B16-F1 HDFa 
N
H
N
NR1R2
O
R
 
5 H n-C10H21 H >30 >30 >30 
6 H n-C12H25 H >30 ~30 >30 
7 H n-C14H29 H 191 382 432 
8 H n-C16H33 H 171 402 281 
9 H n-C18H37 H 211 >30 471 
10 H (E)-Octadec-8-enyl H 161 321 241 
11 H p-Bromophenyl H >30 >30 >30 
N
H
N NR1R2
O
R
 
 
15 H n-C14H29 H 70 70 172 
16 H n-C16H33 H 100 60 601 
17 H n-C18H37 H 541 511 1114 
18 H (E)-Octadec-8-enyl H 80 120 253 
19 3,4,5-trimethoxyl OCH3 CH3 >20 >20 >20 
20 3,4,5-trimethoxyl n-C16H33 H 41 40 131 
21 p-NHCOCH3 n-C16H33 H 50 20 152 
N
H
N NR1R2
O
R H2
C
 
22 3,4,5-trimethoxyl n-C16H33 H 40 40 162 
C
H
R2
S
H
N N
H
O
R1R
 
23 H n-C16H33 H 81 70 151 
24 H (E)-Octadec-8-enyl H 101 120 162 
25 H 2-Fluorene H 17411 1188 >100 
26 H n-C16H33 CH3 131 120 567 
27 H (E)-Octadec-8-enyl CH3 211 171 23739 
28 p-NHCOCH3 n-C16H33 H 19114 17121 >100 
NH
O
NH n-C16H33
 
29 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
120 
 
 
472 
 
 Sorafenib    51 50 151 
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2.3.7 Flow Cytometry Analysis of Active ATCAA Compounds 
 
Flow cytometry analysis was performed on human melanoma A375 to examine 
the effect of the new synthetics on cell cycle progression. Analysis of the DNA content of 
control cells (Figure 2-6, top graphs) showed typical distribution of peaks corresponding 
to cells in G1/G0 phase (65.67~66.97%), S-phase (24.16~28.36%), and G2/M-phase 
(5.97~8.87%). Upon treatment with compounds 3ad and 1b at 1, 5, 10, and 20 µM 
concentrations for 48 h, flow cytometric analysis showed that these compounds 
significantly induced apoptosis (sub-G1 phase) in cancer cells in a dose-dependent 
manner. The accumulation of cells in sub-G1 phase became apparent at 5 µM. 
 
 
2.3.8 ATCAA Inhibited Human Melanoma Colony Formation in Soft Agar 
 
Cells grown in 96-well plates do not reflect many properties associated with 
three-dimensional tumors. Human tumor colony formation assay (ex vivo soft agar colony 
assay) has been suggested as an in vitro method to predict the response of an individual 
patient's tumor to chemotherapeutic agents (104, 105). As a prelude to in vivo animal 
experiments, I investigated the ability of compound 1b and 3ad to inhibit melanoma 
colony formation by using a well-established method (93, 106, 107). I performed studies 
with A375 human melanoma cells. Photos and quantified results are shown in Figure 2-7 
and Figure 2-8. Compounds 1b and 3ad effectively inhibited A375 colony formation at 2 
M, the lowest tested concentration. At a concentration of 20 M, compound 3ad almost 
completely inhibited colony formation, while compound 1b inhibited colony formation 
by 75%. At the highest tested concentration, 100 M, melanoma colony formation was 
completely inhibited by both 1b and 3ad.  
 
 
2.3.9 Antitumor Efficacy of ATCAA on A375 Xenograft Model  
 
I chose human melanoma A375 cells to test efficacy in vivo because ATCAA 
exhibited potency both in vitro assay and colony formation assay against A375 cells. 
A375 xenograft tumors also exhibited faster tumor growth rate. While compound 3ad 
was more potent than was 1b in inhibiting melanoma colony formation, it had much 
poorer selectivity between melanoma cancer cells and fibroblast cells (2.0 fold for 3ad vs. 
8.9 fold for 1b) as shown in Table 2-3. Therefore, I chose 1b for our in vivo studies 
against A375 melanoma tumors. This compound was formulated with 80% Tween 80 and 
20% Captex 200 because of its limited water solubility (108). I first determined the 
maximally tolerated dose (MTD) in ICR (imprinting control region) mice. These mice are 
less expensive than nude mice and are commonly used for toxicity testing. The MTD for 
compound 1b was determined to be 42 mg/kg. Two nontoxic dosages (5 mg/kg and 10 
mg/kg) were used. I also included DTIC (60 mg/kg) the gold standard for melanoma 
treatment, as a positive control to assess the efficacy of compound 1b (109). Briefly, male 
athymic nude mice were injected subcutaneously with 2.5×106 A375 cells. Treatment 
began on day 7 after tumor inoculation, and 1b was injected once a day. Each group had  
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Figure 2-6. Flow cytometry analysis of selected ATCAA compounds.  
Sub-G1 phase accumulation was induced by tested compounds on melanoma A375 cells. 
(This experiment was done by Mr. Chien-Ming Li, Division of Pharmaceutics, College of 
Pharmacy, the Ohio State University). 
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Figure 2-7. Human melanoma A375 cells colony formation in soft agar with ATCAA 
treatment.  
 
 
 
 
 
Figure 2-8. Quantified results of colony formation assay with compounds 3ad and 1b 
treatment.  
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eight mice. The results are shown in Figure 2-9. Compound 1b at 5 mg/kg showed 
moderate melanoma tumor growth inhibition. After 22 days of treatment, the percentage 
of tumor reduction was 25%. At a higher dose of 10 mg/kg, compound 1b showed 
significant melanoma tumor growth inhibition with 62% of tumor reduction. When 
comparing with DTIC at a dose of 60 mg/kg, which inhibited tumor growth by 42% at 
the end of treatment, compound 1b clearly showed superior activity in this human 
melanoma xenograft model. All mice displayed normal activities, and no significant body 
weight loss was observed during the experiment.  
 
 
2.4 Conclusions 
 
ATCAA analogs represent a novel class of potent and selective cytotoxic agents 
for melanoma. Initial analysis indicated that the antineoplastic activity is attributed to 
their ability to induce DNA break and LDH release in melanoma cells. These SAR 
studies revealed that the potency of the compounds depends strongly on the chain length 
and substitutions on the phenyl ring. Our current lead compound is highly potent and 
moderately selective when compared with Sorafenib, a drug used extensively in clinical 
trials for melanoma.  
 
Dr. Yan Lu then synthesized a series of ATCAA compounds and thiazolidine 
ring-opened analogues. Chemical modification and structure-activity relationship of 
ATCAA compounds were investigated with different substituted 2-phenyl, thiazolidine 
ring, 4-position linkage, and 4-carboxamide groups based on biological evaluation 
against melanoma cells. Some compounds are very promising agents against melanoma. 
Compounds 1b and 3ad effectively inhibited A375 melanoma colony formation. 
Compound 1b at a dose of 10 mg/kg significantly inhibited melanoma tumor growth in 
vivo and showed higher efficacy than did DTIC at a dose of 60 mg/kg. These compounds 
did not seem to work via the LPA-GPCR pathway.  
 
Mr. Jianjun Chen also synthesized new imidazole and imidazoline analogs, based 
on our previous studies, by focusing on the structure activity relationship studies of the 
central five-member ring. Although the current compounds displayed lower potency 
when compared with our lead thiazolidine analogs, they may have the distinct advantage 
of being more stable in vivo with the reduced necessity of chiral separations. Some of 
these new compounds have activity similar to Sorafenib.  
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Figure 2-9. In vivo anti-melanoma test of compound 1b on athymic nude mice (n=8 per 
group) bearing A375 xenograft.  
A: Tumor growth curve of control, compound 1b and DTIC treatment. DTIC was used as 
positive control. B: Average body weight change in control and treatment groups. 
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CHAPTER 3. IDENTIFYING NOVEL MOLECULAR STRUCTURES FOR 
ADVANCED MELANOMA BY LIGAND-BASED VIRTUAL SCREENING* 
 
 
3.1 Introduction 
 
In our ongoing efforts to search for small molecules as potential therapeutic 
agents for advanced melanoma, our team recently discovered a new series of thiazole 
analogs that showed very potent activity against melanoma cells in vitro (110). One of 
the best compounds in this series has an IC50 value below 60 nM. Screening results from 
the National Cancer Institute (NCI-60 screening) for our lead compound, LY-1-100, 
indicated nanomolar antiproliferative activity for all the cancer cell lines tested. 
Preliminary mechanism of action studies on this series of compounds indicated that they 
may interact with microtubules (110). In vivo testing with melanoma tumors showed 
substantial growth inhibitory activity for this series of compounds. To further expand our 
understanding of structure-activity relationships and to potentially identify new platforms 
for active compounds, Dr. Wei Li and Dr. William Seibel explored a compound library 
from the University of Cincinnati’s (UC) Drug Discovery Center, which contains 
342,910 small molecules. All compounds are available to us for testing via an established 
agreement. Usually, compounds are shipped within 2 days of request. Therefore, I can 
obtain any compound I select easily for biological testing. Although other compound 
libraries may have more entries than does the UC library, often availability of the 
compounds is an issue. Therefore, I chose this library for our current studies. 
 
In this chapter, I will discuss two ligand-based virtual screening approaches using 
the structure of our lead molecule (Figure 3-1): 1) similarity search based on atom 
connectivity using Scitegic Pipeline Pilot software (Accelrys Software, Inc., San Diego, 
CA) and 2) similarity search based on molecular shape using Schrodinger software 
(Schrodinger, Inc., New York, NY). Results showed that these two approaches are highly 
complementary and lead to different active molecular structures. These structures are 
quite suitable for further structural modification and provide new platforms for our 
anticancer drug discovery efforts.  
 
 
3.2 Experimental Methods 
 
 
3.2.1 Validation of Connectivity Similarity Search 
 
To validate the connectivity similarity search approach, Dr. Wei Li first 
established a relatively small testing compound library. This library contains 22 known 
compounds similar to LY-1-100, 10 known dissimilar compounds, and a diverse set of 
2000 compounds pulled from the University of Cincinnati Drug Discovery Center 
 
 
* This chapter adapted with permission from Wang Z, Lu Y, Seibel W, et al. Identifying novel molecular 
structures for advanced melanoma by ligand-based virtual screening. J Chem Inf Model 2009;49:1420-7. 
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Figure 3-1. Structure and molecular surface of lead compound, LY-1-100. 
This figure was prepared by Dr. Wei Li, Department of Pharmaceutical Sciences, 
University of Tennessee Health Science Center. 
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Compound Library (totally 342,910 compounds). These 2000 compounds were selected 
to be “druglike” in that they adhered to Lipinski rules and were filtered from a wide 
variety of functional groups. Dr. Wei Li seeded the known 32 compounds in the small 
testing library so they could be evenly distributed through the database file. Then Dr. 
Seibel conducted a connectivity similarity search for lead compound LY-1-100 against 
the 2032 testing compound library. The small compound library was subjected to five 
similarity filters in parallel using the ECFP2, ECFP4, ECFC6, FCFP4, and FCFP6 
property sets and Tanimoto distances using LY-1-100 as the lead structure (111-113). 
The top 400 compounds most similar to LY-1-100 from each of these operations were 
ranked by calculated similarity; then an average rank for each compound across the 
methods was calculated. The detailed algorithm of the search is shown in Figure 3-2.  
 
 
3.2.2 Atom Connectivity-Based Virtual Screening 
 
A protocol was designed within Accelrys’s Pipeline Pilot in the UC Drug 
Discovery Center. The entire compound library was subjected to the same five similarity 
filters in parallel as described in the validation process. Then an average rank for each 
compound was also calculated. Our experience suggests that each of the property sets has 
some inherent strengths and weaknesses with respect to any given structure, so we used 
the above multiple, parallel similarity analysis to ensure that the optimal compounds by 
any method were not missed. The detailed algorithm of the search is shown in Figure    
3-2.  
 
 
3.2.3 Validation of Shape Similarity Search 
 
Dr. Wei Li also tested our shape-based virtual screening using the same test 
database. The lead compound, LY-1-100, has a relatively rigid structure. So it has less 
conformer than other molecules. Therefore, Dr Li chose its lowest energy conformer at 
an environment of pH 7.4 as an active conformation, which is consistent with our 
recently reported crystal structure of LY-1-100 (110).  
 
All structures in this database were first prepared with the Ligprep software model 
(Schrodinger, Inc., New York, NY). During this preparation step, hydrogen atoms were 
explicitly added, all possible ionization states were generated between pH 5.0 and pH 9.0 
using the Ionizer module, and the 3D molecular structures were minimized with 
OPLS_2005 forcefield. Tautomers were also generated in this step. All structures were 
then subjected to shape similarity search using the Phase software module. Each structure 
was allowed to sample up to 100 conformers for which molecular shapes were calculated 
and compared with that of LY-100. Similarity scores were ranked from most similar to 
least similar.  
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Figure 3-2. General protocol flowchart for virtual screening validation and virtual screening. 
This figure was prepared by Dr. William Seibel, University of Cincinnati Drug Discovery Center, University of Cincinnati.
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3.2.4 Molecular Shape-Based Virtual Screening 
 
To make the intensive computation of shape-based virtual screening manageable 
for these 342,910 compounds, the database was first broken down into 17 smaller 
databases. Each small database contained about 20,000 molecules and was subsequently 
prefiltered to remove molecules containing reactive groups. Molecules in each small 
database were then prepared by the Ligprep software module to generate proper 3D 
structures with all possible ionization states between pH 5.0 and pH 9.0. Typically 30,000 
to 50,000 structures were produced from this step for each database. Subsequently, 100 
conformations were generated for each of the structures in the database, and the shape of 
each conformation was then compared to that of LY-1-100. A normalized shape 
similarity value was computed for each molecular conformation relative to that of LY-1-
100, with 0 the most dissimilar and 1 the exact same shape. Dr. Li set the threshold for a 
hit as a shape similarity greater than 0.7 regardless of surface property to keep the 
maximum hits. All hits were ranked down from the most similar hit. These calculations 
were repeated for each small database for all the molecules in the original database. 
 
 
3.2.5 Biological Assay and Data Processing 
 
Hits from the two similarity searches were analyzed and their structures 
examined. The top hits were requested from the UC Drug Discovery Center for a 
subsequent two-step in vitro assay. The first step was a fixed drug concentration 
screening assay on two melanoma cell lines. Compounds that killed at least 50% of both 
cancer cells at 10 µM were selected for the second step, and their IC50 values on two 
melanoma cell lines and one control cell line were determined. Human malignant 
melanoma cells A375 and mouse melanoma cells B16-F1 were used to evaluate the 
compounds’ in vitro anticancer activity. Both A375 cells and B16-F1 cells were obtained 
from American Type Culture Collection (Manassas, VA). All cell lines were cultured in 
DMEM media (Cellgro Mediatech, Inc., Herndon, VA), supplemented with 10% FBS 
(Cellgro Mediatech, Inc.), 1% antibiotic/antimycotic mixture (Sigma-Aldrich, Inc., St. 
Louis, MO), and bovine insulin (5 μg/mL; Sigma-Aldrich). Cultures were maintained at 
37°C in a humidified atmosphere containing 5% CO2. 
 
For the initial screening step, A375 and B16-F1 cells were seeded to 96-well 
plates at a density of 4000~5000 cells/well, respectively. After cells adhered to the plate, 
media were changed and test compounds were added together with media at a fixed 
concentration of 10 µM in duplicate. After 48-h incubation, cell viability was evaluated 
by using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (114). This 
assay is based on the bioreduction of MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]. This tetrazolium dye can be 
converted by living cells into a colored formazan product that is soluble in tissue culture 
medium and, therefore, provides a sensitive readout of cell life or death that can be 
monitored spectroscopically. After incubating cells with compounds for 48 h, 20 µL of 
CellTiter 96 AQueous One Solution Reagent was pipetted into each well, which 
contained the samples in 100 µL of culture medium. Plates were incubated for another 
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1.5 h at 37°C in a humidified, 5% CO2 atmosphere. Absorbance was recorded at 490 nm 
in a BioTek EL800 96-well plate reader (BioTek Instruments, Inc., Winooski, VT). Each 
compound’s cell killing rate was normalized against a no-treatment control.  
 
The second step was to further measure the IC50s of active compounds selected 
from the initial step. I used the activity on fibroblast cells as a control to determine the 
selectivity of these compounds between cancer cells and normal cells. Human dermal 
fibroblast cells were purchased from Cascade Biologics, Inc., (Portland, OR) and cultured 
in the same condition as the two melanoma cell lines. After cells were seeded on 96-well 
plates, they were exposed to a wide range of eight concentrations of each compound in 
quadruplicate to determine the IC50 values. Then the CellTiter 96 AQueous One Solution 
Cell Proliferation Assay was used to measure cell viability. IC50 values were calculated 
by nonlinear regression analysis using GraphPad Prism (GraphPad Software, San Diego, 
CA) (115, 116). Each assay was repeated three times on different occasions.  
 
 
3.3 Results and Discussion 
 
 
3.3.1 Validation of Connectivity Similarity Search 
 
Results from the connectivity search using the test database showed that the first 
19 most similar compounds were from the 22 seeded similar compounds according to the 
consensus score (average rank). The lowest rank of all seeded similar compounds was 
31st in the search results. The highest ranking “dissimilar” compound was ranked at 131st. 
This is approximately 6.5% of the way through the small 2032 compound database, 
making it analogous to the 22,106th ranked compound from the original search of the 
342,910 compounds library. This validation exercise clearly showed that similar 
compounds are easily ranked higher than dissimilar compounds by the connectivity 
indices-based methods we used.  
 
  
3.3.2 Connectivity Similarity Search 
 
The connectivity searches produced a combined total of 1292 compounds. To 
illustrate that each property set identified somewhat different similar structures, only 13 
compounds were in common among all five searches, 49 in common among four 
searches, and 160 in common among three searches. Results were consistent with a 
limited number of highly similar compounds and a fairly rapid digression to relatively 
low-similarity compounds. Out of these 1292 compounds, I selected the top-ranked 110 
compounds, middle-ranked 110 compounds, and bottom-ranked 110 compounds to 
screen their activity on the two cancer cell lines: A375 and B16-F1. Our decision to select 
compounds from the top-, middle-, and bottom-ranked compounds was not only to ensure 
testing of any highly similar (and therefore likely to be active) compounds (top-ranked) 
but also to search for active compounds of more divergent structure (middle- and low-
ranked compounds). Each of the 330 compounds was incubated with cells at a 
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concentration of 10 µM for 48 h in duplicate. Percentages of cell death induced by these 
compounds are shown in Figure 3-3. Three active compounds were identified from the 
110 top-ranked compounds (UC-297549, UC-791794, and UC-791475), one active 
compound from the 110 middle-ranked compounds (UC-406551), and four active 
compounds from the 110 bottom-ranked compounds (UC-791814, UC-791792, UC-
792257, and UC-193691). IC50 values for these active compounds were subsequently 
measured on A375, B16-F1, and fibroblast cells (Table 3-1). The best compound 
identified, UC-297549, had an IC50 value less than 1 µM on A375 cells and good 
selectivity between cancer cells and normal cells. Very interestingly, almost all of these 
compounds contained a basic terminal amine group close to an aromatic ring. This 
feature is different from the lead compound structure (LY-1-100), suggesting that adding 
a properly positioned amine group may enhance the activity of LY-1-100. Another 
important feature revealed from Table 3-1 is that a basic terminal amine group may help 
increase selectivity. Among the identified eight active compounds, only one did not have 
the basic terminal amine group (UC-406551). The selectivity of this compound was 
worse than that of the lead compound. All other seven active compounds, which have the 
basic terminal amine group, had better selectivity than our lead compound. Finally, a 
basic terminal amine group is also expected to have the added benefit of a reduced logP 
value and improved water solubility.  
 
With this in mind, Dr. Yan Lu synthesized a new analog of LY-1-100 in which an 
amino group was added to the para-position of the phenyl ring (compound LY-2-183H). 
To our great satisfaction, LY-2-183H was more active and selective than LY-1-100 was 
(Table 3-1). As expected, LY-2-183H had much better water solubility, which is an 
important factor for future in vivo animal testing. Further optimization of this structure is 
currently in progress. 
 
 
3.3.3 Additional Analog Screening Based on Active Compounds Identified from 
Connectivity-Based Screening  
 
Encouraged by the structure of the initial connectivity screening and using the 
same protocol as described above in combination with substructural analysis, I selected 
an additional 40 compounds whose structures were close to the 8 active compounds. 
When I tested the activity for these 40 compounds on A375 and B16-F1 cells, 4 active 
compounds (10% hit rate, Figure 3-4) were identified (UC-792247, UC-792341, UC-
98514, and UC-831104). Their IC50 values against all three cell lines are shown in Table 
3-2. While these four compounds were not as active as was UC-297549, they contained 
more structural features than LY-1-100 and may provide more opportunities for further 
structural modifications. 
 
 
3.3.4 Validation of Shape Similarity Search 
 
During the testing compound library preparation step, the Ligprep process 
generated 6767 distinct structures from the original 2032 entries. Thirty-five ionization  
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Figure 3-3. In vitro screening results for compounds identified from atom connectivity-
based virtual screening.  
Percentage of cell death resulted from compound treatment was normalized by non-
treatment control. Each bar represents the average of two replications.  
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Figure 3-3. (continued)
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Table 3-1. IC50 of lead compound, eight active compounds identified from atom 
connectivity-based virtual screening, and newly synthesized compounds.  
 
UC number Structure IC50SEM (M) (n=3) Selectivity*
B16-F1 A375 HDFa 
LY-1-100 
(Lead 
structure) 
S
N
O
O
O
O
555 
nM 
285 
nM 
354 
nM 1 
297549 
O
Cl
HNO
O
O
122 500100 nM >20 >3 
791814 N
N
NH2
O
O
O
O
81 41 81 1 
791792 
N
N
O
O
O
O
NH2
91 61 101 1 
791794 
N
N
NH2
O
O
O
O 91 81 91 1 
792257 
N
N
O
O
O
O
NH2
101 101 >20 >2 
791475 
N
N
H2N
O
O
O
O
111 91 182 2 
406551 
O
O
O
O
ON
N
H
OOH
111 141 40 0.3 
193691 N
S
S NH2
H2N Cl
Br
71 80 213 3 
LY-2-183H S
N
O
O
O
O
ClHH2N
144 
nM 
113 
nM 
182 
nM 2 
 
*Selectivity is defined as the ratio of IC50 on fibroblast over the IC50 average in the two 
cancer cell lines. 
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Figure 3-4. In vitro screening results for compounds identified from further atom 
connectivity similarity search based on previously identified active compounds. 
All compounds were tested at 10 µM concentration on A375 and B16-F1 melanoma 
cells. Each bar represents the average of two replications. 
 
  
1
3
5
-5.0%
15.0%
35.0%
55.0%
75.0%
95.0%
115.0%
H G F E D C B A
Row
Pe
rc
en
ta
ge
 o
f C
el
l D
ea
th
Column
Cytotoxicity of Compounds in Plate 848 on A375 
1
3
5
-5.0%
15.0%
35.0%
55.0%
75.0%
95.0%
115.0%
H G F E D C B A
Row
Pe
rc
en
ta
ge
 o
f C
el
l D
ea
th
Column
Cytotoxicity of Compounds in Plate 848 on B16-F1 
 59 
 
Table 3-2. IC50 of active compounds identified from further atom connectivity similarity 
search based on previously identified active compounds. 
 
UC 
number Structure 
IC50SEM (M) (n=3) Selectivity*
B16-F1 A375 HDFa 
792247 
N
N
O
O
O
O
NH2 61 40 111 2 
792341 
N
N
O
O
O
O
H2N
61 30 102 2 
98514 
Cl
N
S
H2N
NH
30 300100 nM 60 4 
831104 
O
O
O
O
O
NHN
O
O
 
30 31 61 2 
 
*Selectivity is defined as the ratio of IC50 on fibroblast over the IC50 average in the two 
cancer cell lines. 
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states were generated for the 32 seeded molecules, including 24 similar structures 
(protonated and unprotonated forms for both LY-2-103 and LY-2-84), and 11 dissimilar 
structures (Figure 3-5, seeded similar structures are highlighted in yellow, and dissimilar 
structures are highlighted in red). Validation search results for the seeded structures are 
listed in Figure 3-5. From these results, I can see that the top 26 entries from this search 
contained 20 of the 24 seeded similar structures (86% similar structures from 0.35% of 
total database). The four remaining similar structures ranked at 107, 255, 281, and 1508. 
Twenty-three out of 24 (96%) similar structures were found within the 4.2% of the total 
structures in this sample database. The saturated thiazole ring and the amide bond in LY-
2-74 are responsible for its low similarity ranking of 1508, when compared with the 
molecular shape of LY-100 (Figure 3-1). This structure also showed the worst similarity 
rank in the connectivity-based similarity search (rank 31st). In contrast, the ranks for the 
10 dissimilar structures spanned from 332 to 6712 out of the 6767 structures. In 
summary, I found that this shape similarity search approach could identify similar 
compounds, which provides reasonable validation for screening the entire database. 
 
 
3.3.5 Shape Similarity Search  
 
The classical concept of lock and key interaction between a receptor and its ligand 
indicates that molecular shape is a critical factor for high binding affinity. Similarities in 
connectivity and molecular shape have overlap but also have their own individual spaces. 
To explore potentially new platforms based on the molecular shape of LY-1-100, Dr. Li 
performed shape similarity searches against this database. These searches produced a 
little over 5000 structures that had a similarity score larger than 0.7 and did not contain 
any reactive groups. I selected the 88 top-ranked compounds and performed an initial 
single concentration screening (Figure 3-6). Two active compounds (UC-521092 and 
UC-398535), which are very close analogs, were identified, and their IC50s are shown in 
Table 3-3. The tight criterion (similarity score must be at least 0.7) was likely responsible 
for limiting greater variations for identified structures.  
 
Although still not as active as LY-1-100, these two compounds were more potent 
than compounds identified from connectivity-based virtual screening, with IC50 values in 
the nanomolar range. One important hint revealed from this search was that a properly 
constructed amide linkage between the five-member ring and the trimethoxyphenyl ring 
may be very beneficial to anticancer activity. Previously, Dr. Lu made one compound 
(LY-2-30) containing an amide bond that was not active. Based on results of this 
screening, Dr. Lu prepared another analog in which the direction of the amide bond was 
reversed to directly connect the carbonyl group to the trimethoxyphenyl ring (LY-2-
173b-OTs). The activity of this compound was greatly improved (Table 3-3).  
 
The high activity of compounds identified from this shape similarity search likely 
resulted from the very close structural features to LY-1-100. Obviously, this similarity 
also limited their structural variations; therefore, a dramatically different scaffold from 
LY-1-100 will be difficult to obtain. Hence, at least for this database, shape similarity 
search will not provide completely new molecular structures. On the other hand,  
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Figure 3-5. Seeded structures in validation testing library with shape similarity ranks. 
Seeded similar structures are highlighted in yellow. Dissimilar structures are highlighted 
in red. 
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Figure 3-5. (continued) 
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Figure 3-5. (continued) 
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Figure 3-6. In vitro screening results for compounds identified from molecular shape-
based virtual screening. 
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Table 3-3. IC50 of active compounds identified from a shape similarity search, one 
inactive compound, and one newly synthesized compound based on the information get 
from shape similarity search.   
 
UC number  Structure 
IC50SEM (M) (n=3) Selectivity*
B16-F1 A375 HDFa 
521092 Cl
N
N
H
O
O
O
O
800200 
nM 
200100 
nM 
 300100 
nM 1 
398535 
N
NH
O
O
O
O
O
O 21 400100 nM 
400200 
nM 0.3 
LY-2-30 N
S
O
O
O
N
H
O >100 >100 >100 N/A 
LY-2-
173b-OTs N
S
O
O
O
H
N
O
192 71 534 4 
 
*Selectivity is defined as the ratio of IC50 on fibroblast over the IC50 average in the two 
cancer cell lines. 
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depending on the criteria of the connectivity search, completely novel structural features 
and new molecular platforms could be identified, but loss of activity may be expected. 
These two approaches are therefore highly complementary.  
 
 
3.3.6 Comparison of Two Similarity Search Methods 
 
Generally speaking, the connectivity similarity search gave us more diverse 
structure scaffolds that are bioactive than did the shape similarity search. For example, I 
got eight bioactive compounds in the first round of whole-library connectivity similarity 
search and four bioactive compounds in the further search. I obtained highly varied 
scaffolds such as compound UC193691, in which I found the lead compound 
trimethoxyphenyl ring replaced by an isothiourea group; in compound UC98514, I found 
the lead compound phenyl right replaced by the amidine group. But in the shape 
similarity search, I only got two bioactive compounds, and they both shared very close 
features with the lead compound. On the other hand, the shape similarity search gave us 
more bioactive compounds than did the connectivity search. The two hits from the shape 
similarity search had IC50 values on melanoma cell lines in the nanomolar range, while 
hits from the connectivity search were mostly in the micromolar range. The reason for 
this difference was largely to the result of the inherent algorithm difference of these two 
screening approaches. 
 
We did not choose receptor-based virtual screening because we did not confirm 
the target for this new class compounds at the initial stage. Later mechanism of action 
studies revealed that the target is the tubulin colchicine binding site.  
 
 
3.4 Conclusions 
 
Using both connectivity- and shape similarity-based virtual screening against a 
large database, I identified 14 new molecules from the UC compound library that are 
active against melanoma cells. These molecules provide several new functional groups 
and structure features compared with the lead structure. In summary, the novel 
pharmacophoric elements identified through these virtual screening exercises include a) a 
terminal basic amine group can improve activity and selectivity; b) a properly constructed 
amide linker between the five-member ring and the trimethoxyphenyl ring is beneficial to 
bioactivity; c) the thiazole ring in the lead compound is not necessary for bioactivity, and 
it can be replaced with an N-methylene hydrazine linker; d) an isothiourea group can 
replace the lead compound trimethoxyphenyl ring; and e) an amidine group can replace 
the phenyl ring of the lead compound.  
 
This information is helpful for understanding the structure-activity relationship 
and for further improving compound activity. While the shape similarity search did not 
provide diverse active structures, the active compounds identified were generally much 
more active than those identified by the connectivity search. Combining both 
connectivity and shape similarity search techniques was complementary for our ligand-
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based drug discovery efforts. Further modification of the lead compound is in progress 
based on the information obtained from these virtual screenings.  
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CHAPTER 4. DISCOVERY AND BIO-EVALUATION OF 4-SUBSTITUTED 
METHOXYBENZOYL-ARYL-THIAZOLE AS NOVEL ANTI-MELANOMA 
AGENTS* 
 
 
4.1 Introduction 
 
Microtubule is composed of - and -tubulin dimmer, which plays an important 
role in cell mitosis, motility and organelle distribution (117). The formation of 
microtubule from tubulin is a dynamic process that involves the polymerization and 
depolymerization of - and -heterodimer. These dynamic behaviors are crucial to cell 
mitosis, which is the process of chromosomal division to form new cells (118). 
Interference with tubulin-microtubule dynamics may be one of the attractive potential 
strategies in developing an anticancer drug (119, 120). There are some antitubulin agents 
developed with great potency, which may achieve low nano-molar range in the inhibition 
of cell proliferation by inducing cell cycle to be arrested in G2/M phase and subsequently 
the inhibition of cell division (121, 122).  
 
Tubulin heterodimer has three major known pharmacologic sites, including taxane, 
vinca, and colchicine site. Vinca and colchicine domain ligands destabilize and inhibit 
microtubule formation. Taxane–site agents stabilize and promote the formation of 
microtubules, having the opposite effects of vinca and colchicine domain ligands. Some 
of the antitubulin agents have been successfully developed for clinical use, such as 
paclitaxel on taxane domain, and vincristine, vinorelbine, vinblastine on vinca domain. 
However, they are substrates of P-glycoprotein and have drug resistance issues (123, 124).  
Although no clinical application colchicine-domain binding drugs yet, there are some 
agents which are on the phase I or II stage of development (125, 126). To address the 
drug resistance of antitubulin agents for each binding-domain, many new generation 
antitubulin agents are developed to overcome the issue caused by over expression of P-
glycoprotein and/or the MDR1 (127-130).    
 
I have been actively engaged in searching novel anticancer agents that target on 
tubulin. More recently, a series of 4-Substituted Methoxylbenzoyl-Aryl-Thiazole 
(SMART) has been developed in our laboratory (100). This series compounds was 
developed from 2-aryl-thiazolidine-4-carboxylic acid amides (ATCAA) which I 
discussed in chapter 2. SAR studies of ATCAA indicated that replacement of the lipid 
chain with a bulky aromatic ring in the 4-amide position of ATCAA attached to the 
thiazolidine ring still kept the anti-proliferative activity. This finding afforded us a new 
point to replace the fatty amide chain with a number of aromatic groups, which would 
maintain the cytotoxicity. With further investigation of ATCAA analogues, structure 
modifications were made on thiazolidine ring and 4-carboxylic amide linker. Thus, 
substituted methoxylbenzoyl-aryl-thiazole (SMART) compounds were discovered. 
 
 
*Portions of this chapter adapted with permission from Lu Y, Li CM, Wang Z, et al. Discovery of 4-
substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and 
structure-activity relationships. J Med Chem 2009;52:1701-11. 
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The general structure of SMART agents with as showed in Figure 4-1. The 
SMART agents have a structure containing three conjugated aromatic rings (A, B and C 
rings, respectively) with a ketone linkage between B and C rings. Thiazole was 
introduced in B ring instead of thiazolidine ring in ATCAA. The linker between B and C 
rings was modified from an amide to carbonyl group. The C ring was characterized by 
the presence of differently-substituted phenyl groups, in particular, the 3, 4, 5-trimethoxy 
substituted phenyl at C ring played an important role of antiproliferative activity against 
melanoma.  
 
According to the study, I characterized the biologic effect using three 
representative SMART compounds: SMART-100, SMART-45, and SMART-211. 
SMART-100 and SMART-45 are the most potent SMART compounds in our laboratory; 
however, they exhibit poor solubility. SMART-211 was synthesized to increase solubility 
by adding a hydroxyl- group on the A-ring, and it still remained potent cytotoxicity with 
IC50 value of 120 nM on several melanoma cell lines. I examined these SMARTs on cell 
proliferation in a variety of cancer cell lines including MDR-positive cell lines and 
summarized the SAR. I determined the binding site to tubulin, the ability of inhibition on 
tubulin polymerization. Together with Mr. Chien-ming Li, I determined pharmacokinetic 
parameters on mice, and developed a formulation for the improvement of the poor 
solubility of SMARTs. I also examined the anticancer efficacy using nude mice bearing 
human melanoma A375 xenograft.  
 
 
4.2 Materials and Methods 
 
 
4.2.1 Compounds and Reagents  
 
All the SMART compounds were synthesized by Dr. Yan Lu. Paclitaxel, vinblast-
ine, and colchicine were obtained from Sigma-Aldrich. Ethanol was obtained from Decon 
labs, Inc. Cremophor ELP was obtained from BASF, Inc. CellTiter 96® AQueous One 
Solution Reagent was obtained from Promega.  
 
 
4.2.2 Cell Culture and Cytotoxicity Assay 
The A375 and B16-F1 melanoma cancer cells were obtained from American Type 
Culture Collection (Manassas, VA). WM-164 cells were derived from patient metastatic 
melanoma tumors and were a gift from Dr. Meenhar Herlyn (Wistar Institute, 
Philadelphia, PA). Human Dermal Fibroblast (adult) cells (HDFa) were obtained from 
Cascade Biologics. This cell line was used as control to determine selectivity. The P-gp 
overexpressing multi-drug resistant cell line MDA-MB-435/LCC6MDRI and matching 
sensitive parent cell line were kindly provided by Dr. Robert Clarke (Georgetown 
University, Washington, DC). Cells were grown as monolayers by using standard cell 
culture conditions. All cells were cultured in DMEM (Mediatech, Inc., Manassas, VA), 
supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1%  
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Figure 4-1. Structures of LPA, ATCAA and SMART. 
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antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis, MO), and bovine insulin (5 
µg/mL) (Sigma-Aldrich, St. Louis, MO).  
 
 Cultures were maintained at 37°C in a humidified atmosphere containing 5% 
CO2. 1000 to 5000 cells were plated into each well of 96-well plates depending on 
growth rate and exposed to different concentrations of a test compound for 48 h in three 
to five replicates. Cell numbers at the end of the drug treatment were measured by the 
MTS assay. Absorbance was recorded at 490 nm in a BioTek EL800 96-well plate reader 
(BioTek Instruments, Inc., Winooski, VT). Percentages of cell survival versus drug 
concentrations were plotted and the IC50 (concentration that inhibited cell growth by 50% 
of untreated control) values were obtained by nonlinear regression analysis using 
GraphPad Prism (GraphPad Software, San Diego, CA). 
 
 
4.2.3 Cell Cycle Analysis 
 
Flow cytometry was performed to study cell cycle phase distribution. A375 cells 
were cultured in growth media until the confluence was about 70%, and then cells were 
starved in 0.5% charcoal-stripped serum (CS-FBS) for 48 h before the experiment. A375 
then were treated with 0, 10, 50, 200, and 1000 nM of SMART-100, -45, and -211 for 24 
h in growth media. The cellular DNA was stained with PBS containing 100 g/mL 
propidium iodide, and 100 g/mL RNase A. Flow cytometry assay was used to determine 
the distribution of a population of cells to different stages of cell cycle. 
 
 
4.2.4 In Vitro Microtubule Polymerization Assay 
 
Bovine brain tubulin (0.4 mg) (Cytoskeleton, Denver, CO) was mixed with 10 
M of test compound and incubated in 120 L of general tubulin buffer (80 mM PIPES, 
2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9 and 1 mM GTP). The absorbance of wavelength 
at 340 nm was monitored every 60s for 20 min by the SYNERGY 4 Microplate Reader 
(Bio-Tek Instruments, Winooski, VT). The spectrophotometer was set at 37C for tubulin 
polymerization.  
 
 
4.2.5 Tubulin Colchicine Competition Assay  
 
[3H]colchicine competition-binding scintillation proximity assay (SPA) 
(Cytoskeleton Inc, Denver, CO) was used to evaluate SMART compounds that bind to 
the colchicine binding site on tubulin. Biotin-labeled tubulin (0.5 g) was mixed with 
[3H]colchicine (0.08 µM) (Perkinelmer LLC., Shelton, CT) and varies concentrations of 
SMARTs. Streptavidin-labeled SPA beads (80 g) (GE-healthcare Bio-Sciences Corp., 
Piscataway, NJ) are added, and co-incubated in 200 L binding buffer [80 mM PIPES 
(pH 6.8), 1 mM EGTA, 10% glycerol, 1 mM MgCl2, and 1 mM GTP] for 45 min at 37°C. 
IC50 values (concentrations that inhibited 50% of tritiated colchicine binding) were 
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determined by nonlinear regression analysis with GraphPad Prism (GraphPad Software, 
San Diego,CA). 
 
 
4.2.6 Microtubule Imaging Using Fluorescence Microscope 
 
In order to get a visually appreciable proof of SMART compounds interacting 
with tubulin inside the cells, I examined microtubule arrangement in human melanoma 
WM-164 cells upon treatment with different compounds. I selected the Cellomics 
Cytoskeleton rearrangement kit (Thermo Scientific, Rockford, IL) which is widely used 
for such studies and followed the instructions from the manufacturer. WM-164 
Melanoma cells were treated with each compound for 18 h in duplicate using a collagen-
coated 96-well plate (Becton Dickinson Labware, Bedford, MA). Then cells were fixed 
with 4% paraformaldehyde (Thermo Scientific, Rockford, IL) and permeabillized using 
permeabilization buffer supply from the kit. Primary antibody for tubulin and 
fluorescence labeled secondary antibody were subsequently added to the cells. Cell nuclei 
were stained by DAPI. Whole Cell Stain Green was also applied to all cells. All images 
were acquired with an Olympus IX71 inverted fluorescence microscope (Olympus 
Corporation, Tokyo, Japan) with overlays from separate images of tubulin (red), nuclei 
(blue) and whole cells (green).  For comparison, I also included paclitaxel, colchicine 
along with SMART compound.  
 
 
4.2.7 Pharmacokinetic Studies in Mice  
 
Male ICR mice 6 to 8 weeks of age were used to perform pharmacokinetic study. 
Drug solutions were dissolved in DMSO/PEG300 (80/20) and administrated by a single 
i.v. injection into the tail vein. For SMART-100, 5 and 15 mg/kg of body weight were 
administrated. For SMART-45, 15 mg/kg of body weight was administrated. Blood 
samples were obtained via cardiac puncture under isoflurane anesthesia at 2, 5, 15, and 
30 min, 1, 2, 4, 8, 16, and 24 h after administration, using 3-4 animals per group. Sodium 
heparin (5 L of 1,000 USP units/mL per sample) was used as an anticoagulant. Blood 
samples were collected on ice, and separated by centrifuging at 3000g for 10 min to 
obtain plasma. All samples were stored at -20ºC until analysis.  
 
Protein precipitation method was used for sample preparation. Plasma samples 
were thawed at room temperature.150 µL of acetonitrile (ACN) containing an internal 
standard, a SMART analog, was added to 100 µL of plasma sample, and then was 
thoroughly vortexed for 15 s. After centrifugation at 14,000 RPM for 10 min at 4°C, the 
supernatant was transferred into high-performance liquid chromatography vials and 
directly used for LC-MS/MS analysis.  
 
Plasma concentration-time data were analyzed by non-compartmental analysis 
using WinNonlin 5.2 (Pharsight Corporation, Mountain View, CA). The area under the 
plasma concentration-time curve from time 0 to infinity (AUCinf) was calculated by the 
trapezoidal rule with extrapolation to time infinity. The terminal half-life (t1/2) was 
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calculated as 0.693/λz, where λz is the terminal phase rate constant. The plasma clearance 
(CL) was calculated using the equation CL=Doseiv/AUCinf, iv, where Doseiv and AUCinf, iv 
are the IV dose and corresponding area under the plasma concentration-time curve from 
time 0 to infinity, respectively. Volume of distribution based on terminal phase (Vz) was 
calculated using Vz=Doseiv/(λz*AUCinf, iv). The peak plasma concentration (Cmax) and the 
time when it occurred (tmax) in the IP group were obtained by visual inspection of the 
plasma concentration-time curves. Clearance after IP (CL/F) was calculated as 
Doseip/AUCinf, ip. Volume of distribution after IP (Vz/F) was calculated as 
Doseip/(λz*AUCinf, ip). IP bioavailability (F) was calculated using F=(AUCinf,ip* 
Doseiv)/(AUCinf, iv *Doseip), where Doseip, Doseiv, AUCinf, iv, and AUCinf, ip are the IP and 
IV dose and the corresponding areas under the plasma concentration-time curves from 
time 0 to infinity, respectively. 
 
 
4.2.8 LC-MS/MS Method for Measuring SMART Compounds  
 
Sample solution (10 µL) was injected into an Agilent series HPLC system 
(Agilent 1100 Series Agilent 1100 Chemstation, Agilent Technology Co, Ltd). SMART-
100 and SMART-45 were separated on a narrow-bore C4 column (Varian Inc, 2.1×150 
mm, 5 µm, Palo Alto, CA). Gradient mode was used to achieve the separation of analytes 
using mixtures of mobile phase A (5% acetonitrile containing 0.1% formic acid) and 
mobile phase B (95% acetonitrile containing 0.1% formic acid) at a flow rate of 300 
L/min. Mobile phase A was used at 100% from 0 to 1 min followed by a linearly 
programmed gradient to 100% of mobile phase B within 3 min, 100% of mobile phase B 
was maintained for 1 min before a quick ramp to 100% mobile phase A. Mobile phase A 
was continued for another 8 min towards the end of analysis. 
 
A triple-quadruple mass spectrometer, API QtrapTM (Applied Biosystems/MDS 
SCIEX, Concord, Ontario, Canada), operating with a TurboIonSpray source was used. 
SMART-100 and SMART-45 were infused into the mass spectrometer at 1 mg/L and 10 
L/min to optimize the instrument parameters used for LC-MS/MS. The Q1 full scan 
spectrums of SMART-100 and SMART-45 were first obtained to identify [M+H]+ ion as 
the precursor ion to generate product ion scans for selecting the most distinctive 
precursor-product ion pair. For the most sensitive quantitative analysis, the mass 
spectrometer was operated in the multiple reaction monitoring (MRM) mode, which 
includes m/z 356.2→ 188.2 for SMART-100, 374.2→ 206.2 for SMART-45, and m/z 
434.0 → 266.0 for an internal standard, which is analog of SMART compound. Dwelling 
time was set to 100 ms for each analyst, and 50 ms for the internal standard. Detection 
limit is 0.2 ng/mL for SMART-45, -100, and -211. 
 
The spraying needle voltage was set at 5000 V for positive mode. Curtain gas was 
set at 10; Gas 1 and gas 2 were set at 50. Collision-Assisted-Dissociation (CAD) gas at 
medium, and the source heater probe temperature at 500C. DP, EP, CXE were set at 16, 
10, and 15 V, respectively. Data acquisition and quantitative processing were 
accomplished using AnalystTM software, Ver. 4.0 (Applied Biosystems). 
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4.2.9 Antitumor Efficacy on A375 Xenografted Athymic Nude Mice 
 
A375 cells (5107/mL) were prepared in phenyl red free DMEM media 
containing 10% FBS, and mixed with 1:1 of Matrigel (BD Biosciences, San Jose, CA). 
Tumors were established by injection 100 L of mixture (2.5106 cells per animal, s.c. 
into low flank of mice) to 6-8-week-old male athymic nude mice. Treatments were 
initiated when tumor reached a mean group size of 150 mm3. Tumor volume (mm3) was 
measured with calipers and determined by the formula, π/6  L  W2, where length (L) 
and width (W) are in mm. The formulation of Tween80/Captex200 (80/20) were used to 
prepare SMART-100 (20 mg/kg), and SMART-45 (15 mg/kg). Mice were administrated 
by i.p. daily for 34 days (10 mice per group). 
 
 
4.3 Results and Discussion 
 
I studied the structure-activity relationship (SAR) in our laboratory and selected 
three potent SMARTs to perform the mechanism of action. SMART-100 has no 
substitution on the A-ring. SMART-45 and SMART-211 have fluorine (-F) and hydroxy 
(-OH) on the A-ring, respectively. SMART-45 and -100 have poor solubility; however, 
SMART-211 is a water-soluble compound. The effects of SMART-100, -45, and -211 on 
the proliferation of melanoma cancer cells (B16-F1, A375, and WM-164) and normal 
fibroblast cells are summarized in Table 4-1. SMARTs inhibit the proliferation of 
prostate and melanoma cancer cells with IC50 values in the low nano-molar range. 
Overall, the potency of SMART-45 is similar to SMART-100, and greater than SMART-
211.  
 
 
4.3.1 SAR Studies 
 
 
4.3.1.1 SAR of the B Ring 
 
Please see Figure 4-1 for the designation of A, B, and C ring of SMART 
compounds. In the previous ATCAA compounds, I found the thiazolidine ring, which 
contained a free NH at its 3-position, was important for cytotoxicity. Once the B ring 
thiazolidine moiety was replaced by a thiazoline ring, the antiproliferative activity 
decreased sharply from 600 nM to over 50 µM on WM-164 cell lines (83). The ATCAA-
1 fatty amide derivatives that were most effective against melanoma cell lines were 
examined and shown to have an IC50 2 μM (Table 4-2). Replacement of the long fatty 
chain with a certain aromatic bulky subsistent such as fluorene (ATCAA-2) showed 
inhibitory activity on both cancer cell lines (IC50=2~4 μM). The fluorene group in 4-
carboxylic amide position was also replaced by 3, 4, 5-trimethoxylphenyl group (2a and 
2b), but the potency against both cancer cell lines was lost. The subsequent B ring 
modification from saturated thiazolidine compound 2a to unsaturated thiazole 5 did not 
show any cytotoxicity against either cancer cell line tested. But thiazoline enantiomers 4a 
and 4b (R-isomer and S-isomer, showed similar antiproliferative activities) showed 
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Table 4-1. Cytotoxic activity comparison of representative SMART compounds with 
other anticancer drugs. 
 
Compound name 
IC50SEM (nM) (n=3) 
A375 B16-F1 WM-164 HDFa 
SMART-100 285 555 646 405 
SMART-45 2911 4321 416 407 
SMART-211 9311 1136 9910 28992 
Paclitaxel 123 172 183 123 
Vinblastine 10 51 10 31 
Colchicine 203 295 102 182 
Bortezomib 81 242 81 262 
 
 
Table 4-2. In vitro cytotoxic activity of modified ATCAA compounds. 
 
X C
BS N
A  
A ring B ringa C ringb X 
IC50SEM (M) (n=3) 
B16-F1 A375 
ATCAA-1 p-NHAc-Ph TZD C16H33 CONH 20 20 
ATCAA-2 p-NHAc-Ph TZD 9H-fluoren-1-yl CONH 40 20 
2a Ph TZD 3,4,5-trimethoxyl-Ph CONH >100 >100 
2b 3,4,5-trimethoxyPh TZD 3,4,5-trimethoxyl-Ph CONH >100 >100 
4a(4R) Ph TZL 3,4,5-trimethoxyl-Ph CONH 383 232 
4b(4S) Ph TZL 3,4,5-trimethoxyl-Ph CONH 303 141 
5 Ph TZ 3,4,5-trimethoxyl-Ph CONH >100 >100 
8f Ph TZ 3,4,5-trimethoxyl-Ph CO 555 nM 285 nM 
Colchicine     295 nM 203 nM 
 
aTZD=thiazolidine, TZL=thiazoline, TZ=thiazole 
bFor ATCAA-1, C position contains a lipid chain. 
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improved activity (IC50=14~38 μM) compared with 2a, 2b and 5. When the amide CONH 
linkage between B ring and C ring was replaced by a carbonyl linker, the mixtures of 
thiazoline/thiazole ketone 8f were obtained instead of desired thiazoline ketone, because 
the auto-dehydrogenation between thiazoline and thiazole occurred. Surprisingly, 
introduction of the carbonyl group linker and thiazole led to a significant enhancement of 
growth inhibition of examined cancer cell lines with a low nanomolar level (8f, 
IC50=21~71 nM), which is comparable to the natural anticancer agent colchicine. Thus a 
series of the SMART compounds with B as a thiazole ring were designed and synthesized 
based on the discovery of 8f and their anticancer activity was evaluated against 
melanoma. 
 
 
4.3.1.2 SAR of the C Ring 
 
We started our investigation of the C position of the SMART by introducing 
different substituted phenyls or alkyl chain. Variation of the phenyl substituents has a 
remarkable change in effect on potency. The in vitro assay as shown in Table 4-3 gave us 
an interesting result but only 3, 4, 5-trimethoxylphenyl in C ring (8f) showed excellent 
inhibition against all cancer cells (IC50=28~55 nM). Compound 8g, with a 3, 5-
dimethoxyphenyl group, showed 6-fold average cytotoxicity lower than 8f. Modifications 
of 8f by removal of one methoxy at meta-position (8e) or two methoxy groups (8b, 8c 
and 8d) from 8f led to a dramatic loss in activity (IC50>20 M). Although ortho- 
substituted monomethoxy compound 8d exhibited weak activity against a certain cell 
lines compared with meta-/para-MeO substituted 8c/8b and dimethoxyphenyl compound 
8e, none of them showed significant potency in inhibition compared with 8f. Similar 
trends were also seen in 8h and 8j with 2-fluorophenyl and hexadecyl in C ring 
modifications.  
 
 
4.3.1.3 SAR of the A Ring 
 
In SAR studies of the ATCAA compounds, I found that the electronic properties 
of substituents of the phenyl ring in the 2-positioin of the thiazolidine ring strongly 
affected the anticancer activity in ATCAA compounds  electron-withdrawing groups 
(EWG) on 2-phenyl gave higher activities than those with electron-donating groups 
(EDG). Dr. Lu also introduced different para-substituted EWG and EDG on A phenyl 
ring of the SMART molecules. From the IC50 value against these cancer cell lines, 
electronic effects of A ring phenyl substituents did not show clear influence on 
antiproliferative activity. Introduction of a weak EWG (4-F in 8n, IC50s: 33~43 nM) or 
weak EDG (4-CH3 in 8k, IC50s: 11~21 nM), both increased the potency compared with 8f 
(see Table 4-4). The replacement of para- position with strong EWG such as NO2 (8p), 
CN (8q), CF3 (8t) or introducing strong EDG (3, 4-dimethoxy) to A phenyl ring (8o) 
exhibited comparable antiproliferative activity.   
 
To compare the effects of ortho-, meta- and para- substitutions, a fluoro atom was 
introduced to different positions of A phenyl ring (8l, 8m and 8n). The various o-, m-, p- 
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Table 4-3. In vitro cytotoxic activity of SMART compounds with C rings modification. 
 
Compounds  C Ring IC50SEM (M) (n=3) 
B16-F1 A375 
NS
O
C
 
8a Ph >100 >100 
8b 4-Methoxy-Ph >100 >100 
8c 3-Methoxy-Ph >100 >100 
8d 2-Methoxy-Ph 5921 7033 
8e 3, 4-Dimethoxy-Ph >100 >100 
8f 3,4,5-Trimethoxy-Ph 555 nM 285 nM 
8g 3, 5-Dimethoxy-Ph 35020 nM 17010 nM 
8h 2-Fluoro-Ph >100 >100 
8j Hexadecyla 1918 16  15 
 
aCompound 8j has a lipid chain at C ring position. 
 
 
Table 4-4. In vitro cytotoxic activity of SMART compounds with A rings modification. 
 
Compounds A Ring IC50SEM (nM) (n=3) 
B16-F1 A375 
 
8f Ph 555 285 
8k 4-Methyl-Ph 2110 115 
8l 2-Fluoro-Ph 2711 309 
8m 3-Fluoro-Ph 28736 30425 
8n 4-Fluoro-Ph 4321 3314 
8o 3, 4-Dimethoxy-Ph 16129 3410 
8p 4-Nitro-Ph 5612 389 
8q 4-Cyano-Ph 5316 5924 
8t 4-Trifluoromethyl-Ph 9216 235 
8u 4-Bromo-Ph 325 132 
8v 4-Ethyl-Ph 708 172 
8x 4-Pyridine >100000 >100000 
8y 2-Pyrimidine 2300860 4100740 
8z 2-Thienyl 3815 207 
10 Ha >100000 >100000 
 
aCompound 10 has a proton at A ring position. 
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A
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substituents did not exhibit equal activities. o-fluoro substituted 8l showed the lowest 
IC50s (27~30 nM) against melanoma cells. 8n has similar average IC50s (33~43 nM) 
against melanoma compared with 8l. Meta-substituted compound 8m showed lowest 
activity on melanoma cells (IC50s: 287~304 nM). 
 
Turning to the effects of steric hindrance group on the A phenyl ring substituents, 
I found that p-bromo (8u, IC50s: 13~32 nM) caused a slightly decrease in antiproliferative 
activity relative to p-fluoro position (8n, IC50s: 6~12 nM). Reduced activity against both 
cancer cell lines is obvious when p-methyl (8k, IC50s: 11~21 nM) was replaced with a p-
ethyl group (8v, IC50s: 17~70 nM).   
 
To investigate if phenyl played an essential role at A ring in cytotoxicity, Dr. Lu 
also removed phenyl at 2-thiazole position and compound 10 was obtained. This 
modification caused a total loss of activity compared with 8f. The replacement of the A 
ring by pyridine (compound 8x) had the same effect. Moreover, substituting 2-pyrimidine 
in A ring (compound 8y) also caused a significant loss of activity (IC50s: 2~4 µM). 
However, introducing the thiophene replacement of phenyl (8z) into A position slightly 
improved the potency (IC50s: 20~38 nM) compared to 8f (IC50s: 28~55 nM).   
 
 
4.3.1.4 SAR of Pharmaceutically Acceptable Salt Groups to the SMARTs 
 
Most of the SMART compounds have good solubility in organic solvents such as 
CHCl3, CH2Cl2 and DMSO. But they show poor water-solubility. Dr. Lu designed and 
synthesized water-soluble salts of the SMART by introducing a hydrophilic group such 
as NH2 (8w) and COOH (8r) into A ring and generated the HCl or sodium salt. Another 
modification is replacing A/C rings in 8a with pyridine (8i, 8x, 8y) or pyrimidine rings, 
which could also be converted into HCl salts. These modifications reduced the calculated 
LogP values (LogP=3~4) compared with 8a and 8f (LogP=4, See Table 4-5). Introducing 
p-amino to A phenyl (8w) is the only case to increase the antiproliferative activity (HCl 
salt, IC50s: 11~29 nM) compared with 8f against all cell lines. Although replacing phenyl 
with pyrimidine (8y) kept partial activity against both cancer cells, the potency range was 
markedly reduced from nano-molar to micromolar compared with 8f. Unfortunately 
introducing COOH to para- phenyl A ring and pyridine to A or C rings (8i, 8r, 8x) all 
resulted in the total loss of the anticancer activity. A total loss of potency was seen in the 
methyl ester 8s of acid 8r against both cancer cell lines. Demethylation of compound 8f 
afforded water soluble 3, 4, 5-trihydroxyphenyl at C ring compound 11, but this 
demethylation results in complete loss of antiproliferative activity against all tested 
cancer cells, which also points out the importance of 3, 4, 5-trimethoxyphenyl at C 
position. 
 
 
4.3.1.5 SAR Summary 
 
The general SAR of SMART compounds on melanoma cells was summarized in 
Figure 4-2. Present SAR studies revealed that 3, 4, 5- trimethoxyphenyl was the essential
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Table 4-5. In vitro cytotoxic activity of SMART compounds containing hydrophilic 
group. 
 
Compounds Structure IC50SEM (nM) (n=3) CLogPa 
B16-F1 A375 
8i NS
C
O N
>100000 >100000 4 
     
8iHCl  >100000 >100000 - 
     
8r 
S N
O
O
O
O
COOH
>100000 >100000 4 
8s 
S N
O
O
O
O
COOCH3
>100000 >100000 4 
8x 
N
S N
O
O
O
O
>100000 >100000 3 
     
8xHCl  >100000 >100000 - 
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Table 4-5. (continued) 
 
Compounds Structure IC50SEM (nM) (n=3) CLogPa
B16-F1 A375 
8y 
N N
S N
O
O
O
O
 
2300860 4100740 3 
8wHCl S N
O
O
O
O
NH2HCl
2910 112 - 
11 S N
OH
OH
OH
O
>100000 >100000 3 
8a NS
C
O
>100000 >100000 5 
8f S N
O
O
O
O
555 285 4 
 
a Calculated LogP data using Chemoffice 2005, Chemdraw Ultra 9.0 software. 
b LogP value were calculated based on free base.  
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A
B
(d). Ketone C=O linkage significantly improved the potency compared with
CONH linker.
(c). C ring is specific for 3, 4, 5-trimethoxyl
substituted phenyl
(a). A ring: No obvious electronic effect. p-F-Ph, 
p-CH3, p-NH2-Ph is helpful for potency.
(b). Thiazole ring kept potency, thiazoline 
and thiazolidine ring lost potecy
 
 
Figure 4-2. SAR summary of the SMART compounds. 
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group in the C ring to keep excellent antitumor potency. p-Fluoro, p-NH2 and p-CH3 
substituents in A ring will increase the activity, with no clear difference in effect on 
activity between EWG and EDG when A are substituted phenyl rings. The carbonyl 
linkage between B ring and C ring played an important role for the high potency. 
 
 
4.3.2 SMARTs Overcome Multi-Drug Resistance on Drug Resistant Melanoma Cells 
 
MDA-MB-435/LCC6MDRI cells over-express P-gp, and were used to test 
whether SMARTs were substrates of P-glycoprotein comparing to its parental cell line, 
MDA-MB-435. I demonstrated that paclitaxel, vinblastine, and colchicine were more 
resistant against MDR-positive cells than those with the parent sensitive cells. Please see 
Figure 4-3 for selected dose-response curves and Table 4-6 for summary of results. The 
resistance indexes were 69.3, 27.5, and 65.8 respectively. In the meantime, SMARTs did 
not show significantly difference on those two cell lines. The resistance indexes were 
around 1. This strongly suggested that SMARTs were not substrates for P-glycoprotein.  
 
 
4.3.3 SMARTs Target Tubulin on Colchicine Binding Site 
 
The strategy I used here to find out the cellular target of SMART compounds is 
the same as I described for ABI compounds in Chapter 5. I first did a cell cycle analysis 
for A375 cells after treatment with SMART-100, -45, and -211 (0, 10, 50, 200, and 1000 
nM) for 24 h prior to staining with propidium iodide and cell cycle analysis. The 
proportion of cells in G2/M phase increased when treated with 50 nM of SMART-100 
and -45, and SMART-211 showed the effect until the concentration was 200 nM. Some 
representative cell cycle distribution graphs were shown in Figure 4-4. Quantified 
representation of all results was shown in Figure 4-5. SMART-100 and SMART-45 had 
no effect on cell cycle distribution below 50 nM.  About 16% of untreated cells were 
observed in G2/M phase, whereas the cells treated with more than 50 nM of colchicine or 
SMART compounds showed a greater proportion of cells in G2/M phase. The increase in 
G2/M phase cells was accompanied by a decrease in G1 populations, relative to control.    
 
In vitro tubulin polymerization assay was used to identify the target of SMART 
compound on tubulin. This experiment was performed by my colleague Mr. Chien-Ming 
Li. He demonstrated that SMART-100 inhibited tubulin polymerization in a dose-
response manner in the previous study (15). In the current study, 10 M of SMARTs 
were used to examine the inhibition of tubulin polymerization. In Figure 4-6, all three 
SMART compounds inhibited tubulin polymerization, indicating that SMARTs did target 
on tubulin. SMART-100 showed similar inhibitory ability as SMART-45, and greater 
than SMART-211. In vitro tubulin polymerization could be blocked by SMARTs, and the 
ability of inhibition on tubulin polymerization was also related to their IC50 values on cell 
anti-proliferation. 10 M of substrates were examined in this study because high 
concentration of tubulin (4 mg/mL) was used to form microtubule. 
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Figure 4-3. Dose response curves showed SMART compounds overcome multi-drug 
resistant for melanoma compared with colchicine and paclitaxel.  
R: resistance index, this value were calculated by dividing IC50 values on multi-drug 
resistant cell line MDA-MB-435/LCC6MDR1 by IC50 values on the matching sensitive 
parent cell line MDA-MB-435. 
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Table 4-6. SMART compounds showed equal potency against multi-drug resistant 
melanoma cells and parent sensitive cells. 
 
Compounds Structure 
IC50SEM (nM) (n=3) Resistance 
index (R) * MDA-MB-
435 
MDA-MB-435 
/LCC6MDRI 
SMART-293 
HN
S N
C
O
O
O
O
91 112 1 
SMART-183H S
N
O
O
O
O
NH2HCl
122 111 1 
Colchicine  101 65850 66 
Paclitaxel  41 27741 69 
Vinblastine  400100 pM 111 28 
 
*Resistance indexes were calculated by dividing IC50 values on multi-drug resistant cell 
line MDA-MB-435/LCC6MDR1 by IC50 values on the matching sensitive parent cell 
line MDA-MB-435.  
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Figure 4-4. Cell cycle analysis showed SMART compounds and colchicine arrested 
A375 cells in G2/M phase after incubation for 24 h.  
 
 
 
Figure 4-5. Quantified cell cycle analysis results showed SMART compounds and 
colchicine arrested A375 cells into G2/M phase in a dose dependent manner. 
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Figure 4-6. SMART-100 inhibited in vitro tubulin polymerization in a dose dependent 
manner. 
This experiment was done by Mr. Chien-Ming Li, Division of Pharmaceutics, College of 
Pharmacy, the Ohio State University. 
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[3H]colchicine competition-binding assay was used to confirm that SMART bind 
to tubulin at the colchicine binding site. In the meantime, I also measured the relative 
binding affinity. Binding graph (Figure 4-7) showed that: 1), SMART compounds can 
competitively bind to tubulin colchicine binding site. As concentration of these three 
testing compounds increased from 0.1 µM to 100µM, more and more tritiated colchicine 
were competitively stripped away from tubulin. Thus gave out lower and lower SPA 
counts.  2), SMART compounds have relatively high binding affinity to the tubulin 
colchicine binding site. Table 4-7 Showed that software calculated IC50 value for binding. 
SMART-100 has the highest binding affinity among the three tested compounds. Its 
value is close to colchicine, although a little bit higher than that. 3), the binding affinity 
was positively correlated with in vitro anti-melanoma activity. The higher of the binding 
affinity, the higher is the anti-melanoma activity. In our experiment, the D value is 0.08 
µM, the Kd value is around 1 µM according to literature (131). So the IC50 is very close 
to Ki value. Our result is quite comparable with literature reported Ki value for colchicine 
binding to tubulin. On the binding graph, some data point is a little bit below 0. That is 
caused by experimental variation. Theoretically, the maximum inhibition is 0.  
 
Microtubule images (Figure 4-8) showed that all four tested compounds results in 
cytoskeleton rearrangements. There is a significant difference between paclitaxel and 
other two compounds (Colchicine and SMART-100). Treatment with paclitaxel resulted 
in condensation of microtubules nice surrounding the nuclei compared with control, 
consistent with its mechanisms of action for stabilizing microtubules. On the contrary, 
treatment with colchicine or SMART-100 all has similar effect on microtubules, and 
result in some degree of microtubule fragmentations, consistent with their common 
mechanism of action for destabilize microtubules.      
 
In summary, our data clearly showed that SMARTs triggered several molecular 
events, which include binding to colchicine site of tubulin, inhibiting on tubulin 
polymerization, arresting cells in G2/M phase and resulting microtubule fragmentation.      
 
 
4.3.4 Pharmacokinetic Properties of SMART-100, SMART-45 and SMART-211 
 
I first examined SMART-100 at a dose level of 5 mg/kg (Figure 4-9). The plasma 
concentration-time profiles of SMART-100 after single IV and IP administration are 
shown in panel A and B of Figure 4-9. The derived pharmacokinetic parameters are 
shown in Table 4-8. The formulation I used for both injections were DMSO/PEG300 
(80/20). SMART-100 appeared rapidly in plasma after IP injection with peak level (Cmax) 
observed in less than 2 min after administration. This suggested a rapid absorption of the 
compound from the injection site. The compound was distributed extensively in the body 
with a volume of distribution of 112 L/kg. A very high clearance of 223 mL/min/kg 
indicates extensive metabolism and rapid elimination. The high clearance resulted in a 
relative short terminal half-life of 349 min after IV and 358 min after IP administration 
despite of the huge volume of distribution. The IP bioavailability is only 31%. I thought 
the poor bioavailability was largely due to the poor water solubility of the compound and 
too simple formulation.  
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Figure 4-7. Tubulin binding assay showed SMART compounds competitively bound to 
tubulin colchicine binding site in a concentration dependant manner. 
As concentration of these compounds increased from 0.1 µM to 100µM, more and more 
tritiated colchicine were competitively stripped away from tubulin. Thus gave out lower 
and lower SPA counts. The negative control paclitaxel just gave out a flat line because it 
didn’t bind to the colchicine binding site on tubulin. Each data point represents an 
average of three replicates.  
 
 
Table 4-7. Comparison of tubulin binding affinity and in vitro cytotoxic activity between 
SMART compounds and known tubulin interacting drugs.   
 
Compounds IC50SEM (n=3) 
For tubulin binding (µM) On A375 (nM) 
SMART-100 73 285 
SMART-45 224 2911 
SMART-211 382 9311 
Colchicine 10 203 
Paclitaxel N/A 123 
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Figure 4-8. Microscopic images of immunofluorescence labeled microtubules inside 
WM-164 melanoma cells showed microtubule modality was dramatically changed after 
compounds treatment for 18 h.  
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Figure 4-9. Measured plasma concentration-time profiles (mean±SD) after bolus 
administration of 5 mg/kg SMART-100 to ICR mice (n=3 per group). 
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation, 
DMSO:PEG300=80:20 (v/v). 
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Table 4-8. Pharmacokinetic parameters of SMART-100, SMART-45, and SMART-211. 
 
Route Compound and dose t1/2 (min)
AUCinf 
(ng·min/mL)
AUClast 
(ng·min/mL)
Clearance 
(mL/min/kg)
Vz  
(mL/kg)
Vss  
(mL/kg)
Bioavailability
(%) 
IV 
SMART-100 5 mg/kga 349 22434 22159 223 112311 24803  
SMART-100 15 mg/kga 140 115336 115221 130 26274 4926  
SMART-45 15 mg/kga 141 134340 134051 112 22643 6588  
SMART-211 15 mg/kga 334 168759 151526 95 45954 5420  
         
IP 
SMART-100 5 mg/kga 358 7038 6771 710 366859  31 
SMART-100 15 mg/kga 308 17645 17189 850 378339  15 
SMART-100 15 mg/kgb 123 55842 55760 269 47507  48 
SMART-45 15 mg/kgb 182 72001 71719 208 54674  54 
SMART-211 15 mg/kgb 208 122578 122440 122 36700  73 
 
aCompound was formulated with DMSO:PEG300=80:20 (v/v). 
bCompound was formulated with Tween80:Captex200=80:20 (v/v).
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I then examined SMART-100 at a dose level of 15 mg/kg and compared two 
different formulations for IP injection. One is DMSO/PEG300 (80/20), one is 
Tween80/captex200 (80/20). The later formulation was one of the self-emulsifying drug 
delivery systems (SEDDS), which contained a mixture of oil (captex200) and surfactant 
(Tween80), and improved the solubility of our lipophilic SMARTs (132). The plasma 
concentration-time profiles of SMART-100 after single IV and IP administration are 
shown in panel A, B, and C of Figure 4-10. The derived pharmacokinetic parameters are 
shown in Table 4-8. Compared different dose of SMART-100 with the same 
DMSO/PEG300 (80/20) formulation, higher dose (15 mg/kg) gave lower bioavailability 
(15% vs. 31%). This may be due to higher concentrated SMART-100 in DMSO/PEG300 
(80/20) precipitated out more after IP injection. Thus more compounds became 
unavailable for absorption. Absorption of SMART-100 after IP injection with 
Tween80/captex200 (80/20) formulation was slower than DMSO/PEG300 (80/20). The 
former one had a tmax of 15 min vs. the later one of 1 min. That’s because the former 
formulation delayed the release of compound. With the help of this new formulation, the 
bioavailability was increased from 15% to 48%. 15 mg/kg of SMART-100 had 5.1-fold 
area on under the curve (AUC) than the dose with 5 mg/kg. The other parameters like t1/2, 
volume of distribution, and clearance also changed dramatically along with dose change. 
This suggested that SMART-100 may have non-linear kinetics.  
 
I next examined SMART-45 and SMART-211 at a dose level of 15 mg/kg with 
the new formulation for IP injection. The plasma concentration-time profiles of SMART-
100 after single IV and IP administration are shown in panel A and B of Figure 4-11 and 
Figure 4-12. The derived pharmacokinetic parameters are shown in Table 4-8. The IP 
bioavailability of SMART-45 and –SMART-211 were 54% and 73% respectively. This 
confirmed the new formulation’s ability to increase bioavailability. I then used this 
formulation for our further in vivo xenograft studies, and no toxic effects were found in 
the vehicle group of A375 xenograft models, suggesting that this formulation was safe to 
use for long-term (more than one month) xenograft studies. 
 
With the same dose of 15 mg/kg of SMART-45 and SMART-100, the parameters 
of AUC (min•ng/mL), t1/2 (min), Vz (L/kg), and CL (mL/min/kg) were very close to each 
other. That can be understood by their similarity of chemical structure and lipiphilicty. 
SMART-211 has relative lower clearance and thus its terminal half life was relatively 
longer. But overall SMART compounds exhibited high clearances and short half-life. 
Once-daily regimen was designed to improve compounds exposure and treatment 
efficacy for our xenograft studies. 
 
The calculated clearances of SMART compounds are much higher than the mouse 
hepatic blood flow rate. There maybe three reasons account for this. First, this may be 
due to expetimental error. Especially when drug concentration is close to detection limit, 
the measurement error is relatively large. Second, this may be due to incomplete tail vein 
injection. The drug amount actually got into the vein may be is less then what we planned. 
Third, SMART compounds may have extra-hepatic metabolism. For example, the 
enzyme in the blood, speen, heart or other organs may be can metablize these compounds.   
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Figure 4-10. Measured plasma concentration-time profiles (mean±SD) after bolus 
administration of 15 mg/kg SMART-100 to ICR mice (n=3 per group). 
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation, 
DMSO:PEG300=80:20 (v/v). C: i.p. injection, formulation, Tween80:Captex200=80:20 (v/v). 
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Figure 4-11. Measured plasma concentration-time profiles (mean±SD) after bolus 
administration of 15 mg/kg SMART-45 to ICR mice (n=3 per group). 
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation, 
Tween80:Captex200=80:20 (v/v). 
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Figure 4-12. Measured plasma concentration-time profiles (mean±SD) after bolus 
administration of 15 mg/kg SMART-211 to ICR mice (n=3 per group). 
A: i.v. injection, formulation, DMSO:PEG300=80:20 (v/v). B: i.p. injection, formulation, 
Tween80:Captex200=80:20 (v/v). 
0.1
1
10
100
1000
10000
100000
0 200 400 600 800 1000
C
on
ce
nt
ra
tio
n 
(n
g/
m
L
)
Time (min)
0.1
1
10
100
1000
10000
0 200 400 600 800 1000
C
on
ce
nt
ra
tio
n 
(n
g/
m
L
)
Time (min)
 97 
 
4.3.5 Antitumor Efficacy of SMARTs on A375 Xenograft Model 
     
I examined 20 mg/kg of SMART-100 and 15 mg/kg of SMART-45 treatments on 
A375 human melanoma xenograft model. Nude mice were administrated i.p. every day 
for consecutive 32 days when the tumor size was ~150 mm3. As shown in Figure 4-13, 
SMART-100 and SMART-45 exhibited significant inhibition of tumor growth. Summary 
of the data was presented in Table 4-9. The average tumor size in control group increased 
by about 13 folds. I obtained 4.8-fold and 4.2-fold tumor increases in SMART-100 
treated (20 mg/kg) and SMART-45 treated (15 mg/kg) groups, respectively.  SMART-
100 reduced tumor growth rate with a %TGI of 70% (20 mg/kg treatment), and SMART-
45 inhibited 72% (15 mg/kg treatment).  I also calculated %T/C for our efficacy study. 
With 20 mg/kg treatment of SMART-100 and 15 mg/kg treatment of SMART-45 on 
A375 xenograft, I observed %T/C values of 36% and 33%, respectively. The data 
indicated that SMART-100 and -45 were pretty active in inhibiting A375 xenografts 
growth on athymic nude mice.  
 
In the mean time, the general activities of mice in all groups were normal during 
the treatment period. At the conclusion of the experiment, the group average body weight 
increased by 3.1g for control group, 2.2g for SMART-45 treated group, and 2.4g for 
SMART-100 treated group. Corrected by group average tumor weight, which were 1.3g 
for control group, 0.6g for SMART-45 treated group, and 0.6g for SMART-100 treated 
group, the net group body weight gain were 1.8g for control group, 1.6g for SMART-45 
treated group, and 1.8g for SMART-100 treated group. One mouse in control group, one 
mouse in SMART-100 treated group, and two mice in SMART-45 treated group died 
during the experiment period. I also observed big hard lumps in the injection sites of dead 
mice. So I guess the death of the mice was due to injection, not the toxicity of compounds 
treatment. No any other acute toxicity phenomenon was observed.  
 
 
4.4 Conclusions 
 
We have discovered a new class of simple synthetic compounds based on a 2-
aryl-4-(3, 4, 5-trimethoxylbenzoyl)-thiazole molecular skeleton, which was derived from 
thiazolidine ring modification of ATCAA structures. Chemical modification of different 
substituted aryl in A and C rings and structure-activity relationship of the SMART were 
investigated based on biological evaluation against melanoma cells in vitro. I have 
demonstrated that SMARTs are very potent in inhibiting melanoma cell proliferation in 
vitro. In the meantime, our data also showed SMARTs overcame multi-drug resistance in 
drug resistant melanoma cell line, suggesting they are not substrates for P-gp. Mechanism 
of action studies showed these compounds bound tubulin at the colchicine binding site 
thus inhibit tubulin polymerization. The in vivo efficacy studies showed that SMARTs 
significantly inhibited A375 melanoma tumor growth on nude mice xenograft models. 
The dramatic biologic effect of SMARTs suggested that it has great potential for 
melanoma chemotherapy.  
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Figure 4-13. In vivo efficacy of SMARTs on nude mice bearing A375 melanoma 
xenograft tumor (n=10 per group). 
A375 cells (2.5106) were injected s.c. on the right flank. The compounds were given by 
i.p. daily when tumor size was 150 mm3.  
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Table 4-9. Summary of mice number, mice body weight change, and tumor size change 
during in vivo efficacy experiment. 
 
Groups 
Number of 
animals 
Body weight (g) 
Mean±SEM 
Tumor size (mm3) 
Mean±SEM TGIa T/Cb 
Start End Start End Start End 
Vehicle 
control 10 9 19±2 22±3 165±11 2183±279 N/A N/A 
SMART-100, 
20 mg/kg 10 9 19±2 21±2 160±15 775±107 70% 36%
SMART-45, 
15 mg/kg 10 8 19±2 21±3 164±12 722±135 72% 33%
 
aTGI (tumor growth inhibition) were measured on the final day for drug-treated 
compared with vehicle-treated mice and calculated as 100× {1-[(Treated, final - 
Treated,day1)/(Control, final - Control, day1)]}. 
bT/C were generated from the mean-treated tumor volume on the final day divided by the 
mean control tumor volume on the final day times 100.  
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CHAPTER 5.  NOVEL IMIDAZOLES TARGET TUBULIN POLYMERIZATION 
AND OVERCOME MULTI-DRUG RESISTANCE IN METASTATIC 
MELANOMA 
 
 
5.1 Introduction 
 
 I have previously dicussed the discovery of substituted methoxylbenzoyl-aryl-
thiazole (SMART) compounds that showed good anti-melanoma activity both in vitro 
and in vivo (100). But poor solubility and fast metabolism were two major problems 
associated with these compounds. After a thorough structure-activity relationship (SAR) 
study and extensive lead compound modification, we discovered a new class of 
compounds: 2-aryl-4-benzoyl-imidazoles (ABIs). The general structure of this class of 
compounds is shown in Figure 5-1. Mr. Jianjun Chen used an imidazole ring to replace a 
thiazole ring for the following two reasons: (a) To increase water solubility. The 
imidazole ring has a lower LogP value and a higher pKa value compared with the 
thiazole ring. Thus, imidazole compounds are more hydrophilic and more basic. It is also 
easier to make them into salt, thereby further increasing water solubility. (b) To increase 
metabolic stability. The thiazole ring is liable to oxidation, so it can make the whole 
molecule unstable to cytochrome enzymes (133).  
 
To our great satisfaction, I have identified experimentally two advantages of ABIs 
over SMART compounds: (a) slightly increased in vitro activity. The IC50s of some ABIs 
were in the low nanomolar range on several melanoma cell lines. (b) I have discovered 
that the trimethoxyphenyl substituent can be replaced by a metabolically more stable p-
fluorophenyl ring and retain good anticancer activity. In this chapter, I will summarize 
more findinga about ABIs such as their effect on MDR melanoma cells, effect on 
melanoma colony formation, and in vivo anti-melanoma efficacy. I also will explain how 
we identify the cellular target of ABIs. 
 
 
5.2 Materials and Methods 
 
 
5.2.1 Compounds and Reagents  
 
 Compound ABI-270 {IUPAC name: (4-Fluoro-phenyl)-[2-(4-methoxy-phenyl)-
1H-imidazol-4-yl]-methanone}, compound ABI-274 [IUPAC name: (2-p-Tolyl-1H-
imidazol-4-yl)-(3,4,5-trimethoxy-phenyl)-methanone], and compound ABI-288 {IUPAC 
name: [2-(4-Chloro-phenyl)-1H-imidazol-4-yl]-(4-fluoro-phenyl)-methanone} were 
synthesized by Mr. Jianjun Chen in our lab. Bortezomib was obtained from Millennium 
Pharmaceuticals, Inc. (Kansas City, MO) through a material transfer agreement. 
Compound ABT-751 was synthesized by Dr. Yan Lu. Paclitaxel, vinblastine, colchicine, 
dimethyl sulphoxide (DMSO), and Tween 80 were obtained from Sigma-Aldrich (St. 
Louis, MO). Captex 200 was obtained from ABITEC Corporation (Paris, IL). CellTiter 
96® AQueous One Solution Reagent was obtained from Promega Corporation (Madison,  
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Figure 5-1. Structures of SMART, ABI, and three representative ABI compounds: ABI-
270, 274, and 288. 
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WI). DTIC for injection, USP (a formulation for human use), was obtained from APP 
Pharmaceuticals, LLC (Schaumburg, IL).  
 
 
5.2.2 Cell Culture 
 
The A375 and B16-F1 melanoma cancer cells were obtained from American Type 
Culture Collection. WM-164 cells were derived from patient metastatic melanoma 
tumors and were a gift from Dr. Meenhar Herlyn (Wistar Institute, Philadelphia, PA). 
The P-gp overexpressing multi-drug resistant cell line MDA-MB-435/LCC6MDRI and 
matching sensitive parent cell line were kindly provided by Dr. Robert Clarke 
(Georgetown University, Washington, DC). Cells were grown as monolayers by using 
standard cell culture conditions. All cells were cultured in DMEM (Mediatech, Inc., 
Manassas, VA), supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 
1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis, MO), and bovine insulin (5 
µg/mL) (Sigma-Aldrich, St. Louis, MO).  
 
 
5.2.3 In Vitro Antiproliferative Activity Assay 
 
 The CellTiter 96® AQueous One Solution Cell Proliferation Assay was used to 
determine the activity of each compound (please see reference Chapter 3 Section 3.2.5 
Biological Assay and Data Processing, for details). 
 
 
5.2.4 Colony Formation Assay in Soft Agar 
 
 B16-F1 melanoma cells were plated at a colony-forming density (2000 cells per 
well on six-well plates) on top of 0.8% base agar. Cells were grown in 0.4% agar together 
with DMEM medium supplemented with fetal bovine serum and an antibiotic-
antimycotic solution at 37°C in an atmosphere of 95% air and 5% CO2 (93). Cells were 
treated with compounds ABI-270, -274, and -288 at different concentrations (20, 100, 
and 500 nM). Compounds were added to the media from 1-mM DMSO stock solutions, 
and a corresponding dilution of DMSO was used as control. Cells were grown for 14 
days. Plates were photographed, and the number of colonies was measured by Artek 880 
Automated Colony Counter (Artek Systems Corporation, Farmingdale, NY). 
 
 
5.2.5 Animals 
 
 Female C57BL/6NHsd mice, age 7-8 weeks, were obtained from Harlan 
Laboratories, Inc. (Indianapolis, IN). Male double homozygous SCID hairless outbred 
(SHO) mice, age 6-8 weeks, were obtained from Charles River Laboratories International, 
Inc. (Wilmington, MA). The laboratory housing the animals met all Association for 
Assessment and Accreditation and Laboratory Animal Care specifications. All of the 
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procedures were conducted in accordance with the guidelines of our Institutional Animal 
Care and Use Committee.  
 
 
5.2.6 In Vivo Antitumor Study 
 
 For C57BL/6 mice, logarithmic growth phase B16-F1 (5×105) cells were injected 
subcutaneously (s.c.) in the right dorsal flank. For SHO mice, logarithmic growth phase 
A375 (5×107/mL) cells were prepared in phenyl red-free, FBS-free DMEM media and 
mixed at 1:1 ratio with Matrigel (BD Biosciences, San Jose, CA). Tumors were 
established by injecting 100 L of this mixture subcutaneously in the right dorsal flank of 
each mouse (2.5106 cells per mouse). When the tumor reached a mean size of 100~150 
mm3, mice were randomized into 4 groups for C57BL/6 mice and 3 groups for SHO mice 
and treatments were started. The formulation of Tween80/Captex200 (80/20) was used to 
prepare the compound solution. ABI-288 at 15 and 45 mg/kg was used for C57BL/6 mice 
with intraperitoneal (i.p.) injection once daily for 13 days. ABI-288 at 25 mg/kg was used 
for SHO mice with i.p. injection once daily for 31 days. Injection volume was 30 L. The 
control group was given only a vehicle solution injection at the same frequency. DTIC 
was reconstituted with sterile water according to drug usage instructions, and 100 L of 
this solution was given i.p. to each mouse. 
 
 Tumor volume was measured three times a week with a Traceable® electronic 
digital caliper (Fisher Scientific, Inc.) and calculated by using the formula a×b2×0.5, 
where a and b represented the larger and smaller diameters, respectively (94). Tumor 
volume was expressed as cubic millimeters. Data were expressed as mean±SD for each 
group and plotted as a function of time. Tumor growth inhibition (TGI) at the conclusion 
of the experiments was calculated from the formula 100-100*[(T-T0)/(C-C0)] where T 
represented mean tumor volume of a treated group on a specific day, T0 represented 
mean tumor volume of the same group on the first day of treatment, C represented mean 
tumor volume of a control on a specific day, and C0 represented mean tumor volume of 
the same group on the first day of treatment (95, 134). Animal general activity and 
average body weight of each group were monitored during the entire experiment period 
to assess compound acute toxicity. The statistical significance of observed differences 
between growth curves was evaluated by Student’s t test. At the end of treatment, all 
mice were euthanized by CO2, and tumors were harvested for further study.  
 
 
5.2.7 Cell Cycle Analysis 
 
 Flow cytometry analysis was performed as described elsewhere to study cell 
cycle phase distribution (95). A375 cells were cultured in 10 cm tissue culture dishes 
until the confluence was about 80%, and then cells were treated with 0, 10, 50, 200, and 
1000 nM of colchicine, ABI-270, -278, and -288 for 24 h in growth media. Cellular DNA 
was stained with PBS containing 50 g/mL propidium iodide and 100 g/mL RNase A. 
The cell cycle was determined using a BD LSR-II cytometer (BD Biosciences, San Jose, 
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CA) with 10,000 cells scored. Data were analyzed and graphs were prepared using the 
Modfit 2.0 program (Verity Software House, Topsham, ME). 
 
 
5.2.8 In Vitro Tubulin Polymerization Assay  
 
 Bovine brain tubulin (0.4 mg) (Cytoskeleton, Denver, CO) was mixed with 10 
M of tested compounds and incubated in 120 L of general tubulin buffer (80 mM 
PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9, and 1 mM GTP). The absorbance of 
wavelength at 340 nm was monitored every 60 s for 15 min by the SYNERGY 4 
Microplate Reader (Bio-Tek Instruments, Winooski, VT). The spectrophotometer was set 
at 37C for tubulin polymerization.  
 
 
5.2.9 Molecular Modeling  
 
 Dr. Li selected the crystal structure of N-deacetyl-N-(2-mercaptoacetyl)-
colchicine (DAMA-colchicine) in tubulin complex (PDB code: 1SA0) which has been 
most widely used for modeling approaches (135-137). He used Schrodinger Molecular 
Modeling Suite 2009 (Schrodinger LLC, New York, NY) for the docking practice. ABIs 
were built and prepared using the Ligprep module, and they were docked into the 
colchicine binding site using the Glide module in Schrodinger Suite. The best docking 
complexes were subject to restricted molecular dynamics to release any strains by using 
Macromodel module with OPLS-2005 force field. The ligand and its surrounding 
residues within 15 Ǻ were allowed to move freely, while residues outside the 15-Ǻ radius 
were kept rigid.  
 
 
5.2.10 Tubulin Colchicine Site Binding Assay  
 
 Biotin-labeled tubulin (0.5 g/well) (Cytoskeleton, Inc., Denver, CO) was mixed 
with [3H]colchicine (0.08 M) (PerkinElmer LLC., Shelton, CT) and various 
concentrations of tested compounds in 96-well plates. The mixture was incubated at 37°C 
in binding buffer [80 mM PIPES (pH 6.8), 1 mM EGTA, 10% glycerol, 1 mM MgCl2, 
and 1 mM GTP] for 45 min with gentle shaking. At the end of incubation, Streptavidin-
labeled SPA beads (80 g/well) (GE-healthcare Bio-Sciences Corp., Piscataway, NJ) 
were added. Signals were read using a TopCount NXT scintillation counter (PerkinElmer 
LLC, Shelton, CT). IC50 values (concentrations that inhibited 50% of tritiated colchicine 
binding) were determined by nonlinear regression analysis with GraphPad Prism 
(GraphPad Software, San Diego,CA). 
 
 
5.2.11 Microtubule Imaging Using Immunofluorescence Microscope 
 
 Cellomics Cytoskeleton rearrangement kit (Thermo Scientific, Rockford, IL) was 
used to get a visually appreciable proof of ABIs interacting with tubulin inside the cells. 
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WM-164 melanoma cells were treated with each compound for 18 h in duplicate using a 
collagen-coated 96-well plate (Becton Dickinson Labware, Bedford, MA). Then cells 
were fixed with 4% paraformaldehyde (Thermo Scientific, Rockford, IL) and 
permeabilized using permeabilization buffer supply from the kit. Primary antibody for 
tubulin and fluorescence-labeled secondary antibody were subsequently added to the 
cells. Cell nuclei were stained by DAPI. Whole Cell Stain Green was also applied to all 
cells. All images were acquired with an Olympus IX71 inverted fluorescence microscope 
(Olympus Corp., Tokyo, Japan) with overlays from separate images of tubulin (red), 
nuclei (blue), and whole cells (green). For comparison, I also included paclitaxel, 
colchicine and ABT-751, along with ABIs.  
 
 
5.3 Results and Discussion 
 
 
5.3.1 ABIs Have Great Potency on Melanoma Cell Lines 
 
 I tested ABI antiproliferative activity on three melanoma cell lines: A375, B16-
F1, and WM-164. A375 and WM-164 are malignant human melanoma cell lines. B16-F1 
is a pigment-producing mouse melanoma cell line. In order to thoroughly study the SAR 
for ABIs and look for the most efficacious compounds in this set, Mr. Jianjun Chen 
extensively modified the structure and synthesized 55 imidazole analogs. In this 
compound pool, I identified 29 active compounds that have IC50 values less than 10 µM 
on the three selected melanoma cell lines. (The synthesis and SAR of ABIs will be 
published in another chemistry-oriented article). Twelve very active compounds had IC50 
values less than 100 nM. The most active one had IC50s less than 10 nM on A375 and 
WM-164 cells. The structure of three representative compounds is shown in Figure 5-1. I 
compared our ABIs’ activity with other anticancer drugs such as paclitaxel, vinblastine, 
colchicine, bortezomib, and ABT-751 (Table 5-1). Paclitaxel and vinblastine are 
clinically used anticancer drugs known to target cell tubulin (138, 139). Although 
colchicine is not an FDA-approved drug for cancer treatment, its prodrug, ZD6126, is in 
clinical trial for solid tumors (140). Bortezomib is the first therapeutic proteasome 
inhibitor and was approved in 2003 by the FDA for use in multiple myeloma (141). ABT-
751 is known to target the tubulin colchicine binding site. It is a promising drug candidate 
in clinical trial for children with relapsed or refractory neuroblastoma(142).  
 
 From our results, the three representative ABIs showed great potency on all three 
tested melanoma cell lines with IC50s all less than 80 nM. The best compound, ABI-274, 
was even more active than paclitaxel and colchicine on A375 and WM-164 cells. Its 
potency was very close to that of bortezomib. Compared with ABT-751, ABI-274 was 
about 60 times more potent (calculated by IC50 average of three melanoma cell lines). 
The great in vitro potency of the ABIs suggests that they are very good candidates for 
melanoma treatment. 
 
Besides their great in vitro potency, another important improvement is that ABI-
270 and ABI-288 do not have a trimethoxy group in their structure but retain good  
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Table 5-1. In vitro cytotoxic activity of representative ABI compounds and comparison 
with other anticancer drugs. 
 
Compound 
name 
IC50SEM (nM) (n=3) 
A375 B16-F1 WM-164 
ABI-270 31±5 63±7 28±3 
ABI-274 9±2 46±5 8±2 
ABI-288 52±4 73±6 74±9 
Paclitaxel 123 172 183 
Vinblastine 10 51 10 
Colchicine 203 295 102 
Bortezomib 81 242 81 
ABT-751 1111108 2127351 66156 
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activity. The lack of a trimethoxy group differentiated them chemically from previous  
SMART compounds and colchicine, thereby overcoming the metabolic instability 
drawback of the trimethoxy group. 
 
 
5.3.2 SAR Studies 
 
 
5.3.2.1 SAR of Substitutions on the C Ring 
 
Please see Figure 5-1 for the designation of A, B, and C ring in ABI compounds. 
A variety of compounds (5aa-5ai) with an un-substituted A-ring and different C ring 
substituents generally showed moderate activity (Table 5-2), with IC50 values in the 
micromolar range (unless specified, the IC50 value for a specific compound discussed in 
the text is referred to as an average of all three cell lines). The most potent compound of 
this series was 5aa with an average IC50 value of 160 nM. The removal of one of the 
methoxy groups from the 3, 4, 5-trimethoxy on the C ring (5ad, 5ae) led to a significant 
loss of activity (IC50>10 μM for 5ae and an IC50 of 3 μM for 5ad). This finding is 
consistent with results from SMART compounds in which the 3, 4, 5-trimethoxy 
substituted compound was most potent. It should be noted that the compound with 4-
fluoro on the C ring (5af) also showed relatively good activity (IC50=1 μM), a finding that 
has an important implication, because replacing the trimethoxy moiety with a 4-fluoro 
group may provide good activity and improved metabolic stability. Interestingly, the 
position of the fluorine on the C ring was critical for activity because a shift from 4-
fluoro to 3-fluoro resulted in a total loss of activity (IC50>10 μM for 5ag compared with 1 
μM for 5af).  This result suggested that a potential hydrogen bond donor is present close 
to the 4-position of this ring. As shown in the molecular modeling studies below, this 
hydrogen bond donor is likely to be the thiol group in Cys-241 in loop 7 of the β-subunit 
in α/β-tubulin dimer.  
 
Other substituents such as methoxy and methyl at the 3 or 4 position on the C ring 
(5ab, 5ac, 5ah, 5ai) were also evaluated, but none showed good activity (IC50>10 μM). 
As clearly indicated in Table 5-2, the positions of the A and C rings were critical. A 
simple shift of the C ring moiety from position 4 to position 1 in the imidazole ring (B 
ring resulted in total loss of activity (IC50>10 μM for 5aba, 5aaa, 3a, 3x, 3j). This result is 
consistent with recent reports in which the position of the aryl group was found to be 
important for antiproliferative activity (143, 144). Bellina and co-workers reported potent 
antitumor activity for a series of 1, 5- and 1, 2-diaryl-1H-imidazole analogs. While the 1, 
5-diaryl-imidazole analogs have nanomolar activity, a simple shift of the diaryl 
substitution from the 1, 5-position to 1, 2-position resulted in significantly lower activity 
down to the micromolar range (143). Similarly, Wang and co-workers reported that 4, 5-
disubstituted and 1, 5-disubstituted imidazoles are much more active than the 
corresponding 1, 2-disubstituted imidazoles (144).  
 
  
 108 
 
Table 5-2. In vitro cytotoxic activity of ABI compounds with B and C ring modification. 
 
Structure ID R IC50SEM (μM) (n=3) 
A375 B16-F1 WM-164 
 
 
 
5aa 3,4,5-(OMe)3 
200±80 
nM 
100±12 
nM 
100±25 
nM 
5ab 4-OMe >10 >10 >10 
5ac 3- OMe >10 >10 >10 
5ad 3, 5-(OMe)2 3±1 5±1 2±0 
5ae 3, 4-(OMe)2 >10 >10 >10 
5af 4-F 1±0 1±0 1±0 
5ag 3-F >10 >10 >10 
5ah 4-Me >10 >10 >10 
5ai 3-Me >10 >10 >10 
      
 
5aba 4-OMe >10 >10 >10 
5aaa 3,4,5-(OMe)3 >10 >10 >10 
      
 
3a H >10 >10 >10 
3x 4-NO2 >10 >10 >10 
3j 4-OBn >10 >10 >10 
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5.3.2.2 SAR of Substitutions on the A Ring 
 
Because compounds with 3, 4, 5-trimethoxy and 4-fluoro substitutions on the C 
ring showed good activity, a series of compounds was synthesized with fixed 
substitutions on the C ring (4-fluoro or 3, 4, 5-trimethoxy) and different substitutions on 
the A ring (Table 5-3).  These compounds demonstrated excellent antiproliferative 
activity with IC50 values as low as 8 nM on WM-164 cell line (5da). In general, 
compounds incorporating a single substituent on the para-position of the A ring were 
more potent as can be seen from the activities of 5ca, 5cb, 5da, 5db, 5fa, 5fb, 5ga, and 
5gb (IC50=8~110 nM). 5db-HCl salt (IC50=172 nM) showed slightly diminished activity 
compared with the corresponding free base 5db (IC50=109 nM). Compound 5fb (IC50=64 
nM), with a single halogen substituent in the para-position of the A and C rings, 
demonstrated potent and was devoid of a methoxy moiety. Compounds with 3, 4, 5-
trimethoxy substituents on the A ring lost activity completely (IC50>10 μM for 5ea, 5eb), 
suggesting very different binding environments near the A ring and C ring. Removal of 
the 5-methoxy substituent from the A-ring improved activity significantly (IC50=330 nM 
and >10 μM for 5ha, 5ea respectively). Demethylation of the 3, 4, 5-trimethoxy 
decreased activity sharply from 43 nM (5fa) to 4 μM (6fa). Similar results were observed 
for 6ea, 5ka, 5kb, and 6ha due to the demethylation of subsituents on either the A or C 
ring. Electron-donating groups (4-methoxy, 4-dimethylamino, 4-methyl) and electron-
withdrawing groups (4-chloro, 2-trifluoromethyl) on the A ring did not show substantial 
differences in activity. The introduction of a trifluoromethyl group at the ortho position of 
the A ring caused complete loss of activity (IC50>10 μM for 5ia, 5ib). The presence of a 
benzoloxy group at the para position of A ring (IC50=75 nM for 5jb) resulted in a 440-
fold increase in activity when compared with the para-hydroxy compound 5kb (IC50=33 
μM). It is worthwhile to note that compound 5jb, with the 4-fluoro in the C ring, has 
better activity than does its counterpart 5ja, which has a 3, 4, 5-trimethoxy group in the C 
ring (IC50 is 75 nM for 5jb, and 7 μM for 5ja).  
 
 
5.3.2.3 SAR of Additional Substitutions on the B Ring 
 
To our surprise, some of the compounds with a phenylsulfonyl protection group 
attached to the nitrogen of the imidazole ring (4cb, 4db, 4fb, 4ga, 4gb, 4ha, 4jb) were also 
very active with IC50 in the nanomolar range (Table 5-4).Generally the activities of these 
compounds are comparable to their corresponding unprotected counterparts as 
exemplified by comparing the activities of 4cb (43 nM), 4db (111 nM), 4fb (72 nM), 4ga 
(285 nM), 4gb (87 nM), 4ha (268 nM), and 4jb (61 nM) with their corresponding 
unprotected counterparts 5cb (36 nM), 5db (109 nM), 5fb (64 nM), 5ga (131 nM), 5gb 
(72 nM), 5ha (330 nM), and 5jb (75 nM). Other compounds (4ab-4ag, 4ea, 4eb, 4hb, 4ia, 
and 4ib, 1-50 μM) were generally much less active, also in line with their counterparts 
(5ab-5ag, 5ea, 5eb, 5hb, 5ia, and 5ib, 1-50 μM).  
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Table 5-3. In vitro cytotoxic activity of ABI compounds with A ring modification. 
 
Structure ID R1 R2 IC50SEM (nM) (n=3) A375 B16-F1 WM-164
NHN
R1
O
R2
 
5ba 4-F 3,4,5-(OMe)3 205±19 320±41 73±8 
5ca 4-OMe 3,4,5-(OMe)3 30±5 108±12 31±4 
5cb 4-OMe 4-F 31±5 63±7 28±3 
5da 4-Me 3,4,5-(OMe)3 9±2 46±5 8±2 
5db 4-Me 4-F 142±13 222±10 156±19 
5db-HCl 108±11 297±23 112±9 
5ea 3,4,5-(OMe)3 3,4,5-(OMe)3 4800 >10000 >10000 
5eb 3,4,5-(OMe)3 4-F >10000 >10000 >10000 
5fa 4-Cl 3,4,5-(OMe)3 43±5 168±14 26±3 
5fb 4-Cl 4-F 52±4 73±6 74±9 
6fa 4-Cl 3,4,5-(OH)3 3900 1810 2100 
5ga 4-N(Me)2 3,4,5-(OMe)3 82±9 361±29 80±11 
5gb 4-N(Me)2 4-F 56±7 129±11 62±8 
5ha 3,4-(OMe)2 3,4,5-(OMe)3 113±14 1400±200 191±18 
5hb 3,4-(OMe)2 4-F 10000 4210 1400 
5ia 2-CF3 3,4,5-(OMe)3 >10000 >10000 >10000 
5ib 2-CF3 4-F >10000 >10000 >10000 
6ea 3,4,5-(OH)3 3,4,5-(OH)3 >10000 >10000 >10000 
5ja 4-OBn 3,4,5-(OMe)3 5200 10000 5500 
5jb 4-OBn 4-F 93±8 117±16 90±12 
5ka 4-OH 3,4,5-(OMe)3 1600 2400 1800 
5kb 4-OH 4-F 10000 >10000 >10000 
6ha 3,4-(OH)2 3,4,5-(OH)3 >10000 >10000 >10000 
Colchicine  20±3 29±5 10±2 
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Table 5-4. In vitro cytotoxic activity of ABI compounds with protection on B ring. 
 
Structure ID R1 R2 IC50SEM (nM) (n=3) 
A375 B16-F1 WM-164 
NNS
O
O
O
R2
R1
Ph
 
 
 
4ab H 4-OMe >10000 >10000 >10000 
4ac H 3-OMe >10000 >10000 >10000 
4ah H 4-Me >10000 >10000 >10000 
4af H 4-F 630±72 946±86 596±61 
4ag H 3-F >10000 >10000 >10000 
4cb 4-OMe 4-F 36±5 71±8 43±6 
4db 4-Me 4-F 113±14 287±31 107±14 
4ea 3,4,5-(OMe)3 3,4,5-(OMe)3 >10000 >10000 >10000 
4eb 3,4,5-(OMe)3 4-F 3840 >10000 >10000 
4fb 4-Cl 4-F 88±9 107±12 70±6 
4ga 4-N(Me)2 3,4,5-(OMe)3 162±13 1200±90 308±32 
4gb 4-N(Me)2 4-F 55±7 242±26 56±4 
4ha 3,4-(OMe)2 3,4,5-(OMe)3 192±15 970±68 139±15 
4hb 3,4-(OMe)2 4-F 960±59 2000±400 1400±30
4ia 2-CF3 3,4,5-(OMe)3 >10000 >10000 >10000 
4ib 2-CF3 4-F >10000 >10000 >10000 
4jb 4-OBn 4-F 64±7 110±15 48±5 
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5.3.3 ABIs Overcome Multi-Drug Resistance on Drug Resistant Melanoma Cells 
 
 Drug resistance is the major cause of cancer chemotherapy failure. One major 
contributor to multi-drug resistance is overexpression of P-glycoprotein (P-gp). This 
protein is a clinically important transporter protein belonging to the ATP-binding cassette 
family of cell membrane transporters. It can pump substrates including anticancer drugs 
out of tumor cells through an ATP-dependent mechanism (145). To test whether our 
ABIs could overcome P-gp-mediated multi-drug resistance, Dr. Li obtained one P-gp 
overexpressing human melanoma cell line, MDA-MB-435/LCCMDR1, and the matching 
sensitive parent cell line from Dr. Robert Clarke at Georgetown University. I then tested 
three representative compounds ABI-270, -274, and -288 on these two cell lines together 
with colchicine, paclitaxel, and vinblastine. The dose response curves are shown in 
Figure 5-2.The IC50 values and calculated resistance index are shown in Table 5-5. Big 
distance between two curves for paclitaxel, vinblastine, and colchicine means they were 
substrates for P-gp. The two curves of each ABI compound overlapped means they were 
not substrates for P-gp and overcame multi-drug resistance.  
 
The results clearly showed that cell line MDA-MB-435/LCCMDR1 was very 
resistant to colchicine, paclitaxel, and vinblastine. But our ABIs showed equal potency to 
the drug resistant cell line and the sensitive parent cell line. This result strongly suggests 
that ABIs are not substrate for P-gp. Thus, they overcame the multi-drug resistance found 
in MDA-MB-435/LCCMDR1 cells. Note that ABI-274 has a resistance index of 3, 
meaning that MDA-MB-435/LCCMDR1 cells have some resistance to this compound. I 
believe that the reason may be that ABI-274 has a trimethoxy-phenyl group, which makes 
it partially chemically similar to colchicine.  
 
 
 5.3.4 ABIs Inhibit Melanoma Colony Formation in Soft Agar 
 
 Colony formation assay has been generally used to measure the sensitivity of 
tumors to anticancer drugs. Results reflect the therapeutic efficacy of a drug (146). To 
further measure ABIs’ anti-melanoma efficacy, I tested ABI-270, -274, and -288 on 
melanoma colony formation in soft agar. Three different concentrations - 20, 100, 500 
nM - were tested. Representative photos are shown in Figure 5-3. Quantified results are 
shown in Figure 5-4. After 14 days of incubation, about 130 detectable colonies 
(diameter larger than 100µm) were formed in controls (no treatment). Compounds ABI-
270 and -274 effectively inhibited B16-F1 melanoma colony formation even at the lowest 
tested concentration, 20 nM (p<0.05 compared with control). ABI-288 showed effective 
inhibition at 100 nM. All three tested compounds showed complete inhibition of colony 
formation at 0.5 M, further proving ABIs’ anti-melanoma efficacy.  
 
 
5.3.5 ABIs Inhibited Melanoma Tumor Growth In Vivo 
 
 Encouraged by ABIs’ good activity against melanoma cells and inhibition of 
melanoma colony formation in soft agar, in vivo anti-melanoma activity of ABIs was  
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Figure 5-2. Dose-response curves showed ABI compounds overcome multi-drug 
resistance for melanoma compared with other anticancer drugs. 
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Table 5-5. In vitro cytotoxic activity comparison of ABI compounds with other 
anticancer drugs on multi-drug resistant melanoma cell line. 
 
Compound 
 name 
IC50SEM (nM) (n=3) 
Resistance index 
(R)* 
MDA-MB-435 MDA-MB-435 /LCC6MDR1 
Colchicine 101 65850 66 
Paclitaxel 41 27741 69 
Vinblastine 400100 pM 111 28 
ABI-274 51 152 3 
ABI-270 242 304 1 
ABI-288 412 382 1 
 
* Resistance indexes were calculated by dividing IC50 values on multi-drug resistant cell 
line MDA-MB-435/LCC6MDR1 by IC50 values on the matching sensitive parent cell 
line MDA-MB-435.  
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Figure 5-3. B16-F1 melanoma colony formation assay in soft agar for ABI compounds.  
Compounds ABI-270 and 274 effectively inhibited B16-F1 melanoma colony formation 
even at the lowest tested concentration 20 nM (p<0.05 compared with control). ABI-288 
showed effective inhibition at 100 nM. All three tested compounds showed complete 
inhibition for colony formation at 0.5 M. 
  
Control
Control
Control
ABI-274 20nM ABI-274 100nM ABI-274 500nM
ABI-270 20nM ABI-270 100nM ABI-270 500nM
ABI-288 20nM ABI-288 100nM ABI-288 500nM
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Figure 5-4. Quantified representation of colony formation assay using colony counter. 
*p<0.05 compared with control. **p<0.001 compared with control.   
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tested. Compound ABI-288 was chosen because it does not have a trimethoxy group and 
its solubility is better than that of the others. Based on our previous study experience, two 
dose levels, 15 and 45 mg/kg, were chosen. DTIC at 60 mg/kg was used as a positive 
control according to the literature (109). B16-F1 melanoma allograft model on C57BL/6 
mice was first chosen for study. After 13 days of treatment (Figure 5-5), ABI-288 
inhibited melanoma tumor growth (TGI value) by 32% at 15 mg/kg and 82% at 45 mg/kg. 
Student’s  t test p value of ABI-288 at 45 mg/kg compared with control was less than 
0.001, indicating a significant difference. The t test p value of ABI-288 at 15 mg/kg 
compared with control was 0.08, suggesting that this dose was not effective. Comparing 
ABI-288 at 45 mg/kg with DTIC at 60 mg/kg, which had a TGI of 51%, the t test p value 
was about 0.001, suggesting that ABI-288 had substantially better activity than did DTIC. 
I also observed a continuous average body weight loss in the ABI-288 45 mg/kg 
treatment group. For the control and ABI-288 15 mg/kg treatment groups, average body 
weight increased slightly throughout the experiment period.  
 
 To further confirm ABIs’ in vivo activity, A375 human melanoma xenograft 
model on SHO mice was used, and ABI-288 at 25 mg/kg was tested. DTIC at a dose of 
60 mg/kg was used as a positive control again. After 31 days of treatment (Figure 5-6), 
ABI-288 inhibited melanoma tumor growth (TGI value) by 69%, whereas DTIC inhibited 
growth by 52%. The t test p value of ABI-288 treatment versus control was less than 
0.001, suggesting that ABI-288 significantly inhibited melanoma tumor growth at 25 
mg/kg. The t test p value of ABI-288 treatment versus DTIC was less than 0.05, 
suggesting again that ABI-288 had better activity than did DTIC. Average body weight of 
all groups increased slightly throughout the experiment period. Physical activities for the 
mice also looked normal, suggesting that 25 mg/kg was a well tolerated dose for SHO 
mice.  
 
 
5.3.6 ABIs Target Cell Tubulin at the Colchicine Binding Site 
 
 The cellular target of ABIs was determined by the following five experiments.  
 
 
5.3.6.1 Cell Cycle Analysis 
 
 After identifying the great anti-melanoma potency of ABIs and their capability 
for overcoming multi-drug resistance, our next goal was to determine the cellular target 
of this class of compounds. Based on their high potency and behavior similarity with 
other tubulin binding agents on melanoma cells, I hypothesized that these compounds 
may also target tubulin. If our hypothesis were right, ABIs should arrest cells in the 
G2/M phase, so I did a cell cycle analysis. I tested ABI-270, -274, and -288 together with 
colchicine as a positive control on A375 cells. Four different concentrations - 10, 50, 200, 
and 1000 nM - of each compound were chosen to show the dose effect (Figure 5-7 and 
Figure 5-8). For controls (no treatment) without interference, about 16% of A375 cells 
were distributed in the G2/M phase. For the colchicine treatment group, as concentration 
increased from 10 nM to 50 nM, the percentage of cells distributed in the G2/M phase  
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Figure 5-5. In vivo studies on C57BL/6 mice bearing B16-F1 melanoma allograft for 
ABI-288. 
ABI-288 inhibited melanoma tumor growth in a dose-dependent manner. Each mouse 
received 0.5106 cells by s.c. injection into the flank. 30 µL i.p. daily treatments were 
started when tumor size reached ~100 mm3. Control, vehicle solution only; points, means; 
bars, SD. n=5 per group. 
0
1000
2000
3000
4000
5000
6000
7000
8 10 12 14 16 18 20 22
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Days after inoculation
Control
DTIC 60mg/kg
ABI-288 15mg/kg
ABI-288 45 mg/kg
Treatment
starts
 119 
 
 
 
Figure 5-6. In vivo studies on SHO nude mice bearing A375 human melanoma xenograft 
for ABI-288. 
ABI-288 inhibited melanoma tumor growth in a dose-dependent manner. Each mouse 
received 2.5106 cells by s.c. injection into the flank. 30 µL i.p. daily treatments were 
started when tumor size reached ~150 mm3. Control, vehicle solution only; points, means; 
bars, SD. n=5 per group. 
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Figure 5-7. Cell cycle analysis of A375 cells after incubation with ABI compounds and 
colchicine.   
Colchicine arrested most cells into G2/M phase starting from 50 nM. ABI-270, 274, and 
288 also arrested most cells into G2/M starting from 200, 50, and 200 nM respectively.  
  
Colchicine (10nM) Colchicine (50nM) Colchicine (200nM) Colchicine (1µM)
ABI-270 (10nM) ABI-270 (50nM) ABI-270 (200nM) ABI-270 (1µM)
ABI-274 (10nM) ABI-274 (50nM) ABI-274 (200nM) ABI-274 (1µM)
ABI-288 (10nM) ABI-288 (50nM) ABI-288 (200nM) ABI-288 (1µM)
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Figure 5-8. Quantified graphic depiction of cell cycle analysis. 
ABI-274 showed greater potency than colchicine in arresting cells into G2/M phase. 
Although ABI-270 and 288 showed lower potency, they also arrested most cells into 
G2/M phase at higher concentration.  
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increased from 14% to 85%. ABIs had similar results for A375 cells, in arresting them in 
the G2/M phase in a dose-dependent manner. The potency of the different concentrations 
in arresting cells in the G2/M phase positively correlated with in vitro activity.  
 
 
5.3.6.2 In Vitro Tubulin Polymerization Assay  
 
 The findings of the cell cycle analysis strongly supported our hypothesis and 
guided us to test ABIs’ direct effect on tubulin polymerization. I conducted an in vitro 
tubulin polymerization assay by using purified bovine brain tubulin monomer (Figure   
5-9). Three tested compounds - ABI-270, -274, and -288 - all showed a strong inhibitory 
effect on tubulin polymerization. At a concentration of 10 µM and 15 min of incubation, 
the compounds inhibited tubulin polymerization to 17%, 3%, and 22%, respectively, 
compared with control (5% DMSO was used in controls as a promoter for tubulin 
polymerization and to compensate DMSO usage in compound testing). This microtubule 
destabilization effect was similar to that of colchicine and vinblastine but was opposite to 
that of paclitaxel. The results not only confirmed that ABIs can directly interact with 
tubulin but also suggested that they may share the same binding site with colchicine or 
vinblastine. Our next goal was to determine the exact binding site for our compounds. 
 
 
5.3.6.3 Molecular Modeling  
 
 Based on the structure similarity of ABI compounds with colchicine and using 
molecular modeling techniques, Dr. Li first tested whether our compounds could bind to 
the colchicine binding site on tubulin (147, 148). All three compounds showed excellent 
docking scores and their binding poses overlaps with the native ligand very well. As an 
example, the binding mode of ABI-288 (stick model) is shown in Figure 5-10. For 
comparison, he also displayed the native ligand DAMA-colchicine as a wire model in the 
α/β-tubulin heterodimer. The overall structure of ABI-288 and DAMA-colchicine 
overlapped very well. The p-Fluoro phenyl moiety overlaps with the trimethoxylpheny 
moiety which is interacting with the T7 loop in the β-subunit. Similarly, the p-Chloro 
phenyl moiety occupies the other side of the pocket where the seven-member ring of the 
DAMA-colchicine is, with the chlorine atom occupying the pocket where the methoxy 
moiety interacts.  This exciting finding encouraged us to search further for more solid 
experimental proof to confirm the binding.  
 
 
5.3.6.4 Tubulin Colchicine Site Binding Assay  
 
 After comparison, rapid [3H]colchicine competition-binding scintillation 
proximity assay (SPA) was chosen to confirm the binding site and to measure binding 
affinity (131). This method uses SPA technology and requires a close association between 
a solid-phase scintillant (the beads) and the radioligand for a signal to be emitted and 
subsequently detected. Biotin tubulin was the reagent that brings the radioligand and the 
scintillant into close association. When using tritiated colchicine as radioligand, the  
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Figure 5-9. Three representative ABI compounds inhibited in vitro tubulin 
polymerization at a concentration of 10 μM. 
After 15 min incubation, ABI-274, 288, and 270 inhibited tubulin polymerization to 3%, 
17%, and 22% respectively compared with control (5% DMSO in general tubulin buffer). 
This experiment was done by Mr. Chien-Ming Li, Division of Pharmaceutics, College of 
Pharmacy, the Ohio State University. 
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Figure 5-10. Docking of ABI-288 into tubulin crystal structure at the colchicine binding 
pocket. 
Only the related secondary structures in tubulin are shown; ABT-751 is shown as a wire 
model. The overall structure of ABI-288 and ABT-751 overlapped very well in the 
binding pocket. The multiple interactions between ABI-288 and tubulin dimer suggested 
that this compound may have high binding affinity to this pocket. This experiment was 
done by Dr. Wei Li. 
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amplitude of signal was proportional to the number of colchicine binding sites that were 
occupied by this radioligand. When adding a competitor of radio-labeled colchicine, e.g., 
cold (unlabeled) colchicine, to the mixture, the signal amplitude decreased 
proportionately with the concentration of the competitor. This method is very specific for 
tubulin colchicine site binding competitors.  
 
The binding graph (Figure 5-11) clearly shows that ABIs can competitively bind 
to the tubulin colchicine binding site. As the concentration of the three tested compounds 
increased from 0.03 µM to 100 µM, increased tritiated colchicine was competitively 
stripped away from tubulin and emitted lower SPA counts. The negative control, 
paclitaxel, gave only a flat line, because theoretically it should not bind to the colchicine 
binding site on tubulin. Second, ABIs have relatively high binding affinity to the tubulin 
colchicine binding site (Table 5-6). GraphPad Prism calculated IC50 values for binding 
showed that ABI-274 has the highest binding affinity among the three tested compounds. 
Its binding affinity was even higher than that of colchicine. The other two compounds, 
ABI-270 and ABI-288, showed a little lower affinity to this site than did the natural 
ligand colchicine, but they were still very close. Third, the binding affinity was positively 
correlated to in vitro anti-melanoma activity; the higher the binding affinity, the higher 
the anti-melanoma activity.  
 
 According to the Cheng-Prusoff equation, Ki=IC50/(1+D/Kd), where Ki is the 
inhibition constant, D is the concentration of the radioligand, the Kd is the dissociation 
constant of the radioligand to tubulin (149). In our experiment, the D value was 0.08 µM, 
and the Kd value was around 1 µM according to the literature (131). So the IC50 was very 
close to the Ki value. Our result was comparable with the Ki value reported in the 
literature for colchicine binding to tubulin. 
 
 
5.3.6.5 Microtubule Imaging Using Immunofluorescence Microscope 
 
 To obtain visual proof of ABIs interacting with tubulin inside the cells, I 
examined microtubule arrangement in human melanoma WM-164 cells upon treatment 
with different compounds (Figure 5-12). The microtubule images clearly showed that all 
five tested compounds resulted in cytoskeleton rearrangement. There was a significant 
difference between paclitaxel and the other four compounds (colchicine, ABT-751, ABI-
270, and 274). Treatment with paclitaxel resulted in a condensation of microtubules 
orderly lying around the nuclei compared with controls, consistent with its mechanisms 
of action for stabilizing microtubules. On the contrary, treatment with colchicine, ABT-
751, ABI-270, or 274 had similar effects on microtubules and resulted in some degree of 
microtubule fragmentation, consistent with their common mechanism of action for 
destabilizing microtubules. These results also confirmed that ABIs shared the same 
cellular target with colchicine and induced the same cellular effect.  
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Figure 5-11. [3H]colchicine competition-binding assay confirmed ABI compounds 
competitively bound to tubulin at the colchicine binding site. 
As concentration of these compounds increased from 0.03 µM to 100 µM, more and 
more tritiated colchicine were competitively stripped away from tubulin. Thus gave out 
lower and lower SPA counts. The negative control paclitaxel just gave out a flat line 
because it didn’t bind to the colchicine binding site on tubulin. Each data point represents 
an average of three replicates.  
 
 
Table 5-6. Comparison of tubulin binding affinity and in vitro cytotoxic activity between 
ABI compounds and known tubulin interacting drugs.   
 
Compound name 
IC50SEM (n=3) 
For tubulin binding (µM) On A375 (nM) 
ABI-270 32 31±5 
ABI-274 200100 nM 9±2 
ABI-288 42 52±4 
Colchicine 21 203 
Paclitaxel N/A 123 
 
N/A: not available 
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Figure 5-12. Microscopic images of immunofluorescence labeled microtubules inside 
melanoma cells after compounds treatment. 
Treatment with paclitaxel resulted in condensation of microtubules nicely laying around 
the nuclei compared with control, consistent with its mechanisms of action for stabilizing 
microtubules. On the contrary, treatment with colchicine, ABT-751, ABI-270 or -274 all 
had similar effect on microtubules, and resulted in some degree of microtubule 
fragmentations, consistent with their common mechanism of action for destabilizing 
microtubules. 
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5.4 Conclusions 
 
Our team synthesized a set of novel 2-aryl-4-benzoyl-imidazole (ABI) derivatives 
that showed potent activity in a number of melanoma cell lines, as well as in a xenograft 
model. The compounds inhibited tubulin polymerization by binding to the colchicine 
binding site. Structure-activity-relationships were investigated by introducing different 
substituents into the A and C rings. Compared with the earlier SMART compounds, ABI 
analogs showed two improvements. Firstly, ABI compounds showed much better 
resistance index (1) compared with colchicine (66), paclitaxel (69), and vinblastine (28). 
The fact that ABIs can overcome multi-drug resistance suggests a promising future 
development of more drug-like agents.  Secondly, our in vivo study showed that 
compound ABI-288 at a dose of 25 mg/kg gave better tumor suppression than that of 
DTIC at a dose of 60 mg/kg. 
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APPENDIX 
 
 
Tubulin Ligand (Colchicine) Competition Assay Protocol 
 
 
The basic approach to the assay is as follows 
 
1. Set-up scintillation plate reader and warm plate in reader to 37°C. 
2. Prepare compounds to 20x strength (1 mM) in G-PEM buffer plus 10% DMSO. 
3. Prepare tritiated colchicine. Assay life 24 h. 
4. Prepare biotin tubulin on ice. Assay life 4 h. 
5. Prepare streptavidin beads. Assay life 24 h. 
6. Prepare bead/tubulin mixture. Assay life 24 h. 
7. Pipette 10 µL of compound into the wells. 
8. Pipette 10 µL of tritiated colchicine into the wells. 
9. Pipette 180 µL of bead/tubulin into the wells. 
10. Incubate for 45 min at 37°C. 
11. Read plate. 
12. Extract the raw data and calculate percent inhibition. 
 
 
Preparation of compounds 
 
This step is performed before the tubulin is rehydrated because if there is an unforeseen 
error or precipitation occurs, then the experiment can be aborted before rehydrating 
tubulin. Prepare compound stocks at 20x final concentration (usually 1 mM) in 50% 
DMSO, 50% Ethanol or G-PEM plus one of these solvents from 5~50% at room 
temperature. The final organic solvent concentration should not exceed 2.5% (v/v). 
Solubilizing agents such as SDS or Triton X100 can be used up to 0.1% and 1.0% 
respectively. The concentration of compounds may vary depending on the nature of the 
screen, 50 µM final concentration is recommended. The necessary controls are zero 
compound concentration, 1mM colchicine for competition, and 1mM vinblastine for 
noncompetitor. 
 
 
Preparation of buffers 
 
1. Reconstitute General Tubulin Buffer (BST01-010) with 100 mL of Milli-Q water 
and place at 4°C for storage. 
2. Resuspend GTP vial with 100 µL of water, aliquot into 10x10 µL and freeze at -
70°C for storage. 
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Preparation of tubulin protein, in 50 assay aliquots 
 
1. Prepare 1 mL of ice cold G-PEM buffer: On ice, mix 1mL of General Tubulin 
Buffer with 10 µL of GTP stock. 
2. Resuspend 500 µg of T333 in 60 µL of ice cold G-PEM and place back on ice. 
3. Microfuge for 5 min at 14,000g at 4°C. 
4. Carefully pipette 55 µL of supernatant (avoiding the location where a very small 
pellet might be located) into a clean tube on ice. 
5. Pipette into 10x5 µL aliquots on ice, and drop freeze all of them into liquid 
nitrogen. 
6. Store at -70°C, where they are stable for 6 months. 
  
 
Preparation of beads, enough for 50 assays 
 
This step should be performed just prior to the assays because the change of buffer 
decreases the shelf life of the beads to 24 h. 
 
1. Pipette 4.4 mg of Streptavidin-SPA beads into a 15 mL Falcon tube, centrifuge 
3000 rpm for 10 min to pellet the beads. 
2. Carefully pipette off the sup, leaving 100 µL liquid volume above the beads. 
3. Resuspend in 5 mL of General Tubulin Buffer and centrifuge again. 
4. Carefully pipette off the sup, leaving 100 µL liquid volume above the beads. 
5. Resuspend the beads thoroughly in 9.5 mL of General Tubulin Buffer. 
 
 
Preparation of tubulin-beads, enough for 50 assays 
 
These tubulin loaded beads should be made just prior to assay because they will have a 
life time of 24 h at 4°C. 
 
1. Prepare 1mL of ice cold G-PEM buffer: On ice, mix 1 mL of General Tubulin 
Buffer with 10 µL of GTP stock. 
2. Rapidly defrost one vial of biotin tubulin by warming in Milli-Q water for 30 
secs, then place on ice. 
3. Dilute the vial of biotin tubulin with 500 µL of G-PEM buffer. 
4. Pipette the entire volume of biotin tubulin into the 9.5 mL of beads, mix 
thoroughly incubate on a slow 10 rpm rotator at 4°C for 30 min), then use 
immediately, or up to 24 h thereafter if necessary (activity may drop by 40% 
during this time). The tubulin-beads must be kept rotating if aliquots are going to 
be used continuously over the 24 h period. 
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Preparation of tritium colchicine, enough for 50 assays 
 
Dilute 50 µL of [3H]colchicine (specific activity 20~80 Ci/mmole, 1.0 µCi/μL, original 
stock concentration 5~10 µM) into 500ul of General Tubulin Buffer and mix well. This 
makes a sub-stock of 0.5~1.0 µM and a final concentration in the reaction of 25~50 nM. 
If the signal is too low this component can be increased upto fourfold this level, this is 
particularly useful for non-HTS applications where more signal is required. 
 
 
Material and equipment required 
 
Material 
 
Tritiated Colchicine  
Streptavidin SPA beads  
96-well plates Low PB Corning Costar Inc.  
 
 
Equipment 
 
Scintillation Counter Packard Instrument Inc. Tel: 1-800-762-4000 Topcount Microtplate 
Reader 
 
 
Scintillation counter plate reader set-up 
 
Measurement type: Top 
Sensitivity: Highest. 
Read time per well: 10 seconds per read. 
Shaking: 5 s medium, orbital. 
Plate template: Griener GRE96fb (flat, black). 
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Soft Agar Colony Assay Protocol 
 
 
Preparation of 1.6% agar 
 
1. Pre-warm 50 mL autoclave-safe glass bottles in a 40°C water bath. 
2. Heat 1800 mL of deionized H2O in a 4 L flask with 2 L calibration to 80~90°C on 
a hot plate. Use a glass petri cap to prevent evaporation. 
3. Add 25 g of dry Agar to the flask containing the 80~90°C water. Stir with a glass 
rod until lumps disappear. 
4. While the flask is still being heated, adjust the volume to 2000 mL with H2O. Stir 
until thoroughly mixed. 
5. Add 40 mL of the 1.6% agar solution to each of the 100 mL bottles previously 
held at 40°C. Cap bottles loosely. 
6. Autoclave for 15 min on slow exhaust. Allow bottles to cool for a few minutes 
then tighten caps. Store at room temperature or at 4°C. 
 
 
Preparation of the 0.5% agar growth medium dishes 
 
The directions provided below are for 100 mL of 0.5% Agar Growth Medium—enough 
to prepare about 14~60 mm dishes. Volumes may be adjusted for larger sized dishes as 
needed. 
 
1. Prepare the Growth Medium at the desired concentration of FBS, and warm in a 
44°C water bath. 
2. Melt 40 mL of 1.6% agar in a microwave oven until just molten, swirling 
intermittently. Remove the bottle as soon as the agar solution becomes clear. 
3. Cool the 1.6% agar at room temperature for 2 to 3 min. 
4. Place the bottle containing the agar in the 37°C water bath. 
5. When both the Growth Medium and the 1.25% agar have reached 37°C, mix the 
1.6% agar with the Growth Medium to make a 0.5% Agar Growth Medium 
solution. 
6. Pipette 6 mL of the 0.5% Agar Growth Medium mixture into each sterile 60 mm 
petri dish. Avoid forming bubbles and spread the mixture evenly by slowly 
rotating the dish. Note: Reagents such as TPA) or EGF should be added to the 
0.5% Agar Growth Medium just before pipetting it into the petri dishes. 
Typically, a final concentration of 10 ng/mL TPA or EGF is used. Control plates 
to which the solvent (DMSO or water) for the TPA or EGF is added should also 
be prepared. 
7. Allow the 0.5% Agar Growth Medium layer to harden for 30 to 40 min at room 
temperature in a sterile laminar flow hood. 
8. Store the dishes overnight in a 37°C incubator or seal in a bag and store at 4°C. 
The dishes can be stored this way for several days. Note: Refrigerated dishes 
should be warmed to 37°C before use. 
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Preparation of cell suspension and performing the over-agar assay 
 
1. Two or three days before the experiment, plate the cells in a screw-cap T-25 or T-
75 flask in a final volume of 10 to 15 mL of Cell Growth Medium. 
2. Grow the cells in a 37°C, 5% CO2 humidified incubator until the cells are 80 to 
90% confluent. 
3. Wash the monolayer of cells in T-25 flask or T-75 flask twice with 1~2 mL of 
Ca2+, Mg2+ free PBS, aspirating the PBS after each wash. 
4. Add 1 mL of 0.03% Trypsin. 
5. Incubate in a 37°C, 5% CO2 humidified incubator for 3 to 6 min or until 90% of 
the cells are detached. 
6. Add 1 mL of DMEM containing 10% heat-inactivated FBS (DMEM-FBS). 
7. Gently resuspend cells with a sterile pipette three or four times to make a single-
cell suspension. Note: Observe a sample of the suspension with a microscope to 
confirm that it consists of single cells rather than clumps. 
8. Determine the concentration of cells and adjust the suspension to 1×103 cells/mL 
in DMEM-FBS. Note: If the cells are to be plated on the TPA- or EGF-containing 
0.5% Agar Growth Medium, then TPA or EGF should be added to the cell 
suspension just before transferring them onto the plates. The final concentration 
of TPA or EGF should be 10 ng/mL. 
9. Transfer 3 mL of the cell suspension (containing a total of 3×103 cells) to the 
0.5% Agar Growth Medium plate and incubate at 37°C, 5% CO2. 
10. Culture the cells on the 0.5% Agar Growth Medium plate for 14 to 21 days, 
during which time colonies of transformed cells will form in the TPA- or EGF-
treated dishes. 
11. Count the number of cells in each colony and the number of colonies using a 
microscope. Note: Each colony should contain more than eight cells. 
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Cell Cycle Analysis Protocol 
 
 
1. Human melanoma cells A375 were cultured into 10 cm tissue culture dishes till 
80% confluence.  
2. Serum starved for 24 h. Media was then replaced with media containing testing 
compounds at different concentration or vector only in triplicates.  
3. Cells were incubated with compounds for 6 h, trypsinized, and harvested by 
centrifugation.  
4. Cells were then washed with 1×PBS 3 times and resuspended in ice-cold 70% 
ethanol at 4°C overnight.  
5. Ethanol was removed by centrifugation and washing with 1×PBS 3 times.  
6. Finally, cells were pelleted out of PBS and resuspended in 1mL PBS buffer 
containing 100 µg/mL RNase A. cells were incubated at 37°C for 1 h.  
7. After centrifuging cells and aspirating supernatant, resuspend cells in 500 µL of 
propidium iodide (50 µg/mL) in PBS.  
8. Cell cycle was determined using a BD LSR-II (BD Biosciences, San Jose, CA 
USA) with a 10,000 cells scored. Data were analyzed and graphs were prepared 
using the Modfit 2.0 program (Verity Software House, Topsham, ME). 
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Tubulin Imaging Protocol 
 
 
Solution preparation (per 96-well plate) 
 
1. 1X Wash Buffer: Add 30 mL 10X Wash Buffer to 270 mL ultrapure water. Store 
buffer at 4°C for up to 7 days. 
2. Fixation Solution: Add 5 mL of 16% formaldehyde solution to 15 mL of 1X 
Wash Buffer and heat to 37°C in a water bath just before use. Pre-warming the 
Fixation Solution is critical for maintaining cell integrity. Prepare solution just 
before each assay. 
3. 1X Permeabilization Buffer: Add 2 mL of 10X Permeabilization Buffer to 18 mL 
of the 1X Wash Buffer. Store this buffer at 4°C for up to 7 days. 
4. 1X Blocking Buffer: Add 10 mL of the 10X Blocking Buffer to 90 mL of 1X 
Wash Buffer. Store buffer at 4°C for up to 7 days. 
5. Primary Probe Solution: Reconstitute DY554-phalloidin (F-actin kits) by adding 
110 μL for 10 units (550 μL for 50 units) of pure methanol and gently mixing. 
Use the DY554-phalloidin immediately and promptly store any unused portion at 
-20°C.  
6. F-actin and tubulin kits (8402401, 8402402): Add 100 μL of DY554-phalloidin 
and 6 μL of Tubulin Primary Antibody to 5.9 mL of 1X Blocking Buffer. Prepare 
solution just before each assay. F-actin kits (8402501, 8402502): Add 6 μL of 
DAPI, 100 μL of DY554-phalloidin to 5.9 mL of the 1X Blocking Buffer. Prepare 
solution just before each assay.  
7. For the tubulin kits (8402601, 8402602): Add 6 μL of Tubulin Primary Antibody 
to 6 mL of the 1X Blocking Buffer. Prepare solution just before each assay. 
8. Staining Solution (Secondary Antibody): F-actin and tubulin kits (8402401, 
8402402): Add 6 μL of DAPI, 6 μL of the DyLight 649 Goat Anti-Mouse to 6 mL 
of 1X Blocking Buffer. Prepare solution just before each assay.  
9. For the tubulin kits (8402601, 8402602): Add 6 μL of DAPI and 6 μL of the 
DyLight 549 Goat Anti-Rabbit to 6 mL of 1X Blocking Buffer. Prepare solution 
just before each assay. 
10. Whole Cell Stain Solution: Just before use, reconstitute the Whole Cell Stain 
Green by adding 50 μL of DMSO to the tube and mixing. Add 12 μL of the stain 
in DMSO to 12 mL of 1X Wash Buffer. Prepare solution just before each assay. 
Use the Whole Cell Stain Solution immediately and discard the unused solution. 
Whole Cell Stain Green in DMSO may be stored at -20°C for <1 week. 
 
  
Protocol for the cytoskeletal rearrangement kit  
 
1. Dilute the cytochalasin D stock solution (e.g., 3 mM in DMSO) to 30 μM, or 
other test compounds to appropriate concentration, in culture medium. Add 50 μL 
of culture medium to the control wells. Add 50 μL of cytochalasin D in culture 
medium to each treatment well (150 μL final). Incubate for 3 h at 37°C in 5% 
CO2.  
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2. Aspirate culture medium and add 100 μL/well of warmed Fixation Solution. 
Incubate plate in a fume hood at room temperature for 15 min. Using warm  
(37°C) Fixation Solution is critical for maintaining cell integrity.  
3. Aspirate Fixation Solution and wash plate twice with 100 μL/well of 1X Wash 
Buffer.  
4. Aspirate Wash Buffer, add 100 μL/well of 1X Permeabilization Buffer and 
incubate for 15 min at room temperature.  
5. Aspirate Permeabilization Buffer. Add 100 μL/well of 1X Blocking Buffer. 
Incubate at room temperature for 15 min.  
6. Aspirate Blocking Buffer and add 50 μL/well primary probe solutions. Incubate 
for 1 h at room temperature. Note: For whole cell stain and F-actin kits, skip step 
7 and 8.  
7. Aspirate Primary Probe Solution and then wash twice with 100 μL/well of 1X 
Blocking Buffer.  
8. Aspirate Blocking Buffer and add 50 μL/well of Staining Solution (secondary 
antibody). Incubate for 30 min protected from light at room temperature.  
9. Aspirate solution and then wash plate three times with 100 μL/well of 1X Wash 
Buffer.  
10. Add 100 μL/well of Whole Cell Stain Solution. Incubate for 15 min protected 
from light at room temperature.  
11. Aspirate Whole Cell Stain Solution and wash plate three times with 100 μL/well 
of 1X Wash Buffer.  
12. Aspirate Wash Buffer and replace with 150 μL/well of 1X Wash Buffer.  
13. Seal plate and evaluate on the ArrayScan HCS Reader. Store plates at 4°C.  
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